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Abstract 
Pseudokinases make up ~10% of the human kinome and lack one or more of the 
evolutionary conserved amino acids that are typically required to hydrolyse ATP and 
phosphorylate protein substrates. Overexpression of the Tribbles 2 pseudokinase 
(TRIB2) has been identified in subsets of acute myeloid and acute lymphoblastic 
leukaemia as well as drug-resistant solid tumours, marking it out as an important new 
target for drug discovery. TRIB2 is the most ancestral of the three human TRIB 
pseudokinase homologues, which have evolved features distinguishing them from all 
other protein kinases. They are uniquely defined by an unusual αC-helix, which forms 
a binding site for an E3 ubiquitin ligase binding motif in the Tribbles C-terminal tail. 
The pseudokinase domain also retains a binding platform for substrates, such as the 
myeloid transcription factor C/EBPα, which are ubiquitinated by context-specific E3 
ligases. TRIB2 has also been reported to induce AKT phosphorylation at Ser473, 
promoting cell survival. A lack of target-validated small molecule ligands with which to 
probe signalling functions has hindered the analysis of Tribbles pseudokinases.  
This thesis describes a kinase inhibitor-repurposing approach to discover novel TRIB2 
chemical ligands, in order to probe TRIB2 biochemical mechanisms in vitro and 
analyse TRIB2 signalling mechanisms in human cells. By employing a simple thermal 
shift assay, recombinant TRIB2 protein was screened using the Published Kinase 
Inhibitor Set (PKIS), and distinct families of stabilising and destabilising chemical 
ligands were discovered and analysed. The clinically-approved covalent EGFR/HER2 
inhibitors afatinib and neratinib were found to bind covalently to two unique cysteine 
residues in the αC-helix of the TRIB2 pseudokinase domain, causing it to become 
uncoupled from its own C-terminal tail region. Cellular afatinib exposure led to rapid 
proteasome-mediated degradation of both exogenous and endogenously expressed 
TRIB2 in human cell lines. Mutation of the two Cys residues responsible for covalent 
compound-binding in vitro also resulted in TRIB2 stabilisation in cells in the presence 
of afatinib, alongside the maintenance of high levels of pSer473 AKT. Afatinib and 
neratinib were also highly cytotoxic in the TRIB2 overexpressing leukaemia U937 cell 
model, downstream of TRIB2 degradation and the induction of apoptosis. The work 
reported in this thesis suggests new potential therapeutic approaches for the treatment 
of TRIB2-associated diseases.  
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FITC Fluorescence isothiocyanate 
FOXO Forkhead/winged helix class O transcription factors 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GEF Gefitinib 
GPCR G-protein coupled receptor 
GSK3 Glycogen synthase kinase 3  
GST Glutathione-S-transferase 
HCD Higher-energy collisional dissociation 
HER2 Human epidermal growth factor recetor 2 
HER3 Human epidermal growth factor recetor 3 
HER4 Human epidermal growth factor recetor 4 
HM Hydrophobic motif 
HPLC High performance liquid chromatography 
HSP Heat shock protein 
IGF1 Insulin-like growth factor 
IL-8 Interleukin-8 
IMAC Immobalised metal affinity chromatography 
IM-MS Ion-mobility Mass spectrometry 
IP Immunoprecipitation 
IPTG Isopropyl-1-thio-β-D-galactosidase 
ITC Isothermal titration calorimetry 
JAK Janus kinase 
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JH Janus homology domain 
JM Juxtamembrane domain 
kDa Kilodalton 
KSR Kinase suppressor of Ras 
L Litre 
LAP Lapatinib 
LB Luria-Bertani  
LIC Ligation independent cloning 
MAPK Mitogen activated protein kinases 
MBP Maltose binding protein 
MDS Myelodysplastic syndrome 
MEF Mouse embryonic fibroblasts  
mg micro gram 
mL Millilitre 
MLKL Mixed lineage kinase like protein  
MO25 Calcium-binding protein 39  
Mr Relative molecular mass 
MS Mass spectrometry 
MST Micoscale thermophoresis 
mTORC1 Mammalian target of rapamycin complex 1 
mTORC2 Mammalian target of rapamycin complex 2 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
NER Neratinib 
ng nano gram 
NLT N-terminal tether 
NSCLC Non-small cell lung cancer 
NTA Nitrilotriacetate 
N-terminal Amino-terminus 
OD Optical density 
OSI Osimertinib 
OSR1 oxidative stress response kinase 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
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PDB Protein data bank 
PDK1 3-phosphoinositide-dependent protein kinase 1 
PH  Pleckstrin homology 
PI3K Phosphatidylinositol 3-kinase 
PIF PDK1-interacting fragment 
PIP2 Phosphatidylinositol 4,5-bisphosphate  
PIP3 phosphatidylinositol 3,4,5-triphosphate  
PKA Protein kinase A 
PKB/AKT RAC-alpha serine/threonine-protein kinase 
PKC Protein kinase C 
PKIS1 Protein kinase inhibitor set 1 
PLK Polo like kinase 
PRK2 Serine/threonine-protein kinase N  
RNA Ribonucleaic acid 
S6K S6 kinase beta  
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide electrophoresis 
SEC Size exclusion chromatography 
SH Src homology domain  
shRNA Short hairpin RNA 
SOS Son of sevenless 
SPR Surface plasmon resonance 
STE homologues of yeast Sterile 7/11/20 kinases  
STRADα STE20 Related kinase Adapter 
T-ALL T-cell acute lymphoblastic leukaemia 
TBS-T Tris-buffered saline and 0.1% Tween 20 
TCEP Tris(2-carboxyethyl)phosphine)  
TdCD Temperature depedent circular dichroism 
TDD Tribbles degradation domain 
TET Tetracycline 
TFA Trifluoroacetic acid 
TGF Transforming growth factor 
TIE-2 Angiopoietin-1 receptor 
TK Tyrosine kinase 
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TKL Tyrosine kinase like 
Tm Melting temperature  
TNF Tumour necrosis factor 
TRIB Tribbles  
TSA Thermal shift assay 
TYK Non-receptor tyrosine-protein kinase TYK2 
U Enzymatic unit of activity 
UC Ulcerative colitis  
Ve Volume of elution 
VEGF Vasular endothelial growth factor 
Vo Void volume 
VRK3 Inactive serine/threonine-protein kinase VRK3  
WNK With no lysine kianses 
YFP yellow fluorescent protein 
ΔTm Relative difference in melting temperature  
λPP Lambda phosphatase 
μL Microlitre 
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List of amino acids 
Amino acid 3 letter code single letter code 
alanine ala A 
arginine arg R 
asparagine asn N 
aspartic acid asp D 
cysteine cys C 
glutamine gln Q 
glutamic acid glu E 
glycine gly G 
histidine his H 
isoleucine ile I 
leucine leu L 
lysine  lys K 
methionine met M 
phenylalanine phe F 
proline  pro P 
serine ser S 
threonine thr T 
tryptophan trp W 
tyrosine  tyr Y 
valine val V 
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Chapter 1: Introduction 
Background 
In our cells thousands of chemical reactions are being controlled at every instant both 
spatially and temporally. In the 1960s it was realised that the proteins, encoded within 
our genome, carry out these diverse and specialised functions [1]. Adenosine 
triphosphate (ATP), which is commonly referred to as ‘the molecular currency’ drives 
many vital functions in cells, providing energy for muscle contraction, nerve impulse 
propagation and chemical synthesis [2]. ATP is also the substrate for protein kinases 
in cellular signalling, which regulate nearly all aspects of cellular life. Kinases catalyse 
the transfer of the negatively charged ATP gamma phosphate to a specific serine, 
threonine or tyrosine amino acid residue on a target substrate. The localised negative 
charge exerted by the attached phosphate influences the target proteins architecture 
and molecular dynamics, therefore allowing/disallowing the target to perform a 
particular function or interact with another specified protein(s). 2% of the entire 
genome codes for kinases and pseudokinases [3]. The pseudokinase complement of 
the human kinome consists of approximately 60 signalling proteins, which lack one or 
more of the amino acids in the highly conserved motifs typically required to correctly 
align ATP and divalent metal ions, and phosphorylate protein substrates. Recent 
studies in the pseudokinase field have begun to expose the biological relevance of 
pseudokinases, which are now thought to perform a diverse range of physiological 
roles and are connected to a multitude of human diseases. Like canonical kinases, 
pseudokinases drive conformation-dependent signalling associated with both 
physiology and disease [4, 5]. The human ‘pseudokinome’ includes cancer-associated 
signalling proteins such as human epidermal growth factor receptor 3 (HER3), Janus 
kinase 2 (JAK2; JH2 domain) and Tribbles 2 (TRIB2), which have received much less 
attention than conventional kinases. Growing evidence suggests that pseudokinase 
domains represent rational targets for drug discovery, capable of binding small 
molecule kinase inhibitors [6]. Discovering or repurposing biologically and/or clinically-
active compounds that target atypical-conformations of canonical kinases or 
pseudokinases, is an active area of research [4, 5, 7-11]. With the benefit of decades 
of kinase research and the food and drug administration (FDA) approval of over 40 
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clinical kinase inhibitors for cancer and inflammatory diseases [12, 13], the field of 
pseudokianse research is in a strong position to understand how ATP-competitive, 
allosteric, or covalent inhibitors might influence pseudokinase-based signalling 
mechanisms that are relevant to health and disease [5, 14]. 
1.1 Protein kinases 
Kinases bind to ATP and catalyse hydrolysis, transferring the gamma phosphate to a 
target substrate (Figure 1.1). The phosphorylation of a protein substrate is the best 
understood method that kinases use to transfer information within a cell, elicit cellular 
responses and to adequately respond to extracellular stimuli. For instance response 
to growth factors, which stimulate EGFR autophosphorylation, activation of mitogen 
activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K) cascades to 
induce cellular proliferation (Figure 1.2). Protein kinases are divided into eight 
superfamilies, based on their evolutionary relationships: Tyrosine kinases (TK), 
tyrosine kinase-like (TLK), cyclin-dependent kinases (CDK), homologues of yeast 
Sterile 7, Sterile 11, and Sterile 20 kinases (STE), cyclin-dependent kinase, map 
kinase, glycogen synthase kinase 3 and CDK2-like kinases (CMGC), 
calcium/calmodulin-dependent protein kinase (CAMK), the AGC kinases (named after 
the protein kinase A, G and C families and the Atypical protein kinases (Figure 1.3). 
Pseudokinases are found within all of the kinase superfamilies (Figure 1.3B). In order 
to function, kinases have evolved common ancestral structural features in the catalytic 
domain but have also independently evolved diverse mechanisms to regulate cellular 
signalling processes that are not solely based on catalysis [15].    
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Figure 1.1: Simplified mechanism of ATP hydrolysis and phosphate transfer by protein kinases. 
The unmodified substrate (1) possesses an exposed Ser, Thr or Tyr residue amenable to modification. 
Kinases (2) bind to ATP and the substrate to catalyse transfer of the ATP γ-phophate, yielding a 
covalently modified substrate with a negatively charged phosphate group bound to a target Ser, Thr or 
Tyr residue and ADP as a biproduct. Phosphatases (4) perform the opposite role to kinases and 
catalyse the removal of the previously attached phosphate group.    
 
Figure 1.2: General explanation of signal transduction. Extracellular ligands bind to the receptor 
domains of EGFR kinases, including EGFR, HER3 and HER4 (HER2 cannot bind extracellular ligands 
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but can activate other EGFR family members), resulting in dimerization of the intracellular kinase 
domain, trans autophosphorylation and activation of MAPK and PI3K/AKT signalling cascades. 
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Figure 1.3: The human kinome. (A) Depicts the eight major kinase. A black box highlights TRIB1, 
TRIB2 and TRIB3, which flank the close relative SgK495 (also known as STK40). Illustration obtained 
from www.cellsignal.com. (B) Highlights all pseudokinases (red) and depicts their evolutionary 
relationships to canonical kinases. From Boueau etl al (2006) [15].      
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1.1.1 Mechanism of ATP hydrolysis and gamma phosphate transfer 
PKA was the first crystal structure of a kinase to be solved, in 1991 [16]. Amino acid 
sequence alignments from genomic data and local spatial pattern alignments from 
structural data have helped to identify certain key motifs within the designated kinase 
domain, that are pivotal for binding and hydrolysis of ATP [3]. The kinase domain is 
bilobal consisting of a small N-terminal lobe and a large C-terminal lobe. The N-
terminal lobe typically contains 5 anti-parallel β-pleated sheets and an αC-helix. The 
C-lobe is mainly α-helical, containing the designated αF helix and catalytic loop, which 
are vital for aligning the regulatory spine and for the hydrolysis of ATP. The interface 
of the αC-helix between the N-lobe and the C-lobe forms a cleft, which is the binding 
surface for ATP and the substrate to which phosphate is transferred [17] (Figure 1.4A). 
Other structural aspects of the kinase domain are the glycine-rich loop, a conserved 
lysine in the β3 sheet, the αC helix, the catalytic motif, the activation segment and the 
hydrophobic αF-helix (Figure 1.4B).  
1.1.1.1 The glycine rich loop 
In subdomain I the consensus sequence GxGxxG forms the glycine rich loop, which 
occurs within a β-turn-β motif between the β1 and β2 strands of the N-lobe. The 
second Gly residue is the most highly conserved throughout the kinome and 
considered to be the most important [18]. This motif is inherently flexible as there is 
reduced steric hindrance from the hydrogen R group of the glycine amino acids. 
Furthermore, as highlighted in blue (Figure1.4A), this loop is offered space as it faces 
down into the cleft between the N and C-lobes. Upon ATP binding, and a 
conformational change of the kinase from an inactive to an active conformation, the 
glycine rich loop closes down upon the ATP and correctly orientates the γ-phosphate, 
priming transfer to a target substrate [19].  
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Figure 1.4: Structure of EGFR kinase domain with highlighted conserved motifs. (A) The EGFR 
kinase domain (PDB ID: 1M14) with the glycine-rich loop highlighted in blue, the β3 Lys in red, the αC-
helix in green, the catalytic loop in yellow, the magnesium DFG motif in cyan. (B) (Top) The secondary 
structure of PKA represented with key motifs highlighted along with their relative positions. (Bottom) A 
comparison of the conserved kinase domain motifs for EGFR family (pseudo)kinases EGFR, HER2, 
HER3 and HER4. Comparison of the conserved kinase domain motifs for AGC kinases PKA, PKB/AKT 
and PKC, with conserved residues highlighted in red. 
1.1.1.2 The β3 lysine 
In subdomain II the positively charged β3 lysine (highlighted in red) coordinates to the 
ATP α and β phosphates. This helps to stabilise the ATP molecule as the glycine rich 
loop clamps down, exposing the γ phosphate. As described for the structure of PKA, 
the VAIK motif additionally stabilises the adenosine ring of ATP [18]. On movement of 
the kinase from an inactive to active conformation the β3 lysine forms an ionic salt-
bridge with a conserved Glu residue within the αC-helix in order to help correctly 
orientate ATP for catalysis. In biochemical studies, mutation of the β3 Lys to a residue 
with an uncharged side chain (such Ala or Met) reduces the activity of many protein 
kinases [20].  
1.1.1.3 The αC-helix 
The positioning of the αC-helix, the only conserved helix in the β sheet-rich N lobe, is 
an important mediator of conformational changes that take place within the catalytic 
centre [18]. The aforementioned salt-bridge between the β3 Lys and Glu within the 
αC-helix helps coordinate α and β phosphates of ATP. In addition the αC helix also 
makes direct contact with the N-terminal region of the activation loop [21]. 
Conformation of the αC-helix in/out is also governed by the interaction with the DFG 
motif [22]. The position of the αC-helix can be allosterically modulated by interactions 
with regulatory peptides. In many AGC kinases, the dynamic nature of the αC helix, 
can be modulated through activating or inhibitory regulatory mechanisms. In many 
AGC kinases, including protein kinase A (PKA), RAC-alpha serine/threonine-protein 
kinase (PKB/AKT1), protein kinase C (PKC) and 3-phosphoinositide-dependent 
protein kinase 1 (PDK1) there is the presence of a hydrophobic motif (HM), which is a 
C-terminal tail sequence of 50–60 amino acids after the conserved catalytic core [23, 
24]. This HM, consisting of the general motif F/Y-X-X-F/Y-S/T/E/D-F/Y, docks to a co-
evolved hydrophobic surface in the N-lobe created by the αC-helix, known as the 
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PDK1-interacting fragment (PIF)-pocket [25]. Phosphorylation of AKT at Ser473, 
within the HM, results in enhanced binding of the HM to the PIF pocket in-cis and helps 
to stabilise the kinase in an active conformation [20, 26]. Conversely, Src tyrosine 
kinase can be inactivated by a complex of Src-homology domains SH2 and SH3 that 
bind to the αC-helix and to an inhibitory p-tyrosine in the C-terminal tail, stabilising it 
in the inactive conformation [27, 28].   
The cyclin-dependent kinase (CDK) family also provides an example of allosteric 
regulation of catalytic activity via the αC-helix. CDKs are catalytically inactive until 
binding cognate cyclins [29]. In the absence of cyclin, the αC helix serves as a 
conserved cyclin recognition motif that is rotated to an outward state [29]. In this 
conformation the conserved Glu51 of CDK2 cannot form an ionic bond with β3 Lys33. 
However, binding of cyclin directly to the αC helix induces rotation to an inward state 
thus restoring the Lys33-Glu51 ion pair [30]. 
1.1.1.4 Magnesium binding DFG motif 
The DFG motif (Figure 1.4A, cyan) forms a loop within the catalytic spine. The highly 
conserved Asp is responsible for coordinating a positively charged Mg2+ ion, which 
stabilises the negative charges of the ATP phosphate groups and makes polar 
contacts with all three ATP phosphates [31]. In cases of incorrect positioning of the 
DFG motif, the active site is sterically blocked from binding ATP. Structural analysis of 
AKT revealed that the DFG Phe flips over and occupies the position in the catalytic-
spine that is usually filled by the adenine ring of ATP in the active conformation [26]. 
This has been designated as a ‘DFG-out’ conformation, and this serves as a structural 
signature of the inactive form for many kinases. The hydrophobic Phe makes contacts 
with the catalytic motif and αC-helix when the kinase lobes close and the DFG loop 
faces inwards (DFG-in conformation), which stimulates the formation of the 
aforementioned β3 Lys-Glu ionic bond [32]. Finally the Gly stimulates correct 
positioning of the Asp residue through formation of a hydrogen bond. In the DFG-out 
conformation, this hydrogen bond is disrupted and the flexibility of movement offered 
within the DFG loop is a hindrance to Mg2+ ion binding [31].   
1.1.1.5 The catalytic motif 
The Asp in the HRD of the catalytic motif becomes protonated by accepting a hydrogen 
from the hydroxyl group from the R group of the substrate amino acid (either Ser, thr 
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or Tyr) [21]. The Asn residue helps to orientate the catalytic Asp by coordinating an 
Mg2+ ion (therefore two Mg2+ ions can be coordinated in collaboration with the DFG 
motif). The His at the beginning of the motif is highly conserved, serving as a central 
scaffold for the catalytic spine, which binds to the carbonyl of the DFG aspartate and 
makes a hydrophobic contact with the DFG Phe [31]. The HRD Arg is also prevalent 
in most kinases that require phosphorylation of the activation loop for activation. The 
positively charged Arg interacts with the phosphorylated activation loop residue to 
support a link between the catalytic motif, activation loop and the DFG motif [33].     
1.1.1.6 Activation loop phosphorylation 
Normally, kinases with a HRD catalytic motif (as opposed to HxD motif) require 
phosphorylation of the activation loop. For instance phosphorylation of the Thr197 
residue of PKA, which is adjacent to the catalytic HRD Asp, is required for full catalytic 
activity. The phosphate group from the phospho-Thr197 coordinates the αC-helix 
(His87), the catalytic motif (Arg165) and the β9 sheet (Lys189), allowing 
conformational movement from a DFG-out to a DFG-in catalytically active orientation 
[34]. 
Phosphorylation of the activation loop of fibroblast growth factor receptors (FGFRs) 
and insulin-like growth factor receptors (IGFRs) occurs upon dimerization and trans-
autophosphorylation [35, 36]. This autophosphorylation relieves the inhibition caused 
by the activation loop, which would otherwise occlude the active site and prevent 
substrate from binding [36].  
1.1.1.7 The αF-helix  
The αF-helix serves as a central scaffold for coordination and assembly of catalytic 
and regulatory spines (Figure 1.5), which anchors all the elements important for 
catalysis [18]. The αC-helix and the Activation Loop, can be very mobile, which allows 
the hydrophobic spine to be dynamically assembled or disassembled thereby 
regulating the protein kinase activity and was thus designated as the regulatory Spine 
[21]. One of the regulatory spine residues in the C-lobe, is part of the HRD motif of the 
Catalytic Loop. In most kinases this is a histidine whereas in PKA and most of the 
AGC subfamily the His is replaced by a Tyr [37] (Figure 1.3B). The backbone of the 
His/Tyr is anchored to the F-helix through a conserved aspartate (Asp220 of PKA), 
which serves as the base of the regulatory spine. The second hydrophobic spine also 
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encompasses residues from the N and C-lobes, but is completed by the adenine ring 
of ATP and was thus termed the catalytic spine. The catalytic spine is formed from the 
Ala residue in the VAIK motif in the β3 sheet and this interacts with the adenine ring 
of ATP [18].  
 
Figure 1.5: The F-helix and two hydrophobic Spines define the kinase architecture. (A) The 
regulatory spine (red) and catalytic spines (yellow) are connected to the αF-helix (tan) in the centre of 
the C-lobe. ATP completes the catalytic spine and provides a connection between the N and C-lobes. 
(B) Highlighted elements of the catalytic machinery, which are anchored to the αF-helix directly or via 
spines. Figure obtained from [18].  
 
1.2 Mechanisms of kinase domain activation 
1.2.1 C-terminal tail interactions to control activity of AGC kinases 
The mechanism by which protein kinases perform ATP hydrolysis and phospho 
transfer to regulate target proteins in cell signalling has been discussed. However, 
protein kinases are intracellular mediators of signals and have evolved multiple 
regulatory mechanisms to efficiently phosphorylate specific substrates at the time and 
location needed. Certain AGC kinases are regulated by interactions with regulatory 
domains or inhibitory subunits, which can modulate their localisation and ability to 
interact with substrates. Certain kinases from various superfamilies, including many 
AGC kinases, exploit in cis interactions of a C-terminal polypeptide tail with the 
A B
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catalytic domain in order to control substrate binding and catalytic activity. They are 
regulated, in part, allosterically through the interaction of the C-terminal tail with a 
regulatory site by the αC-helix in the N-lobe known as the PDK1 interacting fragment- 
(PIF)-pocket [23, 24, 38]. The PIF-pocket acts like an ON-OFF switch in AGC kinases 
with different modes of regulation. The PIF-pocket was first shown in the crystal 
structure of PKA as the site where the Phe residues, within a hydrophobic motif (HM) 
with the consensus F-T-E-F-COOH in the C-terminal tail, dock to a surface created by 
the αC-helix (PDB 1ATP). Interaction of the HM with the PIF-pocket allosterically 
affects the ATP-binding site and the peptide substrate binding site [26, 39, 40].   
1.2.1.1 Regulation of AKT activity 
AKT is a main effector downstream of PI3K stimulation (Figure 1.2), with the key 
downstream signalling nodes glycogen synthase kinase 3 (GSK3), forkhead/winged 
helix class O transcription factors (FOXO) and mammalian target of rapamycin 
complex 1 (mTORC1). The vast circuitry of the dynamically branching signalling 
networks stemming from AKT stimulation is ubiquitous to nearly every cell in the body. 
Mouse and human genetic studies have also revealed physiological roles for the AKT 
network in nearly every organ system. There are 3 isoforms of the Ser/Thr kinase 
(AKT1, AKT2 and AKT3) and comprehension of their regulatory functions is 
particularly important, given the consequences of AKT dysfunction in various 
diseases, including cancer, cardiovascular disease, insulin resistance, inflammatory 
and autoimmune disorders, and neurological disorders [38, 41-43]. 
AKT is phosphorylated in the activation loop (Thr308 in AKT1) by PDK1, but requires 
phosphorylation at a Ser473 residue, in the HM, by the mTORC2 complex for full 
activation [26, 42]. In vitro AKT from HEK293 cells is inactive, but phosphorylation by 
PDK1 increases activity by ~100 fold [44]. Subsequent phosphorylation of AKT at 
Ser473 by MAPKAP kinase-2 AKT resulted in up to 1000-fold increased activity in vitro 
compared to the inactive form of AKT. When only the Ser473 residue is 
phosphorylated by MAPKAP kinase-2, the total kinase activity of AKT is increased ~6 
fold [44].   AKT has an N-terminal Pleckstrin homology (PH) domain which binds, in 
cis, to the kinase domain, stabilising an inactive conformation and sterically hindering 
binding of PDK1. On growth factor stimulation of receptor tyrosine kinases (RTKs) or 
G-protein-coupled receptors (GPCRs), PI3K is recruited to the plasma membrane, 
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where it phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2), producing 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). [45]. PIP3 binds to the PH domain of 
AKT, thereby disrupting the inhibitory interaction between the N-terminal and catalytic 
domains. Binding of PIP3 to the PH domain also serves to localise AKT to the plasma 
membrane with PDK1 (Figure 1.6A). PDK1 is then able to bind and phosphorylate 
AKT1 at Thr308. In contrast, the HM of ribosomal protein S6 kinase beta (S6K) is 
required to bind in trans to the PIF pocket of PDK1 to be phosphorylated (Figure 1.6B). 
After phosphorylation of the activation loop by PDK1, S6K does not require 
phosphorylation of the HM to interact in cis to fully activate the kinase domain [46]. 
The HM of AKT does not bind in trans to PDK1. Deleting the PH domain (ΔPH-AKT) 
negates phosphorylation at Thr308 by PDK1. However, replacing the C-terminal tail 
of AKT with the C-terminal tail of PRK2 results in AKT phosphorylation at Thr308 [26].     
Figure 1.6: Mechanisms of AKT and S6K activation by PDK1. (A) The PH domain of AKT inhibits 
the kinase domain until binding of PIP3 to the PH domain interrupts this interaction and sequesters AKT 
to the plasma membrane where it is phosphorylated by PDK1 at the activation loop Thr308. 
Subsequently, after phosphorylation of Ser473 by mTORC2, intramolecular binding between the HM 
and the αC-helix of the AKT kinase domain leads to full activation. (B) The C-terminal tail of S6K binds 
in trans to the αC-helix PIF pocket of PDK1 resulting in phosphorylation of S6K by PDK1. Subsequently 
PDK1 dissociates and the HM in the C-terminal tail of S6K binds to the the αC-helix in cis resulting in 
activation.  
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1.2.1.2 PRK2 forms an inactive dimer and is regulated by the C-terminal tail 
Serine/threonine-protein kinase N (PRK) kinases are closely related to PKCs and are 
described to mediate physiological effects downstream of Rho, such as Rho-
dependent cell migration [47]. They are also implicated in the aetiology of prostate 
cancer [48]. PRK2 is auto-inhibited by dimerization of the kinase domain, mediated 
through the N-terminal pseudosubstrate PLK domains and not intramolecular 
interactions [49]. This prevents the interaction with upstream kinase PDK1. Interaction 
of the N-terminal Rho-binding domains with GTP-Rho stimulates interaction with 
PDK1. The HM motif of PRK2, which has a negatively charged Asp in place of a 
phosphorylation site, then binds in trans with the PIF pocket of PDK1 [50]. 
Phosphorylation by PDK1 results in dissociation and supports the formation of an 
active PRK2 monomer with an in cis HM intramolecular interaction with the PIF-pocket.   
1.2.2 Activation by intermolecular interaction 
1.2.2.1 Activation of Aurora kinases 
Aurora kinases are not thought to have N or C-terminal extensions that bind in cis with 
the kinase domain, however there is a regulatory site by the αC-helix in Aurora A that 
binds to TPX2 and similarly where INCENP binds to Aurora B [51-53]. Binding of TPX2 
leads to activation Aurora A in vitro [52], enhancing autophosphorylation of Thr288 (in 
the activation loop). When TPX2 is absent, the activation segment of Aurora A is 
orientated in an inactive conformation. However, binding of TPX2 induces a 10 Å shift 
of the phosphorylated Thr288 from an exposed to a buried position. Thus, TPX2 
synergises with Aurora A to increase phosphorylation and dephosphorylation is 
inhibited [51, 52].    
1.2.2.2 Activation of Polo like kinases (PLKs) 
Domains that flank the kinase domain are important for modulating regulatory 
interactions and activity. Polo-like kinases (PLKs) are mitotic kinases that are close 
relatives to the AGC superfamily of kinases. PLKs have two C-terminal polo-box 
domains (PBDs) that bind to specific target sequences when phosphorylated in order 
to regulate activity and the localisation of the kinase [54]. The crystal structure of the 
PBD shows that the two polo boxes have identical folds comprising of a six‐stranded 
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antiparallel β‐sheet covered by a single α‐helix, with the binding site for a cognate 
phospho‐peptide located at the interface of the two polo boxes [54].  
1.2.2.3 Activation of EGFR family kinases 
The Epidermal growth factor receptors (EGFR) are members of the RTK family of 
kinases, which include EGFR, HER2, HER3 and HER4. They are all composed of an 
extracellular domain, a transmembrane lipophilic domain and an intracellular tyrosine 
kinase domain. With HER2 being the only exception, the extracellular domain is 
responsible for binding to extracellular ligands, such as growth factors, to relay 
information into the cell. The ligands epidermal growth factor (EGF) and transforming 
growth factor-α (TGF-α) selectively bind to EGFR, which induces translocation and 
homodimerisation (with other EGFR proteins) and heterodimerisation (with different 
EGFR members, such as HER2) of the intracellular kinase domain, which leads to  in 
trans autophosphorylation at specific tyrosine residues [55]. The activated kinase 
domains stimulate major signalling pathways, including the Ras/Raf/mitogen-activated 
protein kinase pathway to activate extracellular signal regulated kinase (ERK)1 and 
ERK2, or the PI3K/AKT pathway (Figure 1.2). ERK1 and ERK2 regulate cell growth 
and proliferation, whereas AKT signalling regulates cell survival and apoptosis [56].  
Rather than employing phosphorylation mediated switches for catalytic activation, the 
kinase domain of EGFR proteins move into an active conformation when stimulated 
by allosteric intermolecular interactions following asymmetrical dimerization, whereby 
one kinase domain activates the other. In the cytoplasmic domain, in the N-terminal 
region flanking the kinase domain there is a juxtamembrane segment that links the 
kinase domain to the transmembrane domain. The juxtamembrane domain (JM) has 
two segments; the JM-A segment links to the transmembrane domain and the JM-B 
segment, which on dimerization binds to the C-lobe of the ‘activator kinase’, which 
allosterically stimulates the N-lobe of the ‘receiver kinase’ (Figure 1.7) [57]. In this way, 
the JM-B segment of the juxtamembrane domain forms what is referred to as a 
‘juxtamembrane-latch’. Dimerization, induced by extracellular ligand binding, stabilises 
the helical JM-A dimer, which in turn stabilises the kinase domain dimer, thereby 
activating the kinase domain. In the absence of ligand, alternative dimer formation 
does not lead to activation as the C-terminal tails of the kinase domains inhibit the 
formation of the juxtamembrane latch [57] .  
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Figure 1.7: Activation of EGFR by EGF results in the formation of an asymmetric kinase domain 
dimer. The JM-B region of the juxtamembtrane segment of one of the EGFR monomers binds to the 
C-lobe of the adjacent EFGR monomer forming a dimer. The “receiver” kinase domain is subsequently 
activated by phosphorylation. Obtained from [57].   
1.3 Protein pseudokinases 
In contrast to kinases, pseudokinases are far less-well characterised and lack one or 
more of the previously described key motifs required for ATP binding and 
phosphotransfer. Pseudokinases appear within all kinase superfamilies in humans 
and are components of essentially all sequenced eukaryote kinomes [3, 15]. 
Pseudokinases are scattered throughout the distinct protein kinase subfamilies, 
suggesting that they have evolved from active kinases. Furthermore, there are 
pseudokinase homologues in humans, mice, worms, flies and yeast that lack the 
equivalent catalytic residues [15].  
Increasing biological and structural information have revealed that many 
pseudokinases have evolved unique and interesting mechanisms of controlling 
cellular signalling [6]. The substrates and interactome of pseudokinases are often 
unknown, in both in vitro and in vivo circumstances. Therefore, the ability of signalling 
molecules to be modulated by interacting partners and ligands means that 
pseudoenzymes, with little or no detectable catalytic potential, might still carry out 
essential signalling roles. Pseudokianse signalling could be propagated through either 
low levels of catalysis, made possible by an alternative active site geometry, via 
nucleotide binding-driven allosteric transitions, and/or through the direct modulation of 
binding surfaces [6].  
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Although many pseudokinases are not catalytically active, the ability to bind to and/or 
hydrolyse ATP (sometimes very weakly) can be detected in a number of cases [58]. 
Examples include CASK [59], TRIB2 [60], JAK2 [61], HER3 [62], with-no-lysine 
kinases (WNK1-4) [63], STE20-related kinase adapter protein alpha (STRADα) [64], 
Mixed lineage kinase domain-like protein (MLKL) [65] and kinase suppressor of ras 1 
and 2 (KSR1/2) [66], all of which will be discussed in more detail below. A retained 
affinity for ATP indicates that nucleotide-dependent switching mechanisms may have 
been preserved in the fold in order to regulate a proportion of pseudokinase-
dependent signalling. ATP binding is now understood to be essential for the biological 
activities of non-catalytic pseudokinases such as STRADα [64] and HER3 [62].The 
pseudokinase VRK3 has a diverse interactome, but cannot bind to ATP [67]. The 
VRK3 pseudokinase domain has been crystalised in a constitutively in an active 
conformation and exerts its role as a signalling enzyme perhaps as an allosteric 
modulator, inducing phosphorylation of various nuclear proteins [67]. Indeed, some 
kinases retain full catalytic capabilities in order to exert their signalling potential; WNK 
pseudokinases do not possess the critical Mg2+ coordinating β3 lysine, but have 
evolved an alternate, unique, lysine to coordinate Mg2+, which appears in place of the 
terminal Gly residue of the glycine-rich loop (GRGSFK) [63]. Following a review of 
mechanistic functions of pseudokinases in biology [6], signalling mechanisms can 
simplified  within 5 distinct groups (Figure 1.8).  
1. Allosteric modulator: Regulate the activity of binding partner by forming 
intermolecular interactions to stimulate activation.  
2. Competitor: Competes for binding of particular substrates with other active 
proteins to control signalling output. 
3. Spatial anchor: Forms intramolecular interactions with binding partners to 
control localisation to particular cellular compartments. 
4. Scaffold: To bind to multiple target substrates to instigate signalling activity 
within protein complexes. 
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5. Catalyst: Perform ATP hydrolysis and phosphate transfer, analogous to a 
canonical kinase.    
 
Figure 1.8: Five mechanisms potentially employed by pseudokinases to modulate cell 
signalling. (A) The pseudokinase forms intermolecular interactions with binding partners to influence 
activity. (B) The pseudokinase binds to a common substrate and directly competes with other proteins. 
(C) The pseudokinase dictates localisation of a binding partner by sequestering it to a particular cellular 
compartment. (D) The pseudokianse binds to multiple proteins, forming functional regulatory complexes 
and bridging certain signalling networks. (E) The pseudokinase functioning with non-canonical catalytic 
activity to transfer a phosphate group to a protein substrate. 
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Throughout the last decade it has become increasing clear that rate-limiting cellular 
outputs are not restricted to catalytic turnover. The prospect that many pseudokinases 
still retain (perhaps both regulatory and vestigial) ATP binding activity outlines them 
as potentially valuable new drug targets for small molecule ATP competitive kinase 
inhibitors. Approximately two thirds of pseudokinases have been implicated in range 
of human diseases [6]. In the following section I will briefly discuss the pseudokinases 
currently of most interest, whose biological activities may be susceptible to therapeutic 
intervention with small molecule chemical ligands. 
 
1.4 Pseudokinases in disease 
1.4.1 Janus kinases 
The JAK family of non-receptor tyrosine kinases consist of JAK1, JAK2, JAK3 and 
TYK2, which share homologous regions of sequence termed Janus homology (JH) 
domains [68]. Janus, the roman deity of beginnings and transitions and of 
passageways and endings, is normally depicted as having two faces. Janus kinases, 
aptly named, have two opposing JH domains. The JH1 domain comprises a canonical 
catalytically active kinase domain that becomes activated upon stimulation by type I/II 
cytokine receptors [68]. This regulates a variety of biological processes including 
haematopoiesis and immune response [68]. Normally, the JH1 is negatively regulated 
by intramolecular interactions with the JH2 domain, which contains a pseudokinase 
domain lacking the catalytic Asp residue of the HRD motif [69]. Homology modelling 
analysis suggests that that JAK2 JH1 kinase activity is inhibited due to allosteric 
interactions with the JH2 domain. The JH2 Cys618 residue was predicted to occupy a 
loop between two N-lobe β strands, which restricts conformational flexibility of the JH1 
activation loop by forming interactions with Val1000 and Pro1002 [70]. Furthermore, 
mutation of V617F, which is next to this site, is a highly prevalent oncogenic driver in 
the bone marrow disorder polycythaemia Vera [71].  
Biochemical evidence suggests that the JH2 domain of JAK2 has signalling potential 
with the occurrence of weak catalytic activity. In JAK2, residues Ser523 and Tyr570, 
of the JH1 domain, are potentially phosphorylated by the JH2 domain [72]. Although 
targeted inactivation of the JH1 domain abolishes Tyr570 phosphorylation in vitro, 
therefore indicating the JH1 to be rate-limiting in this process. Despite retaining the 
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ability to bind to ATP, the JH2 domain of JAK1 and TYK2 are catalytically inactive in 
vitro, and neither possess the JH1 domain Ser523 or Tyr570 residues, which is 
potentially indicative of a lack phosphorylation driven regulation [73]. Interestingly, 
ATP binding stabilises the JH2 domain of TYK2 (without significant structural 
rearrangement), which allosterically regulates the JH1 domain by evoking stabilisation 
of the inactive conformation [73]. Indeed, deletion of the JH2 domain causes enhanced 
kinase activity in JAK2 and JAK3 [74].    
Janus kinases have arguably been the most intensively studied pseudokinases to date 
and this can be directly attributed to the occurrence of multiple disease-driving somatic 
mutations in JH2 domains [75]. A prominent gain of function oncogenic variant of JAK2 
(V617F) [76], that has been strongly implicated in multiple myeloproliferative 
neoplasms and is used diagnostically to guide therapeutic intervention strategies 
owing to its occurrence in approximately 95% of polycythaemia Vera and 
approximately 60% of essential thrombocythemia and primary myelofibrosis cases 
[71]. This amino acid substitution consequently results in hyperactivation of JAK2 and 
constitutive downstream STAT signalling due to a presumed destabilisation of the 
auto-inhibitory JH1–JH2 interaction [77]. Interestingly, ATP binding to the 
pseudokinase domain of JAK2 was recently shown to be essential for the 
hyperactivation phenotype of pathogenic JH2 mutants such as V617F [78]. This clear 
association with human malignancies, combined with the documented ATP-mediated 
regulation of the pseudokinase domain, suggests that JH2 domains might be suitable 
small-molecule drug targets for the treatment of cancer and auto-immune diseases. 
Incidentally, ruxolitinib, an orally available tyrosine kinase inhibitor that targets the 
JAK1 and JAK2 JH1 canonical kinase domains, was the first US FDA approved 
inhibitor for the treatment of myelofibrosis [79], and has also been approved for 
patients with polycythaemia Vera to control thrombotic events that fail to respond to 
hydroxurea [80].  
1.4.2 HER3 
The clinically significant pseudokinase HER3 belongs to the EGFR family RTKs. The 
HER3 pseudokinase domain is classified as such as it lacks a canonical catalytic Asp 
[15]. In spite of this, much like JAK2, HER3 is able to tightly bind ATP in an atypical 
manner and also exhibits extremely weak kinase activity, although it is unclear how 
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significant this activity is for the biological function of HER3 [81]. Ligand-induced 
heterodimerisation of HER3 with EGFR or HER2 stimulates allosteric trans-activation 
of these kinases and modulates a myriad of cellular responses including downstream 
activation of the PI3K/AKT signalling pathway [82, 83]. HER3 overexpression and 
mutation has been associated with a multitude of human cancers including ovarian, 
prostate, colon, pancreas, stomach, oral cavity, and lung [83, 84] and is a potential 
diagnostic marker for breast cancer, where it is amplified in around 60% of cases [85].  
One of the major consequences of aberrant HER3 activation is over stimulation of 
PI3K/AKT signalling which is a critical pro-survival pathway in cellular proliferation and 
has been linked to the development of multidrug resistance in certain cancers [86]. 
This is exemplified by the fact that dual-targeting of HER3 and EGFR has proven an 
effective method of overcoming acquired resistance against EGFR targeted 
therapeutics [87]. A study using primary human non–small cell lung carcinoma 
(NSCLC) H226 cells, resistant to both cetuximab and erlotinib, revealed that dual 
targeting of EGFR and HER3 with a monoclonal antibody, MEHD7945A, could inhibit 
tumour growth and cell-cycle progression in parallel with perturbed EGFR/HER3 
signalling. Interestingly, several cancer-associated somatic mutations that confer a 
gain-of-function phenotype for HER3 have also been reported [84] [19]. A novel HER3 
V855A somatic mutation was discovered in a clinical samples from a patient with 
advanced chemotherapy-resistant NSCLC. Val 855 is at the same position as L858 in 
EGFR, which frequently mutates to Arg to increase catalytic activity of EGFR in cases 
of acquired resistance to Type I ATP competitive inhibitors such as gefitinib and 
erlotinib. Co-expression of HER3 V855A and wild-type HER2 was shown to enhance 
ligand-induced transformation of murine and human cell lines. Immunoprecipitation 
experiments revealed that HER V855A has greater physical interactions with HER2, 
than WT, leading to enhanced PI3K pathway activation. The mechanisms of V855A 
HER3 induced activation of HER2 are not fully understood; future structural 
information might reveal a unique mechanism in HER3/HER2 catalytic functions. 
1.4.3 STRADα 
STRADα has a severely degraded kinase domain which is missing the canonical β3 
Lysine, DFG motif and the HRD motif aspartate. STRADα cannot hydrolyse ATP but 
does, however, bind to ATP in an Mg2+ independent manner [64]. Despite lacking 
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catalytic activity, structural and biochemical analysis has revealed that STRADα is an 
allosteric regulator of the tumour suppressor LKB1 (also known as STK11). 
Interestingly, its function is contingent on the adoption of an active conformation, which 
it assumes upon cooperative binding with both ATP and scaffolding partner, Calcium-
binding protein 39 alpha (MO25α) [64]. Although the MO25α/β isoforms are not related 
to cyclins at the primary sequence level, the STRADα/MO25α complex somewhat 
resembles the interaction between CDK2 and cyclin A. Cyclin A binds to the αC-helix 
of CDK2 as well as the preceding loop. In the CDK2/cyclin A complex the cyclin 
molecule orients Glu51, from the CDK2 αC-helix, in order for it to form a salt bridge 
with the β3 Lys33 [30], thereby stabilising CDK2 in an active conformation. 
Comparatively, the position of MO25α in the STRADa/MO25a complex is centred on 
helix αC-helix and the loop preceding this helix [64]. The interaction between Glu118 
from the αC-helix and Arg100 from the VAIK (VTVR in STRADα) motif (analogous to 
the Glu51-Lys33 interaction in CDK2) is maintained, via two water molecules [64].  
Formation of the LKB1-STRADα-MO25α heterotrimeric tumour suppressor complex 
results in LKB1 dependent phosphorylation of AMP-activated protein kinase (AMPK) 
and the inhibition of cellular proliferation signalling pathway [88].  Affinity purified 
complexes of GST-tagged LKB1, FLAG-tagged STRADα and myc-tagged MO25α, 
expressed in HEK293 cells, activated AMPK-related kinases in vitro [88]. Several 
human cancers, and the rare inherited disease Peurtz-Jeghers syndrome, are the 
consequence of loss of function mutations in LKB1 that perturb binding to- and 
activation by STRADα and Mo25 [15]. Activation of LKB1 by anti-diabetes drugs, such 
as metformin, in PTEN deficient mice delayed tumour onset [89], which positions 
STRADα, a critical upstream modulator of LKB1 activity, as potential therapeutic target 
for the manipulation of downstream LKB1 effectors. 
1.4.4 Kinase suppressor of Ras 1 and 2 (KSR1/2) 
KSR 1 and 2 exert their roles as signalling proteins by forming scaffolds, which 
coordinate formation of the oncogenic Raf-MEK-ERK signalling complex [66]. They 
are also important regulators of immune function and metabolism [66]. Crystal 
structure analysis reveals that the kinase domain of human KSR2 binds to ATP and 
forms a complex with MEK1 by interactions that are mediated through their respective 
activation segments and C-lobe αG-helices. The mutual constriction of the active site 
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activation segments means that KSR2 is maintained in an inactive conformation. 
KSR1 and KSR2 both lack the canonical β3 Lys and despite this, however, they are 
proposed to have catalytic function towards MEK1 as a substrate [66]. Structural and 
biochemical analysis revealed that BRAF allosterically stimulates KSR2 catalytic 
activity, contingent on formation of a side-to-side KSR2–BRAF heterodimer. 
Additionally, this heterodimerization results in an increase of BRAF-induced MEK 
phosphorylation. Aberrant activation of Ras-Raf-MEK is an oncogenic driver for a large 
proportion of human cancer. As key regulators of MAPK signalling cascades, KSR 
proteins are a potential therapeutic target of Ras-driven tumours [66].  
Disease associated mutations of KSR2 that disrupt KSR2 signalling through the Raf-
MEK-ERK pathway have also been linked to obesity, insulin resistance and impaired 
cellular fuel oxidation [86]. In a cohort of 2,101 individuals with severe early-onset 
obesity and 1,536 controls, sequencing analysis revealed that multiple rare variants in 
KSR2 that disrupt signalling through the Raf-MEK-ERK pathway to impair cellular fatty 
acid oxidation and glucose oxidation in transfected HEK 293 cells [90]. Using available 
crystal structure information as a template, the KSR2 kinase domain modelled with the 
discovered mutations, which revealed that the P662L, E667V, and R684C mutations, 
which lie within the N-lobe of the kinase domain in a region involved in B-Raf binding, 
are directly involved in intermolecular interactions. Residue P662 was predicated to 
be involved in B-Raf interaction and residue R684 is predicated to form a salt bridge 
with Glu664 of B-Raf, which explains how mutation of these residues leads to reduced 
binding [90]. Other point mutations, located in the C-lobe of the catalytic domain, also 
lie close to the KSR2-MEK interface and are likely to disrupt KSR2-MEK interactions. 
In myocytes transfected with WT KSR2 palmitate-stimulated oxygen consumption 
increases. However, this effect was reduced for the KSR2 kinase domain mutants [90]. 
Studies using mouse embryonic fibroblasts (MEFs) from Ksr2−/− mice have 
suggested that the interaction between KSR2 and AMPK may contribute to their 
abnormal energy homeostasis and metabolism [91].   
Merlin is a KSR1 binding partner in schwannomas cells, which suppresses KSR1 
function by preventing its binding to c-Raf [92]. KSR1 overexpression has been 
suggested to be involved in many pathological phenotypes caused by Merlin loss, 
including multipolar morphology, enhanced cell-matrix adhesion, focal adhesion, 
increased proliferation and survival. Furthermore, proteomic analysis reveals that 
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KSR1 also interacts with several Merlin downstream effectors, including E3 Ubiquitin 
Ligase CRL4DCAF1 [92], suggesting that KSR1 is a potential therapeutic target for 
Merlin-deficient tumours.  
1.4.5 Mixed lineage kinase domain like protein (MLKL) 
MLKL possesses low micromolar, cation-independent affinity for ATP despite lacking 
a glycine rich loop and evolving a non-canonical HGK and GFE residues in place of 
the typical DFG and HRD motifs, but lacks the ability to catalyse the transfer of 
phosphate [93]. Structural analysis shows that MLKL retains the overall topology of a 
bilobial kinase domain. Analysis confirmed that MLKL was in an ‘active’ conformation, 
with the β3 lysine coordinating a conserved Glu residue in the αC-helix. The catalytic 
HGK motif (in place of HRD) Lys331 is located at the equivalent position normally 
occupied by the canonical catalytic Asp. A K331N mutation acutely reduced MLKL 
affinity for ATP, indicating that this Lys may be involved ATP coordination [65]. This 
could be reminiscent of WNK kinases, which do not possess a β3 Lys, but have 
evolved in an alternate compensatory Lys residue at the end of the glycine rich loop. 
MLKL cannot hydrolyse ATP (on account of other highly degraded remaining motifs) 
but ATP binding might be important for stabilising a functional ‘active’ conformation 
[65]. 
MLKL function is indispensable for tumour necrosis factor (TNF)-α induced necrosis, 
which proceeds via the obligate phosphorylation of two activation loop residues (T357 
and S358) of MLKL by the canonical upstream kinase RIP3 [93]. Phosphorylation at 
these residues stabilises the active conformation of MLKL facilitating the release of 
the N-terminal domain four-helix bundle. This in turn permits MLKL1 oligomerization 
and membrane translocation and subsequent activation of necroptosis [93]. Under 
normal physiological conditions, necroptosis is triggered in response to physiological 
or pathophysiological stimuli, as part of an innate defence against pathogens that 
supress apoptosis [17]. Abrogated regulation of necroptosis, however, is a risk factor 
for a multitude of autoimmune and inflammatory diseases [94], highlighting MLKL as 
a novel therapeutic target. So far, only the biological functions of MLKL in relation to 
necroptosis are understood, but an E351K mutation in the non-canonical GFE 
sequence (which replaces the DFG motif) has also been described in human cancers 
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and this mutant exhibits an increased affinity for nucleotide binding, possibly resulting 
in hyperactivation of the pseudokinase [65]. 
1.4.6 With no lysine (WNK) kinases 
WNK family of serine/threonine pseudokinases (comprising WNK1-4) [95] lack the 
conserved β3 lysine, which was long assumed to be indispensable for nucleotide 
binding and stabilisation of an active kinase conformation [63]. However, WNK kinases 
demonstrate phosphorylation-dependent regulation of a myriad of intracellular 
substrates and this has been made possible by the evolution a novel mechanism of 
catalysis; the terminal residue in the glycine rich loop (normally a Gly in active kinases) 
is a Lys residue in WNKs, which provides a compensatory charge for the binding of 
ATP [63]. Furthermore, it has been proposed that the site normally occupied by the β3 
lysine functions as a chloride sensor by binding to halide ions and inhibiting WNK 
activation by autophosphorylation, thus facilitating a feedback mechanism for the 
regulation of Cl- levels  [96]. In its active state, WNKs phosphorylate and activate SPAK 
and the oxidative stress response kinase (OSR1), which in turn modulate the 
downstream activities of  Na+-driven, Cl−-importing NKCCs (Na+/K+/Cl− co-
transporters) in order to modulate blood pressure and ion homoeostasis [95]. 
WNK kinase homologoues are differentially expressed in various tissues. 
Dysregulation of WNK kinases expressed in neuronal cells have been implicated in 
the aetiology of multiple disease, including hereditary neuropathy and glioma, marking 
them out as potential therapeutic targets [95].  Furthermore, mutations in WNK1 and 
WNK4 have been linked to hereditary hypertension [97]. WNK1 and WNK3 stimulate 
proliferative and invasive activity in glioma cells [98-100]. Conversely, WNK2 
predominantly plays a role as a tumour suppressor and down-regulates cellular 
proliferation by increasing and decreasing activity of Rac1 and RhoA respectively 
[101]. 
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1.5 Tribbles pseudokinases 
Analysis of the tribbles 2 (TRIB2) pseudokinase is the main focus of this thesis and in 
this section I will discuss the diverse functions of tribbles proteins in cellular signalling 
and links to various diseases. The Tribbles (TRIB) pseudokinases control a broad 
array of eukaryotic cell biology by integrating a plethora of signalling networks and 
have evolved unique features distinguishing them from all other protein kinases. There 
are three human Tribbles homologues (TRIB1, TRIB2 and TRIB3), which are Ser/Thr 
pseudokinase members of the CAMK superfamily of kinases. A sequence alignment 
of full length human TRIBs reveal that they are characterised by an N-terminal PEST 
region, a pseudokinase domain with a MEK1 binding site and a C-terminal E3 ubiquitin 
ligase binding region (Figure 1.9). Sequence alignment analysis of the pseudokinase 
domains of human TRIBs with the canonical kinase domain of PKA reveals that TRIBs 
are defined by a unique SLE motif, instead of a DFG motif, which is conserved from 
fly trbl to human TRIBs (Figure 1.10). TRIB pseudokinases possess a canonical β3 
Lys; the β3 motif of TRIB2 being LVCK. The only TRIB pseudokinase domain, 
including fly, that does not possess catalytic Arg and Asp residues is TRIB1, which 
has Gly and Asp residues instead.  
 
Figure 1.9: Alignment of the full length human TRIB homologues. The full length amino acid 
sequences of TRIB2 (1-343 Uniprot Q92519), TRIB1 (1-372 Uniprot Q96RU8) and TRIB3 (1-358, 
Uniprot Q96RU7) were aligned using the MUSCLE tool in and visualised in Jal view. The PEST region 
in the N-terminal domain is boxed in purple, the pseudokinase domain in black, the conserved MEK1 
binding in blue and the E3 ligase binding site in red.  
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Figure 1.10: Sequence alignment of PKA and TRIB (pseudo)kinase domains. Alignment of the 
PKA kinase domain with fly trbl and human TRIB1, TRIB2 and TRIB3 pseudokinase domains. The 
critical motifs for ATP binding and hydrolysis are highlighted. Only Fly Trbl does not possess a β3-lys, 
which has an arg instead. All TRIB pseudokinases have deviant glycine rich loops. All TRIB 
pseudokinases lack a canonical ‘DFG’ (metal-binding) motif. TRIB1 is the only TRIB pseudokinase that 
does not possess a catalytic Arg. (B) The critical motifs for PKA, TRIB2, TRIB1 and TRIB3 are 
highlighted in red.  
 
Facilitating post-translational modifications allows proteins to control signalling though 
a combination of mechanisms. Indeed, both phosphorylation and ubiquitination are 
pivotal in cell signalling, with crosstalk important for controlling outputs. TRIB proteins 
appear to have evolved two main mechanisms of regulating cellular signalling. Firstly, 
the atypical pseudokinase domain retains a regulated binding platform for substrates, 
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which are ubiquitinated by context-specific E3 ligases (Figure 1.11A). Secondly, 
scaffolding functions of TRIB pseudokinases are utilised to integrate certain pathways 
and support the modulation of canonical MAPK and AKT modules (Figure 1.11 B and 
C). 
Figure 1.11: Mechanisms of TRIB pseudokinase signalling. (A) TRIB proteins bind to a variety of 
target protein substrates using the pseudokinase domain. Subsequently, distinct E3 ligases bind to the 
C-terminal DQLVP motif, which then recruits E2 ligases to polyubiquitinate the target substrate resulting 
finally in their proteasome-mediated degradation. (B) TRIB2 binds to AKT and induces phosphorylation 
at Ser473, whereas TRIB3 negatively regulates AKT activation. (C) The C-terminal HPW[F/L] motif 
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targets MAPKK/MEK family members, giving TRIBs the potential to regulate and/or integrate distinct 
stress and proliferative MAPK modules. 
1.5.1 Origin and evolution of tribbles 
TRIB proteins derive their name from the single metazoan fly gene ‘Tribbles’ (Trbl), 
which encodes a pseudokinase with developmental roles in this model genetic 
organism. The fly orthologue of the cell cycle regulating phosphatase M-phase inducer 
phosphatase (CDC25) is called string. String activates CDK1 by dephosphorylation, 
thereby regulating cell cycle progression after G2 phase. During morphogenesis, the 
gastrulating mesoderm cells highly express string, but they do not enter mitosis. 18 
years ago Groβhans and Wieschaus surveyed data from genome-wide screens to 
identify novel regulators of string. There were two genes identified that were proposed 
to negatively regulate string, tribbles and frühstart. By microinjecting trbl mRNA into 
fly embryos, the authors revealed that tribbles inhibited mitosis. Trbl mutant cells 
exhibited premature mitosis, leading to defective gastrulation based on an inability to 
degrade target proteins. A recent study revealed that the human orthologue of trbl, 
TRIB2, is a modulator of CDC25 phosphatases, which it targets for degradation via 
the ubiquitin-proteasome system [102]. Fly trbl was also shown to regulate slbo, the 
mammalian orthologue of which is CCAAT enhancer-binding protein alpha (C/EBPα). 
Human TRIB1 and TRIB2 control hematopoietic differentiation by regulating C/EBPα 
stability through targeted ubiquitination. Fly trbl binds to and negatively regulates AKT. 
In human cells TRIB3 has been shown to directly bind to AKT and negatively regulate 
mTORC2-dependent activation. As AKT stability is not influenced upon binding to 
TRIB3, it is proposed that TRIB3 signalling functions, in this context, are contingent on 
TRIB scaffolding properties. In contrast to TRIB3, it has recently been demonstrated 
that TRIB2 can directly bind to and stimulate AKT phosphorylation of AKT at the C-
terminal regulatory site Ser473, but not the activation loop Thr308 residue [103], which 
is dependent on the presence of an intact C-terminal tail (containing the E3 ligase 
binding motif).   
Taxonomic analysis of TRIB related sequences reveals that they are almost 
exclusively restricted to metazoans; they are not present whatsoever in non-metazoan 
eukaryote kinomes, including fungi and plants [104]. Perhaps this is indicative of 
evolved functions equipped to utilise ubiquitin based regulatory mechanisms. Eyers 
and colleagues (2017) [104] recently proposed that the TRIB2 sequence is the most 
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ancestral. TRIB2 sequences can be detected in early metazoan kinomes, such as 
Nematostella vectensis and Amphimedon queenslandica, with TRIB1 and TRIB3 
sequences occurring in more recently evolved metazoans, presumably as a result of 
genome-wide duplications. Orthologues of TRIB3 are confined to vertebrae metazoan 
lineages and it could be argued that the three homologous were specifically 
nominated, after genome-wide duplications, driven by evolutionary pressure unique to 
regulatory requirements in higher organisms. Furthermore, while most mammals 
possess at least a single copy of TRIB1, TRIB2 and TRIB3, some harbour multiple 
copies, suggestive of gene duplications that are functionally relevant.      
1.5.2 Insights into TRIB structure and function 
The C-terminal tail of TRIBs instigate protein–protein interactions in cis with the 
pseudokianse domain, which is readily identified as a distinguishing feature of TRIB 
pseudokinases. No detectable similarity is observed at this locus between TRIB 
primary sequences and any other evolutionarily related protein (pseudo)kinases, 
defining the tail as a statistically unique feature [104]. Although these motifs are not 
observed in the C-terminal tail of other protein kinases, they are predicted to engage 
with the TRIB pseudokinase domains in a manner analogous to canonical, well-
studied AGC protein kinases, such as PKA and AKT. 
Two recent studies, from the lab of Peter Mace (University of Otago), published crystal 
structures of TRIB1 [105, 106], revealing that TRIB1 undergoes conformational 
change relative to its substrate-free structure and to its C/EBPα substrate-bound 
structure. In the substrate-free state there is an intramolecular interaction between the 
E3 ligase binding region in the TRIB1 C-terminal tail and the αC-helix of the 
pseudokinase domain. Interestingly, substrate binding triggers an allosteric 
modulation that leads to release of the C-terminal tail from, and conformational 
rearrangement of, the pseudokianse domain to a closed ‘active’ like conformation. In 
accordance with molecular dynamics and biochemical studies, release of the C-
terminal tail link substrate recruitment to Constitutive photomorphogenic protein 1 
(COP1) [105].  
Crystal structures of TRIB1 reveal a bilobal pseudokinase domain with a degraded 
ATP binding site and a Tyr134 residue protruding into the active site, which would 
occlude ATP binding [105]. Interestingly, the equivalent residue in TRIB2 is Cys104, 
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which would exert less steric hindrance and would perhaps explain why TRIB2 can 
very weakly bind to ATP in the absence of divalent metal cations. Moreover, without 
allosteric interactions from C/EBPα, rearrangement into a canonical SLE-in (canonical 
DFG-in) position is sterically prevented by the aC-helix Tyr134[105]. Tyr134 and 
Leu226 (of the SLE motif) rotate upon substrate binding, away from the active site, 
which is facilitated by 3.2 Å movement of Tyr134, causing it to pack on top of Leu226 
(Figure 1.12). Consequently, Leu226 packs to complete the regulatory spine, thereby 
fulfilling a closed SLE-in conformation [105].   
 
 
Figure 1.12: Conformational change in the TRIB1 αC-helix. Structural analysis of TRIB1 αC-helix 
and SLE motif regions showing relative organisation of Tyr134 and Leu226 between the substrate free 
SLE-out state (left) and substrate bound SLE-in state (right). Figure modified from [105]. 
 
TRIB1 and TRIB2 share ~72% sequence identity, decreasing to ~50% for TRIB3, with 
a high degree of homology in the C-terminal domain. Using the crystal structure of 
TRIB1 (PDB 5CEM) as a template (Figure 13A), a TRIB2 model was generated by 
automated homology modelling using Swiss Prot (Figure 1.13B). The quality estimate 
values for the TRIB2 model (with an overall QMEAN of -2.9) suggest an accurate 
representation of the potential TRIB2 structure. The αC-helices appear to be highly 
similar (green), which supports the interaction with the E3 ligase biding site in both 
TRIB1 and TRIB2 (blue). The C-lobes of the TRIB1 crystal and TRIB2 model exhibit 
similar structural features of active kinases PKA (Figure 1.13C). The close structural 
homology between TRIB1 and AMP-regulated kinases is interesting, given the fact 
that TRIB3 has been proposed to regulate the stability of AMPK effectors, including 
acetyl Coenzyme A carboxylase (ACC) [105, 107].     
αC-helix movement
Substrate binding
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Figure 1.13: C-terminal tail interaction with the (pseudo)kinase domain. (A) Crystal structure of 
TRIB1 (5CEM) in the substrate free SLE-out confirmation with C-terminal tail (blue) interacting in cis 
with the αC-helix region (green). (B) Model of TRIB2 based on TRIB1. (C) Crystal structure of PKA 
(1ATP) showing C-terminal tail (blue) interactions with the kinase domain.  
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TRIB1 and TRIB2 are predicated to have an intact αF-helix that assembles to help 
form the catalytic and regulatory spines. The N-terminal lobes of TRIB1 and TRIB2 
are more unusual. As well as having a truncated and distorted αC-helix, the glycine 
rich loop, which links the β1 and β2 strands, is shorter than usual and therefore 
restrictive [105]. Furthermore, the truncated C-helices of TRIB1 and TRIB2 are packed 
closer to the β3-strand, thereby decreasing plasticity of potential movement.  
1.5.3 Biology of TRIB2 
1.5.3.1 TRIB2 mediated degradation of C/EBPα in AML 
The C/EBP family of bZIP transcription factors are involved in a variety of physiological 
processes ranging from control of the cell cycle to cellular differentiation. Recent 
biochemical analysis revealed that TRIB1 binds to C/EBPα, β and γ homologous, with 
phosphorylation of C/EBPβ negatively regulating the interaction in vitro [105]. C/EBPα 
is an important transcription factor in myeloid cell differentiation and cell cycle 
regulation. It is able to achieve this through a variety of mechanisms, which include 
upregulation of the CDK inhibitor p21 and the inhibition of CDK2/CDK4 activity [108]. 
There are two isoforms of C/EBPα. C/EBPα p42 is the full length protein and contains 
a degron in the N-terminal domain, which is exploited by TRIB2, which targets it for 
ubiquitination and proteasome-mediated degradation [109]. Conversely, the truncated 
p30 isoform, resulting in gene splicing and the occur ace of an alternate start codon, 
is spared by TRIB2 [109]. The C-terminus of C/EBPα contains a series of regularly 
interspersed hydrophobic residues, which ultimately leads to the positioning of these 
residues on one particular side of an α-helix. As a result the C-termini of two bZIP 
monomers dimerize through intermolecular interactions [110]. The resulting scissor-
like complex allows the charged basic regions of the C-terminus to make contact with 
the major groove of sequence-specific regions of DNA conforming to the consensus 
sequence RTTGCGYAAY [110]. Upon binding these regions, the C/EBP transcription 
factors are able to modulate the expression of their target genes [111]. As the p30 
isoform is an N-terminal truncated protein, it can still bind to DNA and modulate 
transcription and is therefore oncogenic. Imbalance in levels of p30 and p42 C/EBPα 
leads to disturbed granulopoiesis and the onset of acute myeloid leukaemia (AML) 
[109].  
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TRIB2 overexpression alone drives fully penetrant and lethal AML in mice [109]. 
Conversely, TRIB3 expressing cell-transplants do not promote leukemogenesis, 
consistent with its inability to degrade C/EBPα Mice reconstituted with bone marrow 
cells, expressing TRIB2, displayed enlarged spleens and lymph nodes with an 
extensive involvement of myeloblasts and immature myelomonocytic cells, and due to 
the >20% proportion of blast cells, AML was the diagnosis. Flow cytometry confirmed 
the immature phrnotype [109]. In order to elucidate which regions of the TRIB2 were 
responsible for disturbed differentiation of granulocytes, a myeloid 32D cell line was 
engineered to express a variety of TRIB2 truncations and point mutants. Degradation 
of C/EBPα was negated by the deletion of either the COP-1 binding site or a mutation 
within the kinase domain, whereas an N-terminal mutant, which had a complete 
catalytic domain and total COP1 binding sequence integrity, could still reduce p42 
C/EBPα protein levels [112]. Interestingly, mutation of the TRIB2 D326QLVP331 
sequence to an AQLAA or mutation of the conserved Lys in the catalytic motif was 
unable to promote C/EBPα degradation [112]. 
Deregulation of the transcription factor E2F1 also occurs in AML, resulting in the 
perturbation of cell cycle and apoptosis. Keeshan and colleagues (2014) [113] 
discovered that E2F family members directly regulate TRIB2 expression in leukemic 
cells and identified a regulatory feedback loop. The p30 isoform of C/EBPα lacks the 
mitotic inhibitory, transactivation domain in the N-terminus, which is responsible for 
inhibition of the c-Myc promoter by E2F1. E2F1, 2, 3 and 4, but not E2F5, activate the 
TRIB2 promoter with overexpression of E2F1 leading to increased levels of TRIB2 
mRNA [113]. Adjacent to the E2F1 binding sites in the TRIB2 promoter, there is a 
C/EBP binding site, where both isoforms of C/EBPα can bind [113]. There is an inverse 
correlation between TRIB2 promoter activity and the levels of C/EBPα p42 when co-
transfected with E2F1. However, increasing amounts of C/EBPα p30 co-transfected 
with E2F1 increases TRIB2 expression [113]. From clinical AML samples, high TRIB2 
expression correlated with high E2F1 expression levels [113]. 
1.5.3.2 TRIB2 in acute lymphoblastic leukaemia (ALL) 
There is currently no evidence available to implicate the involvement of TRIB1 and 
TRIB3 in ALL, in contrast there is growing evidence for a role of TRIB2 [109]. TRIB2 
expression is highest in the lymphoid compartment of haematopoietic cells and 
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properly regulated expression is important for normal differentiation in B and T-cell 
lineages [114]. TRIB2 was first identified in a screen for downstream effectors of 
NOTCH1 signalling in ALL and activating NOTCH1 mutations were found to induce 
pathogenicity related to increased TRIB2 expression. Activating NOTCH1 mutations 
occur in 50% of all acute lymphoblastic leukaemias (T-ALL) [115]. TRIB2 is a NOTCH1 
target gene. High TRIB2 expression is also associated with NOTCH1 acute 
lymphoblastic leukaemia (ALL) and is regulated by the transmembrane receptor 
NOTCH1 following proteolytic cleavage [115]. The levels of NOTCH1 protein are 
controlled by ubiquitination through FBXW7 [109, 115, 116] . Analysis of samples from 
60 clinical paediatric ALL patients with either NOTCH1 or FBX7W mutations revealed 
that TRIB2 expression was increased, with the highest expression observed in 
patients that have a mutation to the PEST domain of NOTCH1, which regulates 
stability and proteasome-mediated turnover. Analysis of TRIB2 expression across 16 
different subtypes of human leukaemia demonstrated that TRIB2 expression was 
higher in ALL phenotypes as compared to other phenotypes including AML, chronic 
lymphocytic leukaemia (CLL), myelodysplastic syndrome (MDS) and chronic myeloid 
leukaemia (CML) [115]. 
1.5.3.3 Tumour suppressor role of TRIB2 in T-ALL  
The thymus is a lymphoid organ where progenitors from the bone marrow (BM) commit 
to T-cell lineage development before differentiation into functional naive T cells, and 
subsequent export to the periphery as part of the adaptive immune system [114]. 
TRIB2 knock out mice do not display any obvious phonotypical changes. Furthermore, 
TRIB2 knock out does not affect the hierarchical organisation of the murine 
hematopoietic system and is thus dispensable for myeloid cell differentiation in steady 
state conditions [114]. TRIB2 expression is highest in the lymphoid compartment cells 
so it is not surprising that overexpression of TRIB2 in T-cells does not lead to 
malignancy. I fact, in models of T-ALL, TRIB2 plays an important tumour suppressor 
role and is essential for balanced proliferation of developing murine thymocytes [114]. 
TRIB2 knock out causes developing thymocytes to become highly proliferative but with 
heightened sensitivity to in vivo genotoxic drug treatment with the common 
chemotherapeutic agent 5-fluorouracil-induced. Furthermore, TRIB2 knock out, in 
NOTCH1-induced murine T-ALL, led to enhanced T-cell leukemic transformation 
associated with impaired MAPK signalling. In the human disease, low levels of TRIB2 
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expression correlate with a mature T-ALL phenotype and high levels of expression 
with an immature phenotype.  
1.5.3.4 TRIB2 in non-small cell lung cancer (NSCLC) 
Proteasome-mediated degradation of C/EBPα due to TRIB2 overexpression has also 
been implicated in the development of NSCLC [117]. Cultured NCl-H1650 lung cancer 
cells injected into NOD/SCID mice had 76 fold higher TRIB2 expression due to a gene 
amplification that occurred in 12% of tumours that developed. However, knockdown 
of TRIB2 transformed the cells ability to be proliferate, suggesting that oncogenisity 
was driven through TRIB2 expression. Indeed, short hairpin RNA (shRNA) mediated 
knock down of TRIB2 in injected NOD/SCID mice did not result in tumour growth [117].  
Subsequent analysis revealed that depletion of TRIB2 levels, by knock down, resulted 
in elevated quantities of C/EBPα; these cells matured into defined lineages. 
Conversely, TRIB2 expressing cells maintained an immature phenotype. Interestingly, 
although COP1 was expressed it was not found to be bound to TRIB2 [117]. The E3 
ligase TRIM21 was in fact required for TRIB2 targeted degradation of C/EBPα in lung 
tissue [117]. This suggests that context and cell-specific expression E3-ligases are 
involved in TRIB2 mediated substrate regulation. When an independent lung cancer 
cell line, A549, as transfected with microRNAs that target the 3’UTR of TRIB2, levels 
of C/EBPα increased, causing the rate of proliferation to decrease. A459 cells 
transfected with the microRNA into mice developed smaller tumours compared to the 
TRIB2 expressing controls [118]. 
1.5.3.5 Stability of TRIB2 are modulated by SFCβ-TRCP and Smurf1 
In liver cells, the stability and ubiquitination of exogenous TRIB2 is controlled by the 
ubiquitin E3 ligase SCFβ-TRCP [119]. Knockdown of SCFβ-TRCP resulted in increased 
levels of FLAG-tagged TRIB2 to be detected. Furthermore, in immunoprecipitations 
TRIB2 was bound to SCFβ-TRCP.  SCFβ-TRCP was found to regulate TRIB2 stability by 
binding to a region in the N-terminal domain termed the TRIB2 Degradation Domain 
(TDD) [119]. SCFβ-TRCP binding is usually regulated by phosphorylation of its 
substrates. This includes the PERIOD, which contains a phosphodegron that has a 
phospho-Thr in the N-terminal domain in a TSGSYS motif. Interestingly, TRIB2 also 
possesses this motif, although it is not known if these Ser residues are 
phosphorylated on SCFβ-TRCP binding. In another study, p70S6K was proposed to 
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phosphorylate TRIB2 at Ser83, which was required for ubiquitination and 
proteasome-mediated degradation of TRIB2 by Smurf1 [120]. Indeed, silencing of 
p70S6K, negated degradation of TRIB2.  
1.5.3.6 TRIB2 in liver cancer 
TRIB2 protein is highly expressed in a subsets of hepatocellular carcinoma and its 
expression is closely correlated with β-Catenin cytoplasmic/nuclear accumulation in 
hepatocellular carcinoma tissue [121]. TRIB2 was found to have higher expression in 
βCatenin mutated HepG2 cells than βCatenin wild-type Huh7 and Hep3B cell lines, 
indicating that Wnt pathway activation correlates with TRIB2 expression [121]. Similar 
to AML and NSCLC subsets, TRIB2 also regulates degradation of C/EBPα in liver 
cancer cells. Levels of C/EBPα increase following TRIB2 knockdown in HepG2 cells 
[121]. The regulation of C/EBP was independent of TRCP and high C/EBPα levels 
prevented the YAP-TEAD interaction, which is important for YAP mediated 
transcriptional activation. In this context, TRIB2 functions as a signalling nexus to 
integrate the Wnt/βCatenin, Hippo/YAP and C/EBPα pathways in cancer cells [121]. 
1.5.3.7 TRIB2 in malignant melanoma 
FOXO transcription factors (forkhead/winged helix class O transcription factors) 
orchestrate gene expression programs known to control a variety of cellular processes 
such as cell cycle, apoptosis, DNA repair and protection from oxidative stress and 
abrogation is a key feature in many cancers [122]. Screening of an RNAi library against 
7914 human genes identified TRIB2 as a regulator of FOXO activity [122]. TRIB2 
mRNA levels are elevated in clinical samples of malignant melanoma. TRIB2 mRNA 
levels were significantly increased in 70% of malignant melanoma samples, compared 
to healthy samples. Interestingly, high TRIB2 mRNA transcription was not observed in 
samples from other skin tumour sources, including non-basal skin carcinoma [122]. 
Subsequent analysis revealed that TRIB2 mRNA levels were higher in stage III/IV 
lesions and immortalised lines derived from high grade skin malignancies. TRIB2 was 
found to negatively regulate FOXO target Bim, although the mechanism of inhibition 
is still unknown. In the melanoma cell line G-361, after knockdown of TRIB2 the cells 
were less invasive and growth was inhibited by cell-cell contact. Further to this, when 
G-361 were transplanted into SCID mice and TRIB2 knocked down, the tumours that 
formed were, on average, smaller [122].  
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The evidence that TRIB2 can both target cell context specific substrates for 
proteasome mediated degradadation and bind to key signalling proteins, facilitating 
their activation, in numerous types of hematopoetic and solid cancers, potentially 
marks TRIB2 out as an interesting, novel therapeutic target.  
1.5.3.8 TRIB2 induces phosphorylation of AKT at Ser473  
The fundamental reason for failure of chemical therapy in patients with cancer is due 
to acquired resistance. Hill and colleagues (2015) [103] hypothesised that TRIB2 
expression, in exogenous isogenic cell lines, contributed to resistance to PI3K and 
mTOR inhibitors (including the dual PI3K/mTOR inhibitor BEZ235). It was found that 
upon treatment with BAY439 (PI3K selective), BEZ235 (dual PI3K/mTOR) or BAY236 
(RICTOR selective) in various cancer model cell lines (including U2OS, HEK293, 
G361 and SK-Mel28), overexpressing exogenous TRIB2, had increased resistance 
characterised by a signiﬁcantly lower sub-G1 cell population and a reduction of 
caspase-3 cleavage [103]. Interestingly, treatment of AKT selective inhibitors, 
including BAY931 and AKT inh.VIII, were effective independent on whether or not 
TRIB2 was expressed. In the melanoma (SK-Mel28) and osteosarcoma (U2OS) cells 
with high TRIB2 expression, signiﬁcantly higher levels of pSer473Ak were identified. 
Knock down of TRIB2 resulted in perturbed AKT phosphorylation at Ser473. This 
effect, however, was not observed for pThr308-AKT. It was subsequently discovered 
that TRIB2 directly interacted with AKT but not RICTOR in immunoprecipitations and 
PCAs. The TRIB2/AKT1 interaction was demonstrated to be as significant as the 
known AKT1/JIP1 interaction [103, 123].  
To address whether or not over expression conferred resistance to PI3K or mTOR 
inhibitors in vivo, the established 293T cells were subcutaneously injected into the 
flanks of NOD/SCID mice. Tumours formed equally regardless of TRIB2 expression 
status. Oral administration of the PI3K/mTOR dual inhibitor BEZ235 to mice 
transplanted with 293T cells not expressing TRIB2, resulted in xenograft tumour 
regression along with a statistically significant increase in survival.  However, 293T-
TRIB2 tumours were highly resistant to BEZ235 treatment [103]. 
In order to assess whether or not TRIB2 expression status influenced prognosis under 
clinical circumstances, tumour tissue samples were collected from patients with 
melanoma, pancreatic and colon cancer prior to standard anti-cancer therapies (DTIC, 
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gemcitabine or paclitaxel). In comparison to samples from individuals with healthy 
tissue, TRIB2 mRNA and protein expression was signiﬁcantly increased. Interestingly, 
no significant differences in TRIB1 and TRIB3 expression levels were detected 
between healthy and diseased tissues. Furthermore, increased TRIB2 expression 
correlated with increased pSer473 AKT and pSer253 FOXO3a protein levels. Indeed, 
of the clinical samples where TRIB2 expression levels were significantly higher, there 
was a correlation with poorer clinical outcome [103]. 
There is not yet any data to support a regulatory role of TRB1 in AKT activation. There 
is evidence, however, supporting the conjecture that TRIB3, in fact, negatively 
regulates AKT by preventing phosphorylation at both Thr308 and Ser473 residues 
[124]. Treatment of HEK293 cells with insulin-like growth factor (IGF1) for just 15 
minutes induced detectable phosphorylation of AKT at Thr308 and Ser473. However, 
overexpression of exogenous FLAG-tagged TRIB3 inhibited AKT phosphorylation at 
both sites without effecting total amounts of AKT protein. It was subsequently revealed 
that overexpression of FLAG-TRIB3 reduced AKT activity in vitro by employing kinase 
assays, from HEK293 immunoprecipitates, and a peptide substrate corresponding to 
the consensus sequence recognised by AKT [124]. To determine whether the 
inhibitory action of TRIB3 on AKT was relevant under physiological circumstances, 
endogenous TRIB3 expression was disrupted in hepatocytes by RNAi. RNAi-mediated 
knockdown of TRIB3 in HepG2 cells potentiated AKT phosphorylation at Thr308 and 
Ser473 in response to IGF [124].   
1.5.3.9 Inhibition of MAPK signalling modules by TRIB2 
TRIB2 has been proposed to be a novel regulator of interleukin-8 IL-8 induced 
inflammatory response driven through inhibition of MEK1, MEK4 and MKK7 [125]. 
THP-1 monocytes treated with acetylated low density lipoprotein (AcLDL), to induce 
MAPK mediated inflammatory response, had lower levels of TRIB2 expression [125]. 
By using ELISA and measuring TRIB2 RNA it was observed that knock down (with 
siRNA) of TRIB2 potentiated LPS-induced IL-8 production, which was due to 
enhanced activation of the extracellular signal regulated kinase JUN kinase MAPK 
pathways. Furthermore, the endogenous level of TRIB2 expression in primary human 
monocytes was inversely correlated to the cell’s ability to produce IL-8. To confirm a 
physical interaction between MEK1, MEK4 and MKK7 in live monocytes a yellow 
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fluorescent protein (YFP)- based protein fragment complementation assay (PCA) was 
employed. This approach is based on the observation that the interaction of two fusion 
proteins coupled to the N or C-terminal of the proteins of interest will lead to re-folding 
and generate an active fluorophore, which can be observed by microscopy [126].  
 
1.6 Targeting protein kinases and pseudokinases with small 
molecules 
 
In 2001 imatinib, marketed by Novartis, was approved as a first line of treatment for 
CML patients with the hyperactive bcr-abl fusion gene and is on the World Health 
Organization's List of Essential Medicines. Non-coincidentally, after the approval of 
imatinib, there has been extensive research from all major pharmaceutical companies 
to develop kinase selective inhibitors to treat numerous cancerous and inflammatory 
diseases; to date there are nearly 40 FDA approved clinical kinase inhibitors. Most 
protein kinase inhibitors are reversible competitive ATP mimicking compounds that 
are broadly classified into two subgroups: type I inhibitors bind to the kinase active site 
and stabilise a DFG-in active conformation, whilst type II inhibitors (such as imatinib) 
stabilise the DFG-out inactive conformation. The latter compounds achieve this by 
occupying a hydrophobic groove adjacent to the ATP binding site that is accessible 
when the αC helix and DFG motif are in an outward orientation [127]. Due to the highly 
conserved nature of the kinase fold and specific mechanism of ATP binding and 
hydrolysis (section 1.1.2), finding selective ATP-competitive inhibitors for particular 
kinases has been extremely challenging. SB 203580 was an early example of a 
selective type I inhibitor that targets p38 MAPK α and β isoforms, but not the very 
closely related γ or δ isoforms. This specificity among MAP kinase isoforms arose due 
to the presence of a bulky ‘gatekeeper’ Met in the latter, which imparts steric hindrance 
to inhibitor binding [128]. Indeed, promiscuous inhibitors that target multiple 
dysregulated signalling pathways may be a pharmacological asset [127], however this 
could well increase the risk of adverse side effects such as vomiting, diarrhoea, muscle 
pain, headache, and rashes, which are commonly observed in the use of oncological 
kinase inhibitors. An ideal approach, especially in the treatment of non-cancer related 
diseases, is logical mechanistic targeting of a specific protein. In this way, targeting of 
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pseudokinases that are known to be dysregulated in certain diseases may be useful, 
in large due to the fact that these proteins have often evolved divergent mechanisms 
of regulation and possess atypical amino acid compositions and structural 
architecture, which could potentially be exploited for more exquisite selectivity [6]. 
Indeed, only ~25% of mammalian pseudokinase domains have been structurally 
characterized (Table 1). Many of the remaining pseudokinases, whose structures have 
not yet been elucidated (table 2), are implicated in the aetiology of many diseases and 
may yet be targetable by repurposing current kinase inhibitors.      
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Pseudokinase Crystal 
Structure of 
pseudokinase 
domain, amino 
acid residues 
and PDB ID 
Function in humans Diseases 
associated 
when 
deregulated 
Refs 
ADCK3 Pseudokinase 
domain (256-647, 
PDB ID: 4PED) 
UbiB family member with a 
putative protein kinase like 
fold that forms an electron-
transferring membrane 
complex involved in 
isoprenoid lipid biosynthesis in 
the mitochondria. 
Cerebellar ataxia 
Estrogen receptor-
positive breast 
tumours 
Glioblastoma 
multiforme 
Steroid-resistant 
nephrotic 
syndrome 
[129] 
CASK CaM 
pseudokinase 
domain (1-337, 
PDB ID: 3MFT). 
CaM 
pseudokinase 
domain (1-337) 
bound to 3'-AMP 
(PDB ID: 3C0G). 
CaM 
pseudokinase 
domain (1-337) 
bound to ADP 
(PDB ID: 3C0H). 
CaM 
pseudokinase 
domain (1-337) 
bound to ANP 
(PDB ID: 3MFR). 
 
Contributes to neural 
development and regulation of 
gene expression. 
Neurological 
diseases 
[59, 130] 
HER3 Pseudokinase 
domain 698-1019 
(PDB ID: 3KEX), 
684-1020 ( PDB 
ID: 3LMG) 
pseudokinase 
domain bound to 
bosutinib 
698-1020 (PDB 
ID: 4OTW) 
EGFR/HER3 
heterodimer (682-
1022, 698-1020,  
PDB ID: 4RIW). 
Binds to neuregulin 1, forms 
heterodimers with other HER 
family members and activates 
PI3K/AKT signalling. 
Lung, melanoma, 
breast, pancreatic, 
prostate, ovarian, 
colon and gastric 
cancers 
[81, 131-133] 
ILK Pseudokinase 
domain/alpha-
parvin core 
complex (183-
452,   PDB ID: 
3KMU) 
Regulates actin 
polymerisation by linking 
integrins to the actin 
cytoskeleton. 
Breast, prostate, 
brain, and colon 
cancers 
[134] 
JAK1 JH2 domain (561-
860,  PDB ID: 
4l00) 
JH2 pseudokinase domain of 
JAK1 facilitates regulatory 
functions and is needed both 
for suppression and full 
activation of JH1 domain 
catalytic activity. 
Gynecological 
tumours 
Psoriasis 
Rheumatoid 
arthritis, Crohn's 
disease 
[135] 
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Multiple sclerosis 
Myelofibrosis 
JAK2 JH2 domain (536-
812, PDB ID: 
4FVP) 
JH2 domain 
bound to Mg-ATP 
(536-812, PDB 
ID: 4FVQ) 
V617F mutant 
JH2 domain 
bound to Mg-ATP 
(536-812,  PDB 
ID: 4FVR) 
E596A V617F 
mutant JH2 
domain bound to 
Mg-ATP (535-
812,  PDB ID: 
5I4N) 
JH2 domain is catalytically 
active and phosphorylates two 
negative regulatory sites in 
JAK2  
(Ser523 and Tyr570) to 
supress JAK-STAT signalling. 
The pathogenic V617F 
mutation promotes a 
confirmation in the JH2 α-C 
helix that enables stimulatory 
interactions with the JH1 
domain. 
Polycythemia vera 
Acute myeloid 
leukemia 
Somatic 
erythrocytosis 
[136, 137] 
KSR2 Tyrosine 
pseudokinase 
domain (634-950) 
in complex with 
MEK1 (1-393) ( 
PDB ID: 2Y4I) 
 
Scaffolding protein that 
coordinates the formation of 
the Raf-MEK-ERK signalling 
complex. Phosphorylates 
MEK1 upon interaction with 
BRAF. 
Obesity 
Type 2 diabetes 
Tumour Cell 
transformation 
[66] 
MLKL Pseudokinase 
domain (179-471, 
PDB ID: 4M67). 
Pseudokinase 
domain (183-471, 
PDB ID: 4MWI). 
 
Phosphorylated by RIP3 to 
mediate downstream 
necroptosis signalling. 
Autoimmune 
diseases 
Inflammatory 
bowel disease 
Neoplastic 
diseases 
[65, 138] 
PAN3 Drosophila 
melanogaster 
Pseudokinase 
domain bound to 
AMP 
phosphoramidate 
(349-790, PDB 
ID: 4BWP) 
Forms a poly(A)-specific 
RNase complex with the 
exonuclease PAN2, which 
functions in mRNA 
deadenylation. 
Unknown [139] 
ROR2 Pseudokinase 
domain (464-751, 
PDB ID: 3ZZW),  
452-753  ( PDB 
ID: 4GT4) 
Modulates Wnt signalling 
upon receptor stimulation. 
Osteosarcoma 
Renal cell 
carcinoma 
Melanoma 
Colon cancer 
Head and neck 
squamous cell 
carcinoma 
Breast cancer 
[140] 
SGK 223 Pseudokinase 
domain dimer 
(PDB ID: 5VE6) 
Scaffold and an effector of 
Rnd2 GTPase. Stimulates 
RhoA activity to promote 
cancer cell invasion in a Src-
dependent manner.   
Pancreatic ductal 
adenocarcinoma 
Breast cancer 
Colon cancer 
[141-144] 
SGK 269 Pseudokinase 
domain dimer 
(PDB ID: 6BHC) 
Binds to Crk to assist 
recruitment of the 
Src/p130/Cas/Crk scaffold. 
Breast cancer 
Colon cancer 
[145-147] 
STRADα MO25α in 
complex with the 
STRADα C 
terminus (59-431  
PDB ID: 2WTK) 
and LKB1 
Binds to ATP and complexes 
with MO25 to allosterically 
stimulate LKB1 and other 
AMPKs. 
Peutz Jeghers 
syndrome 
Sporadic cancers 
[148] 
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Table 1: Publically available crystal structures of human pseudokinase domains. All 
pseudokinses with solved crystal structures, along with functions and potential links to disease. 
 
Pseudokinse Functions in humans Diseases associated when 
deregulated 
Refs 
EphA10 The receptor domain binds to 
Ephrin-A ligand members but its 
functions in cell signalling are 
unclear. 
Breast cancer 
Colon Caner 
Prostate cancer 
[155, 
156] 
EphB6 Binds to Ephrin-B1, which 
induces EphB6 
transphosphorylation by a 
catalytically active EphB partner 
to initiate signalling. 
Triple-negative breast cancer 
B cell leukaemia 
Lung cancer 
Prostate cancer 
Melanoma 
Gastric cancer 
Neuroblastoma 
[157, 
158] 
GCN2 Pseudokinase domain regulates 
function by interacting with GCN2 
kinase domain. 
Alzheimer's disease 
Xenograft tumour growth 
Liver, breast, lung and colon 
cancer 
[159, 
160] 
GUCY2C Tyrosine kinase activity in the 
active kinase domain facilitates 
the GC-C signalling pathway. The 
Attention-deficit hyperactivity 
disorder (ADHS) 
Colon cancer 
[161, 
162] 
TITIN Pseudokinase 
domain 32172-
32492 (PDB ID: 
1TKI),  32172-
32492 (PDB ID: 
4JNW) 
Regulator of muscle 
contraction 
Human skeletal 
tibial muscular 
dystrophy Dilated 
cardiomyopathy 
Hypertrophic 
cardiomyopathy 
[149-151] 
TRIB1 Pseudokinase 
domain (83-343, 
PDB ID: 5CEK), 
Pseudokinase 
and C-terminal 
domain (83-371, 
PDB ID: 5CEM) 
Interacts with MKK proteins to 
modulate MAPK signalling. 
Binds E3 ubiquitin ligases to  
degrade target proteins via 
the proteasome 
AML 
CML 
T-ALL 
Megakaryocytic 
leukaemia 
Fatty liver disease 
Coronary artery 
disease 
[106] 
TYK2 JH2 domain 
bound to 5’ ATP 
(556-871, PDB 
ID: 5C03).  
Pseudokinase 
domain bound to 
BMS-066 (575-
869, PDB ID: 
4WOV) 
JH2 domain binds to ATP but 
is catalytically inactive, which 
is functionally important in 
JH1 domain regulation. 
Autoimmune 
disorders including 
systemic lupus 
erythematosus 
(SLE) 
[73, 152] 
VRK3 Pseudokinase 
domain (146-474, 
PDB ID: 2JII) 
VRK3 negatively regulates 
MAP kinase signalling by 
promoting vaccinia H1-related 
(VHR) dependent inactivation 
of ERK in the nucleus. 
Alzheimer’s 
disease 
Parkinson’s 
disease 
[153] 
WNK1 Pseudokinase 
domain (210-482, 
PDB ID: 4PWN) 
Stimulated the activities of 
Na+ driven, Cl—importing 
NKCCs (Na+/K+/Cl- co-
transporters. 
Hereditary 
neuropathy 
Glioma 
Hereditary 
hypertension 
[96] 
STK40 Pseudokinase 
domain (PDB ID: 
5L2Q) 
Negative regulator of NF-
kappa-B and p53. Potential 
modulator in TNFα signalling. 
Elevated 
expression in 
certain cancers 
[154] 
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pseudokinase domain negatively 
regulates the catalytic GC 
domain.  
 
Familial GUCY2C diarrhoea 
syndrome (FGDS) 
Crohn's disease 
Intestinal obstruction 
GUCY2D Plays a role in the recovery phase 
of phototransduction. It is 
potentially involved in re-
synthesis of cGMP. 
Retinal dystrophy 
Leber congenital amaurosis 
(LCA1) 
[163] 
GUCY2F Catalyses the synthesis of cGMP. Colon, lung,  pancreatic and 
breast cancer 
[164] 
IRAK2 Associates with MyD88 and 
IRAK4 to upregulate NF-kappaB 
signalling.  
Colorectal cancer [165, 
166] 
JAK3 JH2 pseudokinase domain 
functions in both suppression and 
full activation of the JH1 domain 
which, modulates various 
biological processes including 
immune system regulation, 
haematopoiesis and metabolism.  
 
Severe 
combined immunodeficiency 
(SCID) 
Cancer 
[68] 
KSR1 Scaffolding protein that 
coordinates the formation of the 
Raf-MEK-ERK signalling 
complex, facilitating their 
phosphorylation and activation in 
regulation of immune function and 
metabolism 
Inflammatory bowel disease [167-
170] 
NPR1 Atrial natriuretic peptide (ANP) or 
brain natriuretic peptide (BNP) 
binds to the extracellular receptor 
domain to stimulate the 
intracellular guanylyl cyclase 
domain to hydrolyse GTP. 
Hypertension, elevated blood 
pressure, salt-resistant 
hypertension, progressive cardiac 
hypertrophy 
Obesity 
Metabolic syndrome 
Colon cancer 
[171, 
172] 
NPR2 C-type natriuretic peptide (CNP) 
binds to the extracellular receptor 
domain to stimulate the 
intracellular guanylyl cyclase 
domain to hydrolyse GTP. 
Achondroplasia 
Endochondral ossification 
Erectile dysfunction 
[173-
175] 
NRBP1 Modulates Wnt signalling as a 
tumour suppressor 
Breast cancer [176] 
NRBP2 Scaffold for the E3 component of 
the ubiquitin conjugation system 
responsible for substrate 
recognition. 
Gliomas [177, 
178] 
PAN3 Forms a poly(A)-specific RNase 
complex with the exonuclease 
PAN2, which functions in mRNA 
deadenylation. 
Unknown [179] 
Ptk7 Binds to Fzd7 and Ror2 to 
stimulate Wnt5a signalling via 
Jnk. 
Breast, colon, lung  esophageal, 
gastric cancers 
Liposarcoma 
AML 
T-ALL 
ALL 
[180, 
181] 
RSKL1 Binds sphingosine kinase 1 and 
peroxiredoxin 3, the implications 
of which are unclear. 
Endometrial cancer [182] 
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RSKL2 RSKL2 binds sphingosine kinase 
1 and peroxiredoxin 3, the 
implications of which are unclear. 
Unknown [182] 
SCYL1 Mediates transport of the KDEL 
endoplasmic reticulum protein 
retention receptor and regulates 
Golgi morphology. 
Amyotrophic lateral sclerosis  [183] 
SCYL2 C-terminal domain interacts with 
components of clathrin-AP1 
complex to regulate clatherin-
mediated endocytosis. 
Unknown [183] 
SCYL3 Unknown Unknown  
Sgk 071 Unknown Unknown  
Sgk 196 Phosphorylates the 6-position of 
O-mannose required for 
dystroglycan function. 
Congenital muscular dystrophy [184] 
Sgk 424 Unknown Unknown  
Slob Unknown Unknown  
STK31 Localises to the centromeres 
during mitosis and promotes cell 
migration. 
Cervical cancer 
Colorectal cancer 
[185, 
186] 
Stradβ Allosteric stimulation of LKB1 in 
axon formation. 
Unknown [187] 
STYK1 Binds to AKT to stimulate activity 
of GSK3β. 
Cancer [188-
190] 
TBCK Rab GTPase activating protein 
that modulates the mTor 
signalling pathway. 
Intellectual disability 
developmental delay, epilepsy, 
dysmorphism and hypotonia 
[191-
193] 
TEX14 Recruited to kinetochores by 
PLK1 and regulates the 
maturation of the outer 
kinetochores and microtubule 
attachment. 
cancer development and 
progression 
[194, 
195] 
TRIB2 Interacts with MEK1, MKK7, AKT 
and p65/RelA   to modulate 
signalling. Binds E3 ubiquitin 
ligases and drives degradation of 
target substrates via the 
proteasome. 
AML 
T-ALL 
Liver cancer 
Melanoma 
NSCLC 
[109, 
121, 
122, 
196, 
197] 
TRIB3 Interacts with MEK1, MKK4, 
MKK7, AKT, MLK3 and PPARγ to 
modulate signalling. Binds E3 
ubiquitin ligase to degrade target 
proteins via the proteasome.  
Parkinson's Disease 
Diabetes 
Breast cancer 
colorectal cancer 
[197-
199] 
TRRAP Acetyl histone transferase 
cofactor. 
Glioblastoma 
Breast cancer 
[200, 
201] 
ULK4 Unknown Ciliopathy 
Neurodevelopmental, 
neuropsychiatric and 
neurodegenerative disorders 
[202, 
203] 
WNK2 Stimulates the activities of  Na+-
driven, Cl−-importing NKCCs 
(Na+/K+/Cl− co-transporters) 
Glioma [95, 
101] 
WNK3 See WNK2 Glioma [95, 
100] 
WNK4 See WNK2 Hereditary hypertension [95, 
97] 
Table 2: Functions and links to disease of pseudokinases with no known structure. 
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1.6.1 ATP competitive inhibitors 
Pseudokinases whose biological functions are linked to ATP hydrolysis and direct 
substrate phosphorylation, such as WNK, are obvious targets for traditional ATP-
competitive inhibitors. However, despite the fact that the majority of pseudokinases 
lack, or have very weak catalytic output, the binding of ATP competitive inhibitors to 
the pseudokinase domain can modulate their signalling output. The pseudokinase 
domain of MLKL can bind to but cannot hydrolyse ATP [58], which formed the rational 
to screen recombinant MLKL in vitro using DSF with the PKIS1. Compound 1 was 
found to bind to the pseudokinase domain of MLKL, which prevented its 
phosphorylation by upstream kinase RIPK3 and prevented necroptosis. KSR2 is a 
scaffold protein with and weak catalytic activity. It was discovered that pan kinase 
inhibitors such as ASC24, can reduce KSR2-dependent phosphorylation of MEK1 at 
non-BRAF phosphorylated Ser residues in vitro [204]. Suppression of JAK signalling 
could also be achieved indirectly with small molecules that promote JH2 auto-inhibition 
of JH1 kinase output, which has already been suggested mechanistically for TYK2. 
Crystal structure analysis of the JAK kinase TYK2 pseudokinase domain revealed that 
binding to an ATP competitive inhibitor stabilised the intra-domain auto-inhibitory 
interaction with the tyrosine kinase domain and blocked downstream signalling [152]. 
Bristol Myers Squibb have recently disclosed that a TYK2 JH2 domain inhibitor will 
proceed to Phase III clinical trials for the skin disease psoriasis. The TYK2 inhibitor 
BMS-986165 induces allosteric inactivation of the JH1 domain by binding to and 
stabilising the JH2 domain. Pfizer is also currently evaluating a TYK2/JAK1 
pseudokinase domain inhibitor, PF-06700841, which is currently at mid stage studies 
for psoriasis, Crohn’s disease and ulcerative colitis (UC). 
There is a reduction in amino acid conservation in regions outside the ATP binding 
pocket, which become exposed when the kinase is maintained in a DFG-out state. 
Therefore Type II kinase inhibitors are potentially more selective. Moreover, there is 
also the greater conformational variability observed between kinases in their inactive 
states [205]. Imatinib is an example of a type II inhibitor, which binds to the active site 
of ABL and stabilises the DFG-out conformation [206]. Activity of pseudokinases may 
be regulated by conformational transitions, which are potentially targetable with small 
molecule inhibitors [207]. Crystal structure analysis of the RNas L pseudokinase 
domain (which is catalytically inactive) adopts an active-like DFG-in conformation 
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when bound to AMP–PNP, which is a non-hydrolyzable ATP analogue. In the absence 
of AMP-PNP the pseudokinase domain reverts to an inactive conformation. 
Homodimerization of the RNase domain only takes place when the pseudokinase 
domains are bound to AMP-PNP and maintained in an active conformation [208].    
1.6.2 Allosteric targeting of kinases 
Allosteric or type III inhibitors exploit alternate binding pockets outside the active site, 
which can be specific to particular kinases, thus the potential for exquisite selectivity 
can be enhanced. Binding of compounds distal to the ATP-binding pocket can drive 
conformational changes. In this regard type III can indirectly influence catalytic activity 
and indeed non-catalytic regulatory (such as scaffolding) functions [209]. For instance, 
the PIF-pocket, by the αC-helix of PDK1 has been targeted [210]. In AKT, the N-
terminal PH domain binds intramolecularly with the kinase catalytic domain, stabilising 
the kinase in an inactive conformation (section 1.2.1.1). Similar to PDK1 allosteric 
inhibitors, AKT inhibitors, including MK2206 stabilise the inactive structure of the PIF-
pocket by binding to the αC-helix, which locks the PH domain to the N-lobe of the 
kinase domain [211]. These inhibitors did not arise from the fruits of structure guided 
design, but rather the binding modes and mechanisms of inhibition were discovered 
serendipitously.   Although no proof of concept for type III inhibition currently exists in 
the public domain for pseudokinases, the growing number of pseudokinases observed 
to undergo ‘kinase-like’ conformational changes to appropriate cellular signalling is a 
promising indication for the potential of this area in biomedical research. 
1.6.3 Covalent inhibitors 
The kinase-activating L858R EGFR mutation is highly responsive to first- generation 
EGFR inhibitors, including gefitinib and erlotinib. However, these patients often 
relapse due to a secondary, drug-resistant mutation in EGFR whereby the gatekeeper 
threonine is converted to methionine (T790M). This second mutation does not negate 
the binding of compounds gefitinib and erlotinib, but rather increases the kinase 
domains affinity for ATP, which means ATP competitive inhibitors are no longer 
effective [212]. Therefore, there has been a concerted effort to generate irreversible 
covalent inhibitors for EGFR in NSCLC. The majority of covalent compounds are 
adapted versions of previously established small molecule inhibitors. With the use of 
crystal structure analysis in tandem with in sillico structure-guided design, kinase 
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inhibitors have been modified by the addition of an electrophilic so called ‘warhead’ to 
enable targeting of specific nucleophilic thiol groups of Cys residues within the kinase 
domain [213]. For instance, analysis of the crystal structure of the quinazoline based 
ATP-competitive inhibitor gefitinib bound to EGFR (PDB: 3UG2), revealed that the thiol 
group of C797 is ~7 Å from the oxygen atom in the oxypropyl morpholine substituent, 
thus suggesting that an electrophilic ‘warhead’ at this position may be suitable for 
covalent bond formation. Indeed, this endeavour has resulted in the development of 
several type IV covalent kinase EGFR family kinase inhibitors, including afatinib and 
neratinib [213]. Crystal structure analysis confirmed covalent bonding of afatinib to 
EGFR while the non-covalent binding mode, typical of reversible binding by gefitinib, 
of hydrophobic and hydrogen bonding interactions were maintained [213]. 
Covalent inhibitors have various potential advantages over reversible inhibitors.  
Specificity may be enhanced via the targeting of a unique Cys residues in the target 
kinase. Secondly, the reactions are more energetically favourable, requiring lower 
inhibitor concentrations that achieve better efficacy. Furthermore, after covalent 
modification of the target terminal inhibition is usually achieved, meaning that new 
protein synthesis must occur in order to re-establish signalling activity. As targeted 
cysteine residues are not uniformly conserved amongst kinases and pseudokinases 
[207], they act as a specificity filter to limit inhibitor promiscuity. One downside is that 
irreversible inhibitors risk forming concentration dependent off-target adducts with 
reactive cysteines of unrelated proteins [207]. Indeed, proteome mapping has 
revealed that third generation covalent EGFR family kinase inhibitors have distinct off-
targets. Patients often relapse due to a secondary, drug-resistant mutation in EGFR 
whereby the gatekeeper threonine is converted to methionine (T790M), which is where 
covalent inhibitors may become an effective therapeutic strategy. In particular, the 
FDA-approved drug osimertinib was found to covalently modify cathepsins in cell and 
animal models, which correlated with lysosomal accumulation of the compound [214]. 
Indeed, exploiting off targeting effects of covalent inhibitors could lend support to 
finding novel drug leads for pseudokinses [207].  
The LUX-Lung trials are the first global, head-to-head trials comparing third- and first-
generation EGFR-directed therapies (afatinib and erlotinib) for patients with EGFR 
mutation-positive NSCLC. The LUX-lung 8 phase III clinical trial compared the 
irreversible quinazoline based inhibitor afatinib with the quinazoline based type I ATP-
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competitive inhibitor erlotinib, as second-line treatment for patients with advanced 
NSCLC. Progression free-survival was significantly longer with afatinib than with 
erlotinib (median 2.4 months compared to 1.9 months) [215]. The overall survival was 
also significantly improved with afatinib compared to erlotinib. The median overall 
survival for afatinib was 7.9 months and was 6.8 months for the erlotinib group. 
Resistance to afatinib inevitably arises due to a C797S kinase domain mutation. 
Interestingly, reversible compounds inhibit the C797S for which the reported third-
generation EGFR candidates fail due to lack of potency from the formation of the 
covalent bond [213].   
An advantage of analysing binding of covalent inhibitors is the prospect to detect 
covalent modification by mass spectrometry. Analysis by isothermal titration 
calorimetry (ITC), however, may be complicated when considering slower off-rates 
due to time dependent irreversible covalent binding. Mass spectrometry was used to 
confirm the covalent modification of HER3 by TX1-85-1. Addition of TX1-85-1 to 
recombinant HER3 followed by proteolysis trypsin and subsequent tandem mass 
spectrometry (MS2) analysis revealed unique modification of Cys721 [216].  
 
1.7 Detecting small molecule interactions with pseudokinases 
1.7.1 Screening 
An effective method to screen canonical kinases with a known substrate would be to 
employ mobility shift assays, to observe percentage conversion of a fluorescent 
substrate peptide by the protein of interest, in the presence of candidate inhibitors. 
However, the majority of pseudokinases are poorly studied and specific targets are 
often unknown or ambiguous. Furthermore, most pseudokinases have very weak or 
no detectable catalytic output, which further limits the use of conventional assays. 
Employing in vitro kinase assays to assess pseudokinase activity faces various 
caveats, a major drawback being lack of sensitivity, especially when distinguishing the 
presence of potential minor quantities of contaminating kinases that may otherwise 
lead to incorrect conclusions. More effective avenues of screening, that many 
pseudokinase researchers have turned to, employ biophysical approaches. 
Biophysical tools are essential for the discovery, development, and characterisation of 
therapeutic proteins and drugs. Biophysical techniques are cheaper, less time 
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consuming and assay complexity is reduced while providing good information content 
data to bolster the efficiency of drug discovery campaigns. 
It is currently estimated that ~40% of all pseudokinases possess detectable nucleotide 
binding activity, and this was established by means of a differential scanning 
fluorimetry (DSF) assay, which is a thermal shift assay (TSA) [58]. Importantly, the 
assay monitors the thermal denaturation of the major protein species, so any minor 
contaminants, including co-purified protein kinases, which would lead to misleading 
results in radiometric in vitro 32P kinase assays, do not contribute to the signal. With 
the recently solved TRIB1 crystal structure, efforts have been made to discover 
chemical ligands that modulate its important regulatory conformations. Inhibitors could 
serve as molecular probes and perhaps as potential therapeutic leads. TRIB1 was 
recently screened by DSF employing the protein kinase inhibitor set 1 (PKIS1). PKIS1 
is a library of 367 ATP-competitive kinase inhibitors, covering ~30 chemotypes 
originally developed to target 24 distinct protein kinases. A subset of dual Angiopoietin-
1 receptor (TIE-2) and vascular endothelial growth factor receptor (VEGF) 
benzimidazole based inhibitors were discovered to increase TRIB1 thermal stability. 
Interestingly, a thyophene based PLK inhibitor, GW804482X, reduced TRIB1 thermal 
stability, rather than stabilising the protein, which is potentially indicative of compound 
binding to alternate TRIB1 conformations. Additionally, MLKL was screened, using 
DSF, against the PKIS1. From this screen the previously discussed compound 1 was 
discovered [217].   
1.7.2 Validation of potential ‘hits’ 
Choice of screening procedure is important and understanding the limitations of 
particular assays is vital. TSAs can be sensitive to different mechanisms of 
interference, such as from fluorescence from compounds that may disrupt readouts 
[218], redox cycling of compounds [219], compounds that induce protein aggregation 
[220], metal chelating compounds and metal contaminants [221]. The probability of 
misidentifying certain inhibitors as genuine hits is reduced by employing downstream 
confirmatory assays.   
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1.7.2.1 Microscale thermophoresis (MST) 
Thermophoresis is also known as the Ludwig–Soret effect and is defined as the 
movement of molecules through a temperature gradient [222]. The properties that 
determine the rate of movement are charge, size and hydration shell [223]. Any of 
these properties can change in a protein upon binding to a ligand. This measurement 
in change of thermophoresis can be used to calculate the affinity of the interaction 
between binding partners, be they protein–protein, antibody–antigen, protein–DNA, 
protein–RNA and protein compound [223]. The company NanoTemper have 
commercialised Monolith instruments to measure the thermophoresis of biomolecules, 
which uses an infrared laser to heat the sample loaded within a capillary. As the laser 
is focused it produces a localised microscopic temperature gradient with a heat range 
of 2–6 °C, and ligand–target protein complexes demonstrate a different movement 
velocity through the temperature gradient compared with unbound molecules. The 
movement induced by the laser is monitored via fluorescence of the target protein or 
from a label previously bound to the protein, such as attachment of a fluorescent dye 
coupled to nitrilotriacetate (NTA) to modify a 6His-tag [223].  
The use of MST is increasingly being reported in fragment-based drug discovery for 
many kinases, such as p38α [224] and MEK1, [225] and bromodomain 9 (BRD9) [226]. 
In a study of MEK1 and BRD9, MST was used to confirm the binding of fragments 
identified first by surface plasmon resonance (SPR) and DSF. Interestingly, MST was 
able to identify additional hits not detected in the first line of screening.    
1.7.2.2 Isothermal titration calorimetry (ITC) 
ITC is a reliable method to determine the Kd of compound binding and is at present 
the gold standard for elucidating binding free energies (ΔG) into enthalpy (ΔH) and 
entropy (ΔS) contributions. Both the binding constant Kd, and the stoichiometry can 
be calculated while ΔG and ΔS are then derived by calculation from the primarily 
measured properties [227]. However, for ITC analysis there is a requirement of a 10-
15 fold excess of either one of the components (protein or compound). The vast 
majority of small molecule inhibitors are non-polar and thus very poorly soluble in 
conventional protein assay buffers), which usually means that very high μM 
concentrations of protein are required (<100 μM). Analysis by ITC would not be 
feasible if the protein of interest is unstable at high concentrations.  
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1.7.2.3 Mass spectrometry (MS) 
Ion mobility-mass spectrometry (IM-MS) can permit the detection of even low 
abundant species in complex samples. Proteins can retain their native folded structure 
in the gas phase and even if a protein ligand complex is maintained only by 
hydrophobic interactions, they can retain integrity [228]. Elucidation of the mass to 
charge ratio (m/z) provides information about stoichiometry, connectivity, and topology 
of protein interactions. At the same time, the charge state after electrospray ionization 
(ESI) can be analysed to give indications of protein shape 5. The affinity between a 
protein and compound can also be determined with results that are consistent with 
established solution-phase methods [229]. 
In IM-MS the protein-ligand complex is ionised by nano electrospray ionization (nESI), 
which results in the formation of an intact complex with few net charges [230]. 
Subsequently the ions are move through an ion mobility cell guided by a weak electric 
field filled with an inert gas (such as helium or nitrogen). Smaller ions experience fewer 
collisions with the gas and thus migrate within the cell at a higher velocity. Finally, the 
ionised sample enters a quadrupole and/or time-of-flight mass analyzer (ToF) followed 
by a detector. As a result, the investigated molecules are not only separated according 
to their m/z as in conventional MS but also according to their size and shape [231]. 
1.8 Aims of this thesis 
The central hypothesis of my thesis is that TRIB2 can bind to small molecule kinase 
inhibitors which in turn may influence TRIB2 functions in cellular signalling. Chapter 3 
discusses my exploration of TRIB2 biochemistry by analysing whether, like TRIB1, a 
regulatory interaction exists between the C-terminal tail region and TRIB2 
pseudokinase domain. By employing a DSF assay, I deduce that TRIB2 can bind to 
certain small molecule kinase inhibitors. The remainder of chapter 3 is dedicated to 
validating the mechanisms of compound binding using a combination of techniques, 
including site-directed mutagenesis, MST, MS, molecular docking and molecular 
dynamic simulations. In chapter 4, I evaluate the effects of TRIB2 interacting small 
molecules in human cells, including an AML-derived cell line. In chapter 5, I discuss 
the conclusions of my work, and some potential future applications.    
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Chapter 2: Materials and methods 
2.1 Chemicals, reagents and antibodies 
The pET Ek/LIC bacterial expression vectors were purchased from Novagen and 
pOPIN bacterial expression vectors from Addgene. The pGEx-6P-1 vector encoding 
C/EBPα was a gift from Dr Karen Keeshan (University of Glasgow, Great Britain). The 
pET Ek/LIC bacterial expression vectors encoding TRIB1 84-343 and TRIB1 84-372 
were a gift from Peter Mace (University of Otago, New Zealand) The Flp-In T-REx 
system (for mammalian expression) including parental cells, pcDNA5/FRT/TO, and 
pOG44 plasmids were purchased from Invitrogen. Restriction enzymes were 
purchased from New England Biolabs (NEB). KOD polymerase was sourced from 
Novagen. All primers were purchased from Integrated DNA Technologies (IDT). All 
buffers were made using Milli-Q water unless otherwise indicated. 
Tetracycline and doxycycline, MG132, AICAR and chloroquine were purchased from 
Sigma-Aldrich. Afatinib, neratinib, osimertinib, ibrutinib, erlotinib, lapatinib, TAK-285, 
BI2536, BI6727, gefitinib and bortezomib were purchased from LC laboratories or 
Selleck. Synthetic stapled C-terminal peptides were a gift from Dr Eileen Kennedy 
(University of Georgia, USA). 
Total AKT, pSer 473 AKT, pThr 308 AKT, total ERK1/2, dual pThr 202/pTyr 204 
ERK1/2, CDC25C, total acetyl coenzyme A carboxylase (ACC), pACC Ser79, cleaved 
Caspase 3 and α-tubulin antibodies were purchased from New England Biolabs. 6His-
HRP and α-FLAG antibodies were purchased from Sigma-Aldrich, Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibody was purchased from Proteintech and a 
polyclonal rabbit α-TRIB2 antibody was raised towards a unique N-terminal human 
TRIB2 sequence and affinity purified prior to evaluation with recombinant TRIB2 and 
a variety of human cellular extracts.  
The PKIS chemical library (designated as SB, GSK or GW compounds) comprises 
367 ATP-competitive kinase inhibitors, covering ~30 chemotypes (~70% with 
molecular mass <500 Da and clogP values <5) that were originally designed as ATP-
competitive inhibitors of 24 distinct protein kinase targets [232]. Compounds were 
stored frozen as 10 mM stocks in dimethyl sulphoxide (DMSO) in 96-well plates.  
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2.2 Transformation of E.coli and plasmid purification 
2.2.1 Generation of chemically competent E. coli 
TOP10 and BL21(DE3)pLysS E. coli strains were streaked onto Luria-Bertani (LB) 
agar plates from a glycerol stock and grown for 18 hours in an incubator at 37 °C. 
From these plates, single colonies were grown in 50 mL of LB media for a further 18 
hours in a shaker incubator (250 rpm) at 37 °C. From the 50 mL subcultures, 2 mL of 
bacteria in suspension were added to 200 mL of fresh LB media and grown to an 
OD600 of 0.6. The cells were then centrifuged at 5000 g for 10 minutes, to pellet the 
cells. The LB media was decanted leaving the pelleted bacteria, which were re-
suspended in buffer 1 (100 mM rubidium chloride, 50 mM manganese chloride, 30 mM 
potassium acetate, 10 mM calcium chloride and 15% (v/v) glycerol). The cell 
suspensions were incubated on ice for 5 minutes and subsequently centrifuged once 
again to pellet the bacteria. The supernatant was decanted and the bacteria was re-
suspended in buffer 2 (10 mM MOPS, 10 mM rubidium chloride, 75 mM calcium 
chloride and 15% (v/v) glycerol) and incubated for a further hour on ice. The chemically 
competent bacteria were then aliquoted at a volume of 200 µL into sterile 1.5 mL 
ependorf tubes, flash frozen in liquid nitrogen and stored at -80°C.     
2.2.2 Transformation protocol 
Chemically competent TOP10 were transformed in order to amplify plasmid stocks for 
purification. Chemically competent BL21(DE3)pLysS was used for protein expression. 
In a 1.5 mL sterile ependorf tube, 20 ng of plasmid DNA was added to 50 µL of 
chemically competent E. coli and incubated on ice for 30 minutes. The mixture was 
subsequently transferred to a water bath, heated to a temperature of 42°C for 30 
seconds in order to initiate bacterial heat shock. The bacteria were then placed on ice 
and left to cool for 2 minutes. 250 µL of  SOC media (2% tryptone, 0.5% yeast extract, 
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added 
to the transformation mixture and incubated at 37°C for 1 hour in a shaker incubator. 
Lastly, 50 µL of bacterial suspension in SOC media was spread on an agar plate with, 
depending on the plasmid, appropriate antibiotic selection markers and incubated for 
18 hours at 37°C.  
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2.2.3 Plasmid purification and sequencing 
Chemically competent TOP10 E. coli were transformed with plasmids and grown on 
agar plates with specified antibiotics for selection. Single colonies were cultured in 5 
mL of LB liquid media for 18 hours and then centrifuged for 5 minutes at 5000 g in 
order to pellet transformed cells. The supernatant was removed and these cells were 
treated sequentially by the constituents of the QIA Spin Miniprep kit, as described in 
the Manufacturer’s instructions (Qiagen). 
Once purified, the concentration of plasmid DNA was quantified by detecting UV 
absorbance at 260 nm, employing a NanoDrop 2000c system (Thermo Fisher 
Scientific). Subsequently 800 ng of plasmid DNA was mixed in a total reaction volume 
of 10 μL with 10 pmol/µL of appropriate sequencing primer (to generate between 500 
and 1200 bp of readable sequence) before Automated Sanger Sequencing (GATC 
Biotech).   
2.3 Mutagenesis 
2.3.1 Site-directed mutagenesis 
To specifically mutate a residue in TRIB2, primers were used that introduce 
designated mutation(s) into the coding sequence. Primers were designed to 
incorporate codons for the desired mutation(s), which were flanked either side by ~15 
bp of coding DNA. The reverse primer was the exact reverse complement of the 
forward primer, so that the entire plasmid, encoding TRIB2, was amplified. The forward 
primers for Cys mutants were:  
C96S:5’gtgtttgatatcagctcctaccaggaatccctg. 
C104S:5’gaatccctggcaccgtccttttgcctgtctgct. 
C104Y:5’gaatccctggcaccgtacttttgcctgtctgct. 
The general polymerase chain reaction (PCR) contained: 10 ng Plasmid template, 0.1-
0.5 μM of forward/reverse primer (optimised case by case), 1 μL KOD hotstart DNA 
polymerase (NEB) (2000 U/ml), 5 μL 10x KOD Buffer (NEB), 10 mM MgCl2 and 5 μL 
10x dNTP mixture (Final concentration 50 μM of each) in final reaction volume of 50 
μL (made up with nuclease free water). For the cycling parameters: Hot start at 95°C 
for 1 minute. Annealing temperature (1 °C bellow the specified primer melting 
temperature) for 30 seconds followed by amplification at 70°C for 16 minutes. These 
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parameters were cycled 30 times before a final hold at 70°C for 10 minutes. The PCR 
products were incubated with DpnI (20U) for 1hr at 37°C to eliminate the template 
(purine methylated) DNA. The PCR products were subsequently transformed into the 
TOP10 E. coli and expanded overnight in 3 mL of LB after single colony selection. 
After purification of plasmids by QIA miniprep QuickSpin Kit (Qiagen), successful 
mutagenesis was determined by Sanger Sequencing (GATC Biotech). 
2.3.2 Truncation mutants 
Primers were designed to flank the desired coding region of DNA for amplification, 
whilst incorporating the required sequences for LIC cloning. For the generation of 
pET30 encoding FLAG-His-TRIB2, the forward primer incorporated a sequence which 
codes for FLAG peptide (GACTACAAAGACGATGACGACAAG) after the start codon. 
PCR products were analysed by agarose gel electrophoresis, purified by gel extraction 
(Qiagen) and the DNA then quantified by UV absorbance detected employing a 
NanoDrop. 
2.3.2.1 Agarose gel electrophoresis and purification of cDNA fragments 
After PCR amplification DNA products were isolated using electrophoresis in 1% (w/v) 
agarose gels. 1 g of agarose (Sigma-Aldrich) was added to 100 mL of Tris-acetate-
EDTA (TAE) buffer and dissolved by heating in a microwave. After slight cooling the 
intercalating DNA stain ethidium bromide was added to a final concentration 5 μg/mL. 
The 1% agarose solution was added to a gel cast and left to solidify on cooling. The 
gel was placed in a tank containing 1% TAE buffer and the DNA was subsequently 
electrophoresed at a constant field strength of 6.7 Vcm-1 for ~45 min. A UV 
transilluminator was employed to visualise the migrated DNA with reference to a 1-10 
kb DNA ladder, (New England Biolabs). The visualised DNA fragments were cut from 
the gel with a sterile scalpel and transferred to sterile 1.5 mL ependorf tubes. DNA 
was extracted and purified using the QIAquick Gel Extraction kit, as described in the 
manufacturer’s protocol (Qiagen). The DNA content was then quantified by UV 
absorbance, employing a NanoDrop. 
2.3.2.2 Ligation-Independent Cloning (LIC) 
The purified PCR products (0.2 pmol), flanked by the LIC overhangs, were incubated 
with 0.4 μL T4 DNA polymerase (3000 U/ml) with 2 µl 10X NEB buffer 2, 100 mM DTT, 
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0.5 µl dATP (100 mM) and 0.2 µL of 100X BSA stock solution with a final reaction 
volume of 20 μL for 30 minutes at ambient temperature. The reaction mixture was 
subsequently incubated for 20 minutes at 75°C in order to inactivate the polymerase.   
The pET30 vector was linearized and treated with T4 polymerase, firstly by incubation 
with 5 µl 10X NEB buffer 3, 5 µg pET30/LIC vector DNA, 2.5 µL BsaI restriction 
enzyme (10U), and nuclease free water to a volume of 50 µL. The BsaI digested vector 
was resolved by agarose gel purification and purified using gel extraction (Qiagen). 
600 ng BsaI-digested pET30 vector was then treated with T4 DNA polymerase as 
follows: 2 µL 10X NEB buffer, 600 ng BsaI-digested pET30, 0.5 µL dTTP (100 mM) 1 
µL DTT (100 mM), 0.2 µL of 100X BSA and 0.4 µL of T4 DNA polymerase (3U) were 
incubated to a volume of 20 µL in nuclease free water for 30 minutes at ambient 
temperature. Then, to inactivate the polymerase, the reaction mixture was incubated 
for 20 minutes at 75°C. 
In order to anneal the linearized vector and treated insert, they were mixed and 
incubated for 5 minutes at ambient temperature. Next 1 µl of EDTA (25 mM) was 
added followed by a further 5 minute incubation at ambient temperature. The plasmids 
were subseqntly transformed into TOP10 E. coli form amplification. 
2.4 Recombinant protein expression 
Bacterial expression vectors were transformed into) BL21(DE3)pLysS and streaked 
onto agar plates (with appropriate selection markers) and incubated for 18 hours at 
37°C. All TRIB2 and TRIB1 proteins and PKA were encoded in pET30 vectors, which 
have resistance to kanamycin (50 µg/mL). The pGEx-6P-1 vector encoding C/EBPα 
carries resistance to ampicillin (50 µg/mL). BL21(DE3)pLysS possess an additional 
plasmid, which expresses T7 lysozyme and carries a resistance to chloramphenicol 
(34 µg/mL). For expression of each protein, a single colony from the agar plate was 
transferred to 100 mL of LB media (with antibiotics) and incubated for a further 18 
hours at 37°C in a shaker incubator (250 rpm). The subcultures of E. coli were then 
transferred to larger volumes of LB media (10 mL of subculture per litre of LB media). 
For expression of each protein this was between 4 and 8 litres of culture medium. The 
flasks were incubated at 37°C in a shaker incubator until bacteria reached an OD600 
of 0.8 nm, at which point protein expression in was induced by the addition of sterile 
isopropyl-1-thio-β-D-galactosidase (IPTG) at a final concentration of 0.2 mM. The 
cultures were incubated at 18°C for 16 hours in a shaker incubator rotating at 250 rpm. 
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Subsequently the cultures were centrifuged at 5000 g for 10 minutes and the bacteria 
pellet was collected. 
2.5 Recombinant protein purification 
The bacterial pellets obtained (section 2.4) contained expressed protein, which were 
subsequently lysed. Proteins were then purified using a combination of techniques.  
2.5.1 Lysis of E. coli 
For purification of all TRIB2 proteins, from pET30 plasmids, E.coli was lysed in ice 
cold Bicine pH 9.0 lysis buffer (20 mM Bicine pH 9.0, 300 mM NaCl, 0.1% Triton X-
100, 10 mM imidazole, 1 mM DTT, 10% glycerol and a cOmplete protease inhibitor 
cocktail tablet (Roche)). For purification of all other proteins E coli was lysed in 20 mM 
Tris-HCl pH 7.4 (with all other buffer components the same). The cells suspended in 
the lysis buffer were then sonicated for 30 second intervals on ice at an amplitude of 
16 microns using a 3 mm exponential microprobe attached to a MSE Soniprep 150 
plus motor unit. After sonication, the samples were centrifuged at 4°C for 1 hour at 
5525 x g to pellet cellular debris. The supernatant of the cell lysate contained the 
expressed protein, which was subsequently purified by immobilised metal affinity 
chromatography (IMAC) or glutathione-S-transferase (GST) pull down. TRIB2, TRIB1 
and PKA proteins all possessed 6His-tags and were therefore amenable to purification 
by IMAC. C/EBPα on the other hand possessed a GST tag.    
2.5.2 IMAC of recombinant His tagged proteins 
 After centrifugation to remove cellular debris the cleared lysate was filtered and then 
applied to a 5 mL Ni Sepharose His Trap HP column (GE Healthcare), which had 
previously been  equilibrated in 5 column volumes of filtered, degassed wash buffer 
(20 mM Bicine pH9.0/ 20 mM Tris-HCl pH 7.4, 500 mM NaCl, 20 mM imidazole, 1mM 
DTT) The column was subsequently washed with 5 further column volumes of wash 
buffer followed by elution of theHis-tagged protein with 10 mL of elution buffer (20 mM 
Bicine pH9.0 / 20 mM Tris-HCl pH 7.4, 100 mM NaCl, 300 mM imidazole, 1 mM DTT 
and 10% glycerol). Throughout the elution process 500 μL fractions were collected. 
Samples of the flowthrough were also collected. All fractions were immediately 
transferred to ice and 5 μL samples taken, which were analysed by SDS-PAGE (see 
section 2.8). 
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2.5.3 Purification of full length GST-p42 C/EBPα 
Following cell lysis, instead of employing IMAC, GST-His-C/EBPα was purified by GST 
pull down. Glutathione Sepharose beads were incubated with the cleared lysate for 2 
hours at 4°C under gentle agitation. The beads, with bound GST-His-C/EBPα, were 
pelleted by centrifugation at 1000 g followed by resuspension in 30 column volumes 
of wash buffer (20 mM Tris pH 7.4, 100 mM NaCl, 1 mM DTT and 10% glycerol). This 
process was repeated 3 times. GST-C/EBPα was subsequently eluted from the beads 
with the addition of 10 mM reduced glutathione in 20 mM Tris pH 7.4, 100 mM NaCl, 
1 mM DTT and 10% glycerol in 3 500 μL fractions, which were analysed by by SDS-
PAGE.  
2.5.4 Size exclusion chromatography 
After IMAC or GST pull-down proteins were further purified by size exclusion 
chromatography in order to isolate monomeric proteins and exchange from the 
IMAC/GST elution buffer to a buffer suitable for biochemical analysis. A Superdex 200 
16/600 column (GE Healthcare)  set up with an Äkta FPLC system (GE Healthcare) 
and a Frac-920 (GE Healthcare) was equilibrated with 2 column volumes of buffer (20 
mM bicine pH 9.0 / 20 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 mM DTT, 10% 
glycerol).The protein applied to the column at a flow rate of  0.5 mL/min. 1.5 mL 
fractions were collected and the elution volume was used to estimate the molecular 
weight of the eluted proteins by comparing their elution volume with reference to 
Molecular Weight standards (Chapter 3). 5 μL samples of the fractions, deduced to 
contain protein from UV absorbance, were analysed by SDS-PAGE.     
2.6 SDS-PAGE 
SDS-PAGE was performed in order to visualise the purity and molecular weight of 
purified proteins. SDS-PAGE was also performed prior to electrophoretic transfer to 
nitrocellulose during immunoblot analysis (section 2.9). Proteins were denatured in 5x 
SDS sample buffer (0.25 M Tris-HCl pH 6.8, 0.25% bromophenol blue, 500 mM DTT, 
5% SDS and 50% glycerol) to a final concentration of 1% SDS and heated to 90°C for 
2 minutes before being subjected to electrophoresis. To detect proteins bellow 32 kDa 
12% polyacrylamide gels were used. To detect proteins predicted to be between 32 
and 80 kDa 10% polyacrylamide gels were used. To detect proteins above 80 kDa, 
such as ACC, 8% gels were employed. Polyacrylamide gels resolved proteins for ~1 
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hour minutes (depending on the percentage) with an electric field strength of 20 Vcm-
1 in running buffer (25mM Tris-HCl, 190mM glycine and 0.1% SDS). Subsequently, 
the resolving gel, containing the proteins, was immersed and incubated in Coomassie 
stain (0.2% Brilliant blue R-250, 7.5% acetic acid, 50% methanol) for ~1 hour with 
agitation. The stained gel was then washed for 16 hours using destain buffer (H20, 
methanol and acetic acid 50/40/10 v/v/v). 
2.7 Bradford assay 
Bovine serum albumin (2mg/mL) (Thermo Scientific) was employed to produce protein 
standards and diluted to concentrations ranging between 0.1 and 0.6 mg/mL and used 
to generate a standard curve in a quantification assay. 200 μL of Coomassie Plus 
Protein Assay Reagent (Thermo Scientific), was mixed with 5 μL of sample. The 
absorbance at 595 nm was detected in a spectrophotometer in a 96-well plate. The 
absorbance of BSA standards were measured relative to a blank (BSA and buffer) and 
a standard curve was plotted (Figure 2.1) to allow estimation of protein concentration 
for unknown samples. 
 
 
Figure 2.1 Bradford Assay Standard Curve for determination of protein concentration. Increasing 
concentrations of BSA were incubated with the Coomassie based reagent before reading the optical 
absorbance at 595 nm in a spectrophotometer. A standard curve was plotted in Excel. 
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2.8 Immunoblotting 
The protein content of samples was quantified by Bradford assay prior to the addition 
of sample buffer and boiling. Samples were subjected to electrophoriesis by SDS-
PAGE. The proteins within the resolving gel were then blotted onto a nitrocellulose 
membrane by electrophoretic transfer. To this end, the resolving gel and nitrocellulose 
membrane were sandwiched together with blotting pads within a cassette and placed 
into a tank containing chilled transfer buffer (25mM Tris, 190mM glycine, 0.1% SDS, 
20% methanol). For transference the current was set to 0.28 amps. The membranes 
with bound proteins were incubated in 5% non-fat milk (Marvel) in Tris-buffered saline 
and 0.1% Tween 20 (TBS-T) for 30 minutes with agitation on a seesaw rocker. 
Subsequently the blocked membranes were incubated for 12 hours at 4°C with primary 
antibody at indicated dilutions in 5% non-fat milk in TBS-T on a rocker. The 
membranes were washed for 5 minutes 3 times in TBS-T and the secondary antibody, 
also diluted to a specific concentration in 5% non-fat milk TBS-T, was incubated with 
the membrane for a further 1 hour at room temperature. The membranes were again 
washed for 5 minutes 3 times in TBS-T before being placed into a developing cassette. 
ECL or ECL select (GE Healthcare) developing agent was added to the membranes 
in accordance with the manufacturer’s protocol and films were exposed and developed 
for the indicated time periods. Immunoblots were quantified using ImageJ software. 
2.9 Buffer exchange of recombinant proteins 
Proteins were first concentrated to 2 mg/mL by centrifugation using a Vivaspin 2 (10 
kDa molecular weight cut off) concentrator column (GE Healthcare). A HiTrap 5 mL 
desalting column (GE Healthcare) was then equilibrated with 5 column volumes of the 
indicated buffer and 2 mL of concentrated protein was loaded by means of a syringe. 
Subsequenty, buffer was passed through the column, employing an Äkta system and 
500 μL fractions were collected. The fractions that corresponded to the peak on the 
elution profile (monitored by the absorbance at 280nm) were assessed by Bradford 
assay and those with sufficient amounts of protein (>0.2 mg/mL) were pooled. The 
proteins were then analysed by SDS-PAGE prior to biochemical assays.   
2.10 TRIB2-C/EBPα interaction ‘pull down’ assays 
A total of 20 μL of GST beads were equilibrated in 20 mM Tris-HCl pH 7.4, 100 mM 
NaCl and 1 mM DTT. Subsequently 10 μL of the beads were incubated with 10 μg of 
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GST-His-tagged C/EBPα, the other 10 μL of beads with 10 μg of recombinant GST 
and incubated at 4°C for 2 hours while mixing on a carousel. The GST beads that had 
been incubated with C/EBPα were washed 3 times with wash buffer (20 mM Tris-HCl 
pH 7.4 and 100 mM NaCl), to remove unbound protein, before being aliquoted into 2 
separate ependorf tubes, each containing 5 μg of TRIB2 with a total reaction volume 
of 25 μL. The 10 μL of GST beads that had not been pre-incubated with recombinant 
GST were similarly divided into 2 eppendorf tubes, each containing 5 μg of TRIB2, 
with a total reaction volume equalling 25 μL. These mixtures were then incubated at 
4°C for 2 hours under agitation on a carousel. Each reaction mixture was centrifuged 
for 1 minute at 1000 x g in order to separate out the GST beads. The supernatant was 
discarded and the beads were washed 3 times by re-suspension and centrifugation in 
wash buffer. After washing, 20 μL of elution buffer (20 mM Tris pH 7.4, 100 mM NaCl, 
10 mM reduced glutathione and 1 mM DTT) was added to each reaction and mixed 
before being centrifuged once more at 1000 x g, after which the supernatants were 
collected and added to 5 x sample buffer prior to 5 minutes of boiling. Samples were 
electrophoresed by SDS-PAGE and then analysed by western blotting with an α-6His 
antibody conjugated to HRP, with chemiluminescence detected after the application 
of ECL reagent.   
2.11 Differential scanning fluorimetry PKIS screening and analysis of 
compound binding 
DSF experiments were performed using an Applied Biosystems StepOnePlus Real-
Time PCR instrument using a standard DSF procedure previously developed and 
validated for the analysis of kinases [46, 48] and pseudokinases [47]. In order to 
generate a thermal melting profiles and assess the melting temperature of proteins 
(including WT TRIB2, all TRIB2 mutants and PKA), buffer exchanged proteins (in Tris-
HCl pH 7.4, 100 mM NaCl, 1 mM DTT and 10% glycerol) were mixed with buffer (Tris-
HCl pH 7.4, 100 mM NaCl, 1 mM DTT and 10% glycerol) and SYPRO Orange dye 
(Inivtrogen), which was used as the fluorescence probe. In each reaction the final 
volume was 25 µL, the concentration of protein was 5 µM, the dilution factor of SYPRO 
Orange dye was 1:5000. The 25 µL reaction mixtures were dispensed into individual 
wells of a MicroAmp Fast Optical 96-well reaction plate (Applied Biosystems). For 
every assay at least 2 reaction mixtures were made for each condition and the average 
Tm taken. Mean Tm values were derived from three independent assays. The plates 
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were sealed with optical adhesive covers and the reaction mixtures were vortexed. 
Subsequently the plate was centrifuged for 10 seconds at 500 x g. The plate was 
placed into a real time PCR machine (Applied Biosystems StepOne Plus). The 
machine was set to measure florescence emitted from the sample as the temperature 
was increased (at a rate of 0.3°C/minute) starting from 25°C and ending at 95°C. 
Fluorescence readings were made at 530 nm. Each assay was performed in triplicate 
unless stated otherwise. The data was collected by the StepOne Software v2.1 and 
using a combination of Microsoft Excel and GraphPad Prism 6, the detected 
fluorescence readings for each temperature increment were averaged and thermal 
denaturation curves generated. The thermal profiles were normalised so that the 
lowest value was assigned as 0% and the largest fluorescence reading as 100%. Only 
the melting curve generated by the protein was analysed; temperatures before and 
after the melting profile were disregarded. Linear regression analysis was employed 
by means of fitting the Boltzman sigmoidal equation to the melting curves, which 
allowed the Tm to be deduced. The Tm value determined, being the temperature at 
which 50% of the protein had become denatured.  
In order to analyse the effects of ATP, EDTA and divalent cations on TRIB2, TRIB2 
mutants and PKA stability, the DSF assay was employed to deduce the change in Tm 
values between a buffer control and reaction mixture containing ATP/EDTA/divalent 
cations; this temperature change was referred to as the ΔTm. The reaction mixtures 
were at a final volume of 25 µL, comprising 5 µM of protein, 1:5000 Sypro Orange dye 
and the additions of ATP (10 mM) EDTA (1 mM) and/or MgCl2 (1 mM). The 25 µL 
reaction mixtures were dispensed into individual wells of a MicroAmp Fast Optical 96-
well reaction plate and the experiment was conducted as described above. 
For initial screening, 20 µM of compounds were pre-incubated with 5 µM TRIB2 for 10 
minutes and then subjected to DSF analysis, which was initiated by the addition of 
fluorescent SYPRO Orange. The final concentration of DMSO was 2% (v/v) in all 
conditions. For dose-dependent thermal-shift assays a compound range was prepared 
by serial dilution in DMSO, and added directly into the assay to the appropriate final 
concentration. All control experiments contained 2% (v/v) DMSO, which had 
essentially no effect on TRIB2 stability. 
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2.12 In vitro 32P kinase assays 
Each reaction contained a final concentration of 5 µM of bacterially expressed His-
tagged TRIB2 in 20 mM bicine pH 9.0, 100 mM NaCl, 1 mM DTT, 10% glycerol, which 
was incubated with 1 mM ATP (2.2 µCi γ32P ATP) and either 10 mM of MgCl2 or 1 mM 
EDTA in a total volume of 40 µL. Each condition was performed in duplicate.  
The ATP was added prior to the start of the assays which were staggered to allow for 
termination at the stipulated time points. The assays were performed at 30°C whilst 
on a temperature-controlled Eppendorf shaking platform. The reactions were 
terminated by the addition of 5x SDS loading buffer and heated at 95°C for 5 minutes. 
30 µL of sample of each terminated assay was loaded into 10% SDS PAGE gel and 
the resolved for 60 minutes at 20 Vcm-1. TRIB2 was subsequently transferred to 
nitrocellulose membranes for western blotting and autoradiography analysis. The 
membranes were placed into a cassette that contained a reflector screen and an X-
ray film was placed on top for analysis by autoradiography. The cassette was placed 
in a -80°C freezer and left for seven days. The films were then developed and fixed 
following standard procedures. 
2.13 Microscale thermophoresis 
A Monolith NT.115 instrument (NanoTemper Technologies GmbH) was employed for 
MST analysis. His-TRIB2 was firstly labelled with a NanoTemper labelling kit; the 
fluorescent red dye NT-647 was coupled via N-Hydroxysuccinimide NHS chemistry to 
the N-terminal His-tag, placing the fluorophore away from the pseudokinase domain. 
The labelled TRIB2 was diluted to 5 μM with 20 mM Bicine pH 9.0, 100 mM NaCl, 5% 
glycerol, 0.05% Tween-20 and 2 % (v/v) DMSO. The concentration of TRIB2 was kept 
constant in the assay, while the concetrations of compounds (afatinib and TAK-285) 
were titrated between 1 nM and 50 μM. Near-saturation of binding was achieved, 
allowing for an affinity to be estimated for the reversible interactions of afatinib and 
TAK-285 with the fluorescent labelled His-TRIB2. 
2.14 Mass spectrometry 
Intact mass spectrometry was first used to evaluate the interaction between afatinib 
and TRIB2. Recombinant His-TRIB2 was incubated with afatinib in a 1:10 molar ratio 
for 15 minutes at 20°C, followed by desalting using a C4 desalting trap (Waters 
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MassPREP™ Micro desalting column, 2.1 × 5 mm, 20 μ m particle size, 1000 Å pore 
size). TRIB2 was eluted with 50 % (v/v) MeCN, 0.1 % (v/v) formic acid. Intact TRIB2 
mass analysis was performed using a Waters nano ACQUITY Ultra Performance liquid 
chromatography (UPLC) system coupled to a Waters SYNAPT G2. Samples were 
eluted from a C4 trap column at a flow rate of 10 µL/min using three repeated 0-100 
% acetonitrile gradients. Data were collected between 400 and 3500 m/z and 
processed using MaxEnt1 (maximum entropy software, Waters Corporation).  
In order to evaluate covalent binding of afatinib and neratinib to recombinant TRIB2 in 
vitro, MS2 analysis was employed. 50 µM of compounds were separately incubated 
with 5 µM of purified His-TRIB2 for 15 minutes at 20°C. The samples were then 
denatured denatured with 0.05 % (w/v) RapiGest SF (Waters, UK) and digested with 
chymotrypsin (1:20 protease:protein (w/w) ratio) for 16 h at 25 °C. The addition of 
triflouroacetic acid (TFA) up to 1 % (v/v) was employed to induce RapiGest hydrolysis, 
by incubation for 1 hour at 37 °C. Insoluble protein was cleared from the sample by 
centrifugation at 13, 000 x g for 20 minutes. The samples were then resolved using an 
UltiMate 3000 nano reversed-phase HPLC separation system (Dionex) coupled in-line 
with a Thermo Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific, Bremen, 
Germany). 500 fmol digested peptides were loaded onto the trapping column 
(PepMap100, C18, 300 μm × 5 mm), using partial loop injection, for 7 min at a flow 
rate of 9 μL/min with 2% (v/v) MeCN, 0.1% (v/v) TFA and then resolved on an 
analytical column (Easy-Spray C18 75 μm × 500 mm, 2 μm bead diameter column) 
using a gradient of 96.2% A (0.1% (v/v) formic acid (FA)): 3.8% B (80% (v/v) MeCN, 
0.1% (v/v) FA) to 50% B over 35 min at a flow rate of 300 nL/min. MS1 spectra were 
acquired over m/z 400 – 1500 in the orbitrap (60 K resolution at 200 m/z). Data-
dependent MS2 analysis was performed using a top speed approach (cycle time of 3 
s), using higher-energy collisional dissociation (HCD) and electron-transfer and 
higher-energy collision dissociation (EThcD) for fragmentation, with product ions being 
detected in the ion trap (rapid mode). Data were processed using Thermo Proteome 
Discoverer (v. 1.4) and spectra were searched in MASCOT against the E. coli IPI 
database with the added sequence of full-length 6His-TRIB2 (1-343). Parameters 
were set as follows: MS1 tolerance of 10 ppm, MS/MS mass tolerance of 0.6 Da, 
oxidation of methionine and afatanib binding at cysteine as variable modifications. 
MS2 spectra were interrogated manually by Samantha Ferries.   
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2.15 Molecular modelling and docking studies 
By using the TRIB1 crystal structure as a template (5CEM), SWISS-MODEL was used 
to generate a structural model of TRIB2 (UniProt ID: Q92519) containing the C-
terminal tail (residues 42-343), which was visulised in PyMOL. For molecular docking 
studies the modeled TRIB2 structure was energy minimized using the Rosetta Relax 
protocol [233] and the model with the lowest energy score from 100 potential solutions 
was used for docking. Subsequently, the chemical structures of afatinib (CID 
10184653) and neratinib (CID 9915743) were downloaded from PubChem and both 
compounds were docked using the PyMOL plug in AutoDock Vina [234] with an 
exhaustiveness of 1000, rigid body, and a full protein search space. A binding pocket 
formed between P-loop, αC-helix and the activation loop was the most frequently 
sampled site during blind docking. Compounds were docked to this putative docking 
site using the flexible side-chain covalent docking method implemented in Autodock 
[235]. The enamide group of each compound was covalently linked to the sulfhydryl 
group of Cys 96 and the rest of the compound was treated as a rigid side-chain to 
explore favourable binding poses, the vast majority of which converged on the same 
binding pocket. Each run generated 500 binding poses, which were visualized using 
PyMOL. 
2.16 Maintenance of human cell lines 
Adherent parental Flp-In T-REx-HeLa and parental Flp-In T-REx-HEK293 cells 
(Invitrogen) were cultured in Dulbecco’s Modified Eagle medium (DMEM) 
supplemented with (filter sterilised) 4 mM L-glutamine, 10 % (v/v) Foetal Bovine Serum 
(FBS), Penicillin and Streptomycin (Gibco). Pre-transfection (parental) HeLa Flp-In T-
REx cells were maintained in 4 μg/mL of Blasticidin (Melford), Zeocin 50 μg/mL 
(Invitrogen). HEK293 Flp-In T-REx cells were, however, cultured in 15 µg/mL 
Blasticidin and 100 µg/mL Zeocin. The cells were cultured at 37°C in a 5% CO2 
atmosphere and were passaged approximately every 3 days in a lamina flow hood 
after trypsinising in trypsin/EDTA (Versene) (Gibco). Subsequent to transfection with 
pcDNA5/FRT/TO and pOG44 plasmids, to generate stable cell lines (section 2.19), 
Flp-In T-REx HeLa cells were maintained in 4 µg/mL of Blasticidin and 200 µg/mL 
Hygromycin B. Flp-In T-REx HEK293 cells were cultured in 15 µg/mL of Blasticidin 
and 150 µg/mL Hygromycin B at 37°C in a 5% CO2 atmosphere. 
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The U937 suspension cells were cultured in RPMI supplemented with 4 mM L-
glutamine, 10 % (v/v) Foetal Bovine Serum (FBS), Penicillin and Streptomycin. Cells 
were maintained at 37°C and 5% CO2. The cells were passaged when the 
concentration reached ~ 0.8 x106 cells/mL.  
2.16.1 Generation of ‘freeze down’ mammalian cell stocks 
For adherent cells, each cell line was grown in 6 separate 10 cm dishes to 90% 
confluence. Suspension cells were grown in 6 separate T-75 cell culture flasks with a 
volume of 20 mL of 90% confluent cells in each flask. Cells were harvested by 
trypsin/EDTA (Versine) treatment, washed in PBS and centrifuged for 5 minutes at 
250 g and the cells were re-suspended in 6 mL of fully supplemented DMEM with 10% 
DMSO. Cells were aliquoted at a volume of 1 mL into sterile cryogenic storage vials 
and transferred to an isopropanol controlled rate freezing chamber (Mr. Frosty, Sigma-
Aldrich) for 24 hours, before being moved to a -80°C freezer for storage.  
2.17 Generation of stable tetracycline (TET) inducible HeLa and HEK293 cells 
The Tetracycline repressor protein (TetR), from the E. coli tetracycline (TET) 
resistance operon, has been exploited in Flp-In T-REx to generate a regulatory system 
to express cDNA in mammalian cells. Before transfection, Zeocin selects for the 
pFRT/lacZeo vector that contains an integrated FRT (Flp recombination Target) site.  
Following cotransfection of a Flp recombinase (pOG44) and pcDNA5/FRT/TO vector 
containing the cDNA of interest, the pOG44 expresses the Flp Recombinase and 
homologously recombines the FRT sites in pFRT/lacZeo and pcDNA5/FRT/TO. 
Integration of cDNA to the FRT site causes a frame shift, whereby the cells no longer 
express the Zeocin resistance gene, but become resistant to Hygromycin B thanks to 
the resistance gene incorporated in pcDNA5/FRT/TO. The pcDNA6/TR, which 
encodes the Tet repressor gene, is selected for and maintained by the constant 
presence of Blasticidin. Therefore, after transfection, the TetR blocks initiation of 
transcription by binding to the Tet-operator (TO) in the promoter. However in the 
presence of TET, TetR binds to TET and dissociates from the TO, thereby allowing 
transcription to be initiated.  
The human TRIB2 genes 1-343, 54-343, AQLAA, C96S and C96/104S, which had 
been previously cloned into pET30 were cloned by PCR. For cloning, the forward 
primers incorporated a BamHI restriction site (GGATCC) with 5’ overhang (GCC) 
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followed by the sequence CCACCATGG, containing a start codon and then the first 
20 bp of specified TRIB2 cDNA. Therefore, the forward primers were designed as 
follows  GCC[GGATCC]CCACCATGGTRIB2cDNA. In the reverse primer, 5’ overhang 
followed by a NotI (GCGGCCGC) recognition sequence were 3’ to the insert. This was 
followed by the sequence TTATTATTATCA (containing a TCA stop codon), a 
sequence encoding the reverse complement of FLAG peptide 
(CTTGTCATCGTCGTCCTTGTAGTC) and finally reverse complement encoding the 
C-terminus of specified TRIB2 cDNA.  Thus, the primers were designed as follows: 
GCC[GCGGCCGC]TTATTATTATCACTTGTCATCGTCGTCCTTGTAGTCTRIB2 
After PCR, the TRIB2 inserts were resolved on agarose gel, purified and quantified by 
UV absorbance reading at 260 nm using a NanoDrop. TRIB2 inserts were BamHI and 
NotI digested and mixed with BamHI and NotI treated pcDNA5/FRT/TO vector, at a 
ratio of insert to vector 5:1. Ligation was initiated by the addition of 400U T4 DNA 
ligase (New England Biolabs). In order to confirm successful ligation, the products 
were treated with 10U BamHI and analysed by agarose gel electrophoresis. By 
analysis of the differences in migrated distance during electrophoresis it was possible 
to predict whether the ligation had occurred. Plasmids were Sanger Sequenced 
(GATC) and thentransformed into TOP10 E. coli for amplification and then purification 
(section 2.2.2).  
HeLa or HEK Flp-In T-REx parental cells were cultured to 80-90% confluency in a 6-
well plate. 1 μg pcDNA5/FRT/TOTRIB2 and 9 μg pOG44 were incubated in 250 μL of 
serum free media for 5 minutes at ambient temperature. 10 μL of lipofectamine 2000 
was simultaneously incubated in 240 μL of serum free media for 5 minutes at ambient 
temperature. The DNA and lipofectaine aliquots were mixed together and incubated 
for 30 minutes at ambient temperature before being added to HeLa or HEK Flp-In T-
REx parental cells (that had been washed in PBS and media replaced with fully 
supplemented DMEM). The cells were incubated for 24 hours at 37°C, 5% CO2. Fully 
supplemented DMEM was then replaced onto the cells without selection markers for 
a further 24 hours, at which point the appropriate concentrations of Blasticidin and 
Hygromycin were added to select for cells that had successfully integrated the 
specified TRIB2 transgene. Tetracycline (TET) (sterile-filtered stock solution was 
1mg/ml in 70% EtOH) was added at a final concentration of 1 μg/ml to induce the 
expression of the recombinant protein in the stably transfected cells, and this was 
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confirmed by immunoblotting with an α-FLAG antibody. Cells were grown and ‘freeze 
down’ stocks were generated and stored at -80°C.  
2.18 Transient transfections 
For transient transfections, 40 µg pcDNA5/FRT/TO plasmid, encoding WT TRIB2 or 
indicated TRIB2 mutants, was incubated in 500 µL of serum free media containing 50 
µL of lipofectamine 2000 (Invitrogen) for 30 minutes at ambient temperature. The DNA 
lipofectamine mixture was then added to a 10 cm dish of HeLa cells (~60% confluent) 
for 24 hours. The cells were then washed with PBS and fresh media containing 1 
µg/mL was added. Cells were incubated for a further 16 hours before the addition of 
DMSO (0.1% v/v) or compounds for a further 4 hours prior to lysis and immunoblot 
analysis.  
2.19 Incubation of compounds with human cells 
Adherent HeLa cells were seeded at 2.2 x 106 cells per 10 cm dish in 10 mL of fully 
supplemented DMEM cell culture media. After 24 hours, ± 1 µg/mL (from a 1 mg/mL 
stock) of Tet was added directly to media and the cells were incubated for a further 16 
hours, at which point indicated compounds of specified concretions were added to 
cells. The DMSO concentration between treated and non-treated cells was kept 
constant at 0.1% (v/v).  
U937 cells were incubated in fully supplemented RPMI media at a density of 0.2 x 106 
cells/mL for 24 hours. Cells were then incubated with specified compounds and the 
indicated concentrations for the indicated time period. The DMSO concentration 
between treated and non-treated cells was kept constant at 0.1% (v/v).  
2.20 Human cell lysis 
For adherent HeLa cells seeded into 10 cm dishes, the medium (with floating cells) 
was transferred to a 15 mL falcon tube. Subsequently, 10 mL of warm PBS was used 
to wash the cells. Once the PBS was removed, 1 mL of warm trypsin was added to 
the cells, which were incubated at 37 °C for 1 minute. The detached cells were re-
suspended in the 10 mL of DMEM that was taken from the cells in the first step. Cells 
suspended in medium in 15 mL falcon tubes were centrifuged at 250 g for 5 minutes. 
The pelleted cells were re-suspended in PBS and centrifuged once again at 250 g for 
5 minutes. This time, after removal of the PBS, 100 µL of RIPA lysis buffer (50 mM 
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Tris–HCl pH 7.4, 1 % (v/v) NP-40, 1 % (v/v) SDS, 100 mM NaCl, 100 nM Okadaic acid 
and a protease inhibitor tablet (Roche)) was added to the cellular pellet. The cells in 
lysis buffer were sonicated on ice for 3 seconds at an amplitude of 9. This process 
was repeated 3 times with brief cooling on ice in between each sonication. Following 
this, the lysate was centrifuged at 16,000 g for 20 minutes at 4°C. In order to quantify 
the protein concentrations, a sample of lysate was dilutes 1:20 with 20 mM Tris-HCl 
pH 7.4, 100 mM NaCl buffer prior to Bradford assay analysis.  
U937 cells were grown 20 mL of RPMI in T-75 flasks (Corning). To collect the cells, 
the contents of the flask were centrifuged, in a 50 mL falcon tube, at 250 g for 5 
minutes. The medium was removed and PBS was used to re-suspend the cells. The 
cells were centrifuged once again at 250 g for 5 minutes, prior to the removal of PBS 
and addition of 100 µL RIPA lysis buffer. From this point, the cells were subsequently 
lysed using the same protocol as HeLa cell lysis.   
2.21 Serum block and release procedure 
Stable HeLa cells were seeded with 2.2 x 106 cells in 10 cm dishes for 24 hours (until 
~60% confluent) in fully supplemented DMEM medium (with 10% FBS). Subsequently 
the cells were washed with 10 mL of PBS, and replaced with serum-free DMEM for 16 
hours. The cells were again washed with 10 mL of PBS, which was replaced with fully 
supplemented DMEM (with 10% FBS) ± 1 µg/mL Tet for 16 hours, followed by addition 
of indicated inhibitor for a further 4 hours. Cells were then lysed, and whole cell 
extracts generated with modified RIPA buffer, followed by immunoblot analysis.  
2.22 Immunoprecipitations 
To set up immunoprecipitation experiments, 10 cm dishes were seeded with 2.2 x 106 
stable Hela Flp-In T-Rex cells for 24 hours. Half of the plates were then treated with 1 
µg/mL of Tet to induce FLAG-TRIB2 expression, for 16 hours. Cells were then 
harvested by trypsinisation as previously described (section 2.20) except lysed in 500 
µL of a modified 0.1% SDS and 0.1% NP-40 RIPA buffer (50 mM Tris–HCl pH 7.4, 0.1 
% (v/v) NP-40, 0.1 % (v/v) SDS, 100 mM NaCl, 100 nM Okadaic acid and a protease 
inhibitor tablet (Roche)). The cleared lysates were incubated with 50 µL of FLAG M2 
conjugated agarose beads (Sigma-Aldrich), which had been equilibrated in lysis 
buffer. The lysate and agarose bead mixture was aliquoted into 1.5 mL ependorf tubes 
and placed in a rotating carousel, for gentle agitation, in a 4 °C cold room for 2 hours. 
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The beads were then pelleted by centrifugation for 1 minute at 1000 g and washed 3 
times with wash buffer (20 mM Tris-HCl pH 7.4 and 100 mM NaCl). Subsequently, 10 
µL of 5 mg/mL 3xFLAG peptide (Sigma-Aldrich) was diluted in 150 µL of wash buffer, 
which was then added to the pelleted FLAG beads to elute the FLAG-TRIB2. The 
mixture was incubated on ice for 30 minutes with regular agitation. Both +/- Tet 
immunoprecipitations were then centrifuged and the eluate separated from the beads. 
2.23 Cellular thermal shift assay (CETSA) 
Whole cell CETSAs were performed according to a previously established protocol 
[236]. 2.2 x 106 of Stable HeLa cells were seeded into 10 cm dishes (Corning) and 
incubated for 24 hours before being induced to express FLAG-TRIB2 by the addition 
of 10 µg/mL of Tet for 16 hours, at which point the cells were ~90% confluent. 
Subsequently, the Tet induced cells were incubated with either DMSO (0.1% v/v) or 
100 µM of the specified compound for 1 hour. The intact cells were washed with 10 
mL of PBS. Incubation with 1 mL of trypsin for 1 minute was used to detach adherent 
HeLa cells, which were then re-suspended in full supplemented DMEM medium, 
centrifuged at 250 g for 5 minutes and re-suspended in 5 mL of PBS (per plate). Cells 
suspended in PBS were then aliquoted into PCR tubes at a volume of 50 µL prior to 
heating at the indicated temperature in a PCR thermal cycler for 3 minutes. After 
heating the cells were immediately placed on ice for 2 minutes and then lysed by 3 
short bursts of 3 second sonication at an amplitude of 9. The lysate was cleared by 
centrifugation at 16,000 x g for 20 minutes at 4°C and immediately added to 5 x sample 
buffer. The soluble lysate was analysed for the presence of FLAG-TRIB2 and α-tubulin 
by immunoblotting. 
2.24 Lambda phosphatase (λPP assays) 
Lambda phosphatase assays (λPP) were performed on whole cell HeLa lysates and 
on FLAG-peptide elutions from immunoprecipitation experiments. Purified, 
recombinant λ-phosphatase was provided by Dr Dominic Byrne (University of 
Liverpool). 40 µg of cellular extracts were incubated with 10 ng of λ-phosphatase at 
37°C for 1 hour before being added to 5 x SDS sample buffer followed by immunoblot 
analysis. 
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2.25 Tryan blue cell viability assays 
In order to test the effects of compounds on cell membrane integrity by means of 
deducing cellular viability a Trypan blue assay was employed. U937 cells were seeded 
in a 96 well plate at a concentration of 0.2 x 106 cells/mL 18 hours prior to compound 
addition. Various small molecule inhibitors were added (in triplicate) to a final 
concentrations ranging between 0.5 and 20 μM. After either 4 or 24 hours incubation 
cell samples were taken and diluted in 0.4% Trypan Blue dye solution at a 1:1 ratio. 
Non-viable cells were stained blue, with viable cells were unstained. These cell 
suspensions were incubated in a hemocytometer for 2 minutes at ambient 
temperature. The haemocytometer was then placed in a Countess automated cell 
counter, which was used to calculate the percentage of viable cells in the sample. 
2.26 MTT cell cytotoxicity assays 
To assess the cytotoxicity of kinase inhibitors in U937 cells, MTT assays were 
employed. U937 cells were seeded in a 96 well plate at a concentration of 0.2 x 106 
cells/mL, 18 hours prior to compound addition, which was performed in triplicate, with 
all experiments including a final concentration of 0.1% DMSO (v/v). Compounds were 
added to final concentrations between 10 nM and 20 μM. To quantify U937 cell 
viability, mitochondrial metabolic activity was assessed 72 hours subsequent to 
compound addition. Thiazolyl blue tetrazolium bromide was dissolved in PBS and 
added to cells at a final concentration of 0.25 mg/mL and incubated at 37 °C for 3 
hours. In healthy mitochondria, this presence of NADH reduces the thiazolyl blue 
tetrazolium bromide resulting in the formation of insoluble formazan crystals. The 
reaction was stopped and crystals dissolved by the addition of 50 μL of acidified 10% 
SDS, followed by reading of absorbance at 570 nm. Viability was defined relative to 
DMSO-containing controls incubated for the same period of time. 
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Chapter 3: Biochemical analysis and discovery of novel 
TRIB2 small molecule kinase inhibitors  
 
Introduction 
Tribbles pseudokinases modulate many physiological signalling pathways and are 
potential therapeutic targets, due to overexpression and mutation, which implicates 
them in the aetiology of several human cancers, including leukeamias, melanoma, 
lung and liver cancer [109, 122, 237-239]. A recently reported crystal structure of 
TRIB1 shows a bilobal pseudokinase domain that cannot bind to ATP [106]. However, 
it was suggested that upon binding of the substrate C/EBPα the α-helix and ‘SLE’ motif 
(which replaces the normal DFG motif) undergo conformational rearrangement from 
an ‘out’ inactive-like to an ‘SLE-in’ active-like conformation [105]. In the absence of 
substrate, rearrangement into a ‘SLE-in’ position is sterically prevented by Tyr134 from 
the highly unusual TRIB1 αC-helix. The equivalent residue in TRIB2 is Cys104, which 
might therefore contribute to a different degree of freedom for conformational 
rearrangement. In support of this hypothesis, TRIB2 demonstrates a vestigial affinity 
for ATP and autophosphorylates very weakly in vitro in the absence of magnesium 
ions [60]. In addition, TRIB2 was shown to possess the ability to bind to ‘bulky’ ATP 
analogues upon mutation of the gatekeeper residue (Phe 190) to a small Gly or Ala 
side-chain [60]. These findings support the hypothesis that TRIB2 is ‘druggable’ with 
small molecules, which is one of the subjects of this chapter.  
It is estimated that some 40% of pseudokinases retain the ability to interact with 
adenine-based nucleotides; these proteins are therefore likely to be targeted by ATP-
competitive inhibitors [58, 240]. Capitalising on decades of intensive research, which 
has led to FDA approval of 43 kinase inhibitors to treat cancer and inflammatory 
diseases [241], it may therefore be possible to repurpose biologically active ligands to 
target pseudokinases in therapeutic settings [207].  
Like TRIB2, the pseudokinase MLKL was shown to bind to ATP (though MLKL binding 
was much more robust) in the absence of divalent cations [58, 65]. Hilderbrand et al 
(2014) screened the protein kinase inhibitor set 1 (PKIS1) [242], using a recombinant 
mouse MLKL pseudokinase domain and a thermal shift assay (TSA) [217]. PKIS1 is 
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a validated library of 367 ATP-competitive kinase inhibitors, covering ~30 chemotypes 
that were originally developed to target 24 distinct protein kinases. From this screen, 
an inhibitor was discovered to bind to the MLKL pseudokinase domain and prevent its 
translocation to membranes, which in turn prevented necroptosis in an MDF cell model 
[217].  
I hypothesised that by screening recombinant TRIB2 using PKIS1 and differential 
scanning fluorimetry (DSF), that ligands with the ability to modulate the thermal 
stability of recombinant TRIB2 in vitro could be discovered [242]. A counter-screen of 
potential TRIB2 ligands employed a K90M ATP binding-deficient TRIB2 mutant [60], 
the canonical active Ser/Thr kinase PKA and the closely related homologue TRIB1. 
Experiments were performed to evaluate selectivity and to try to support the use of 
small molecule inhibitors as potential chemical probes of TRIB2 cellular function.  
Biochemical and crystallographic analysis suggests that adaptions in the 
pseudokinase fold of TRIB1, including the αC-helix, interact in cis with the C-terminal 
tail region that contains the conserved E3 ubiquitin ligase binding motif (nominally 
DQLVP) [106]. This interaction was proposed to stabilise TRIB1 in vitro and TSAs 
revealed that deletion of the C-terminal domain reduced TRIB1 thermal stability. I 
hypothesised that a similar mechanism also occurs in TRIB2. To this end a series of 
truncation mutants and a triple point mutant (DQLVP to AQLAA) were investigated to 
test the consequences on TRIB2 stability and relevance for compound binding.  
Finally, I hypothesised that synthetic stapled TRIB2 C-terminal tail peptides, containing 
the COP1 and TRIB pseudokinase domain-binding DQLVP motif, might compete with 
the TRIB2 C-terminal tail for binding to the pseudokinase domain in vitro. Short peptide 
sequences are becoming of interest to target both protein-protein interactions and 
surfaces that are too large to be appropriately targeted by small molecule inhibitors 
[243]. The objectives of the work described in this chapter were: 
1. Evaluate whether the TRIB2 C-terminal tail interacts with the pseudokinase 
domain.  
2. Discover whether small molecule kinase inhibitors or other ligands interact with 
TRIB2.  
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3. Establish that the interaction between the TRIB2 C-terminal tail and 
pseudokinase domain can be targeted with small molecule inhibitors and 
stapled peptides.  
4. Evaluate the molecular mechanism of small molecule interaction.  
 
RESULTS 
3.1 Purification of stable His-tagged TRIB2 
The purification of recombinant His-tagged TRIB2 has previously been optimised by 
Bailey and colleagues [60], where TRIB2 was purified sequentially by immobilised 
metal affinity chromatography (IMAC) and size exclusion chromatography (SEC) in 20 
mM Bicine pH 9.0, 100 mM NaCl, 1 mM DTT and 10% (v/v) glycerol. This buffer was 
important to maintain protein stability during purification [60]. Here, full length (1-343) 
human TRIB2 (Figure 3.1A, top) with an N-terminal 6x His tag was expressed in 
BL21(DE3)pLysS E. coli. After centrifugation and cell lysis, IMAC was used to purify 
His-TRIB2 to near homogeneity (Figure 3.1A, bottom). After elution with 300 mM 
imidazole, the majority of His-TRIB2 eluted in the 2nd to 5th 0.5 mL fractions (Figure 
3.1A). Molecular weight markers were resolved on an S200 gel filtration column to 
generate a standard curve (Figure 3.1B), in order to predict the relative molecular 
mass (Mr) of TRIB2, calculated from the elution volume. Fractions from IMAC 
purifications containing the highest abundance of TRIB2 were pooled and analysed by 
SEC for the purpose of separation from high and low molecular mass impurities, 
prediction of Mr and to permit buffer exchange into 20 mM Tris pH 7.4, 100 mM NaCl, 
1 mM DTT and 10% (v/v) glycerol (Figure 3.1C) for DSF analysis. Subsequent to 
protein injection a peak appears at 20 mL, corresponding to the void volume where 
His-TRIB2 has presumably aggregated or multimerized. Following SEC analysis 
fractions corresponding to monodispersed His-TRIB2, eluting between 45 and 63 mL 
were analysed by SDS-PAGE (Figure 3.1D). At the elution volume 53.5 mL the 
calculated Mr of His-TRIB2 was 43.5 kDa, which is close to the theoretical molecular 
weight of 43.6 kDa. The average yield of protein was 2 mg of TRIB2 per litre of 
bacterial culture, calculated by Bradford assay. Purified protein was aliquoted into 1.5 
mL ependorf tubes, snap frozen in liquid nitrogen and stored at -80˚C prior to analysis. 
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Figure 3.1: Purification of His-tagged TRIB2 from BL21(DE3)pLysS. Chemically competent E. coli 
transformed with pET30 encoding full length His-tagged WT TRIB2 were induced with IPTG for 16 hours 
at 18°C. Subsequent to lysis, (A) His-tagged TRIB2 from cleared bacterial lysate was bound to a Nickel 
column by IMAC and eluted with 300 mM imidazole. Fractions were collected at a volume of 0.5 ml. 5 
μl of sample was boiled with 2 x SDS sample buffer and subjected to electrophoriesis on a 10% SDS 
poly acrylamide gel. Additionally a 5 µl sample of the cleared bacterial lysate, the cell pellet and the 
lysate collected post IMAC (flow through) were analysed alongside. The gel was stained with coomassie 
blue with His-TRIB2 visible at ~45 kDa. (B) Molecular weight standards of β-amylase, alcohol 
dehydrogenase, albumin from bovine serum, carbonic anhydrase and cytochrome C were resolved on 
an S200 column in order to obtain a standard comparison to purified proteins. (C) His-tagged TRIB2 
was further purified by size exclusion chromatography. Fractions 1-8 of the IMAC purified His-TRIB2 
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were pooled and resolved on a S200/60 gel filtration column. Elution of His-TRIB2 apparent from UV 
absorbance at 280 nm. (D) Between the elution volume of 70 and 88 ml from the S200/60 column 1.5 
ml fractions were collected and analysed by SDS PAGE. (E) Western blot of recombinant His-TRIB2: 
Varying amounts of His-TRIB2 that was purified from E. coli was resolved by electrophoresis on a 10% 
polyacrylamide gel. The protein was transferred to a nitrocellulose membrane and probed with an anti-
His antibody conjugated to HRP and detected using ECL reagent.  
 
Utilising an anti 6xHis HRP conjugated antibody a dose dependent response is seen 
when between 1 and 10 ng of purified protein was resolved by SDS-PAGE followed 
by immunoblot analysis (Figure 3.1E). The limit of detection in this experiment was 2.5 
ng of His-TRIB2, with 1 ng being barely visible. Intact mass spectrometry (MS) 
analysis of the SEC purified His-TRIB2 revealed an ion of 43,587.09 Da with the 
predicted Mr of His-TRIB2 to be 43,587.22 kDa (Figure 3.2), supporting the 
identification of the purified protein.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Intact mass spectrum for purified His-TRIB2. SEC purified TRIB2 was desalted into 
0.1% formic acid and 50% acetonitrile and loaded onto a C4 trapping column before intact mass 
spectrometry (MS1) analysis. The Spectrum shows an ion with the molecular mass of 43,588.38 Da. 
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3.2 Effect of Tris, Hepes and Bicine on TRIB2 stability 
In order to assess TRIB2 stability in various buffer conditions, a DSF thermal shift 
assay was used [244]. Purified protein was exchanged into various buffers using a 
desalting column. After buffer exchange, and if required, protein was concentrated 
using an Amicon® Ultra Centrifugal Filter to at least 0.5 mg/mL. The effects of different 
reducing agents present in the buffer was also tested. All buffers tested contained 100 
mM NaCl plus or minus 1 mM DTT.  
20 mM Bicine pH 9.0 was previously shown to be optimal for recombinant TRIB2 
stability [60, 245], however, I was interested to evaluate TRIB2 behaviour at a 
physiological pH for in vitro biochemical analysis and using optimal buffers which have 
been used for the analysis of other pseudokinases [58]. The zwitterion bicine has 
ineffective buffering capacity below pH 8 [246].  TRIB1 (84-372) has previously been 
analysed in 10 mM Hepes at near physiological pH (pH 7.6) [106], so it was decided 
to assess this condition with recombinant His-TRIB2.  
In accordance with previous studies TRIB2 is most stable in 20 mM Bicine pH 9.0 [60, 
245] (Figure 3.3A) with a detected melting temperature of 40.8˚C ± 0.31. His-TRIB2 
was less stable in 20 mM Tris pH 7.4 (38.4˚C), and far less stable in 10 mM Hepes pH 
7.6 (36.6˚C). Bicine, with a pKa of 8.35 at 20°C, is a zwitterionic amino acid buffer that 
does not neutralise hydrogen ions at pH 7.4 [246]. Therefore, a buffer condition of 20 
mM Tris pH 7.4 was chosen for future experiments despite slightly diminished TRIB2 
stability compared to 20 mM bicene pH 9.0. 
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Figure 3.3: Thermal denaturation profiles of recombinant His-TRIB2 in different buffers. (A) 
Representative unfolding profiles are shown for 5 μM His-TRIB2 at different pH values (20 mM bicene 
pH 9.0, 20 mM Tris pH 7.4 and 10 mM Hepes pH 7.6). All buffers contained 100 mM NaCl and 1 mM 
DTT. (B) Thermal denaturation profiles of recombinant His-TRIB2 in 20 mM Tris pH 7.4 buffer with 
different reducing agents. Buffers contained either 1 mM DTT, 1 mM TCEP (tris(2-
carboxyethyl)phosphine) or 1 mM BME (β-mecaptoethanol). 
 
3.3 Analysis of the effect of reducing agent on TRIB2 stability 
In 20 mM Tris pH 7.4, the effect of various established biochemical reducing agents, 
used in protein purification and enzyme assays were tested on His-TRIB2 by DSF 
(Figure 3.3B) [244]. Reducing agents such as dithiotreitol (DTT), tris(2-
carboxyethyl)phosphine) (TCEP) or β-mecaptoethanol (BME) are required to disrupt 
disulphide bond formation by reducing sulphur-sulphur bonds to thiols in cytsteine 
residues to prevent aggregation [247]. When no reducing agent was present, His-
TRIB2 had a lower melting temperature compared to His-TRIB2 in the presence of 1 
mM DTT, TCEP or 2-mecaptoethanol BME. Due to the similarity between the melting 
temperatures of His-TRIB2 in all reducing agents tested, DTT was chosen for future 
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experiments, as it is more stable than BME, cheaper than TCEP and was employed 
in previous assays [60]. 
3.4 In vitro analysis of TRIB2 and C/EBPα interaction 
In order to assess the ability of recombinant TRIB2 purified from E. coli, glutathione-
S-transferase (GST) pull down assays were performed on His-TRIB2 and a previously 
established interaction partner, C/EBPα [105, 109]. The full length p42 isoform of 
C/EBPα, known to be targeted for degradation through binding to TRIB2 in human 
cells [109, 112, 196], was purified from E.coli. It was recently established that 
recombinant TRIB1 binds to recombinant C/EBPα by isothermal titration calorimetry 
(ITC) [106], in addition to a co-crystal structure in which C/EBPα binds at the interface 
where the DQLVP motif interacts with a binding pocket in the TRIB1 αC-helix [105].    
3.4.1    Purification of GST-His-C/EBPα 
Full length p42 C/EBPα with a GST N-terminal fusion tag was purified from bacteria. 
Bacteria were lysed in 20 mM Tris pH 7.4, 100 mM NaCl, 1 mM DTT and 10% (v/v) 
glycerol and soluble protein separated from cellular debris by centrifugation followed 
by glutathione-S-transferase (GST) ‘pull-down’. After washing of GST-C/EBPα bound 
beads protein was eluted with 10 mM reduced glutathione. The flow through and first 
3 elution fractions (1 mL each) were analysed by SDS-PAGE (Figure 3.4A). SEC 
analysis on an S200 column in 20 mM Tris pH 7.4, 100 mM NaCl, 1 mM DTT and 10% 
glycerol (Figure 3.4B) revealed that the majority of protein eluted at 40.0 mL. Samples 
from the corresponding peak observed at 40.0 mL were analysed by SDS-PAGE 
(Figure 3.4C). From SEC analysis the predicted Mr was 79.6 kDa, however the 
estimated Mr for GST-C/EBPα was 64.6 kDa. Indeed the visualised SDS-PAGE bands 
for C/EBPα (Figure 3.4C) appear to correspond to a molecular weight closer to 64.6 
kDa. The GST-tag may have influenced the hydrodynamic volume of the protein and 
caused it to migrate through the column faster [248, 249]. Fractions containing GST-
C/EBPα as established by SDS-PAGE were pooled, aliquoted into 1.5 mL eppendorf 
tubes, snap frozen in liquid nitrogen and stored at -80˚C for later analysis.   
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Figure 3.4: Purification of GST-tagged C/EBPα. (A) E. coli were induced to express GST-tagged 
C/EBPα for 16 hours at 18⁰C. Subsequent to bacterial cell lysis, lysate was incubated with GST-
sepharose for 4 hours at 4°C with gentle agitation. The beads were washed 3 times in 20 mM Tris pH 
7.4, 100 mM NaCl followed by elution of protein with 10 mM reduced glutathione in 3 separate 1 mL 
fractions that were analysed by SDS-PAGE. (B) GST-C/EBPα was further purified by SEC, resolved on 
a S200/60 gel filtration column in 20 mM Tris pH 7.4, 100 mM NaCl, 1 mM DTT and 10% glycerol. (C) 
Samples from SEC corresponding to GST-C/EBPα elution, between the volumes of 36 and 44 mL, were 
analysed by SDS PAGE. 
 
3.4.2   GST ‘pull-down’ of TRIB2 with C/EBPα 
To provide evidence that recombinant TRIB2 is properly folded and binds to a known 
physiological target, 5 μg of recombinant GST-C/EBPα or 5 μg of recombinant GST 
(pre-bound to GSH-sepharose) were incubated with 5 μg of TRIB2 followed by pull 
down interaction experiments. Consistent with a functional interaction it was found that 
GST-tagged C/EBPα interacted with His-TRIB2 in vitro (Figure 3.5). GST displayed no 
detectable interaction with His-TRIB2, consistent with an interaction occurring 
between C/EBPα and TRIB2. 
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Figure 3.5: Interaction of TRIB2 with C/EBPα. The ability of His-TRIB2 to interact with GST-C/EBPα 
was assessed by GSH-sepharose pull-down followed by immunoblotting.  
 
3.5 Analysis of His-TRIB2 ATP binding in vitro 
TRIB2 has previously been shown to bind weakly to ATP, with a predicted Km [ATP] 
of 0.66 mM, and to autophosphorylate very weakly in the presence of ATP and 
absence of Mg2+ ions [60]. The DSF assay was used to examine thermal stability of 
full-length (1-343) His-tagged TRIB2 protein in the presence of ATP, EDTA and MgCl2. 
Autoradiography was also used to evaluate 32P-based autophosphorylation of His-
TRIB2. His-TRIB2 ATP binding analysis was compared side by side with full-length 
His tagged cAMP-dependent protein kinase (His-PKAc), a C104Y TRIB2 mutant and 
TRIB1. Cys 104, within the αC-helix of TRIB2 is changed to Tyr 134 in TRIB1, and has 
been suggested to prevent rearrangement into a canonical DFG-in position in TRIB1 
[106]. The equivalent Cys residue in TRIB2 may therefore allow for more freedom for 
rearrangement in the αC-helix to allow ATP binding. 
3.5.1   TRIB2 binds to ATP and autophosphorylates in the absence of Mg2+ ions 
His-TRIB2 was not significantly stabilised by ATP alone, Mg2+ alone, or in the presence 
of both ATP and Mg2+ (Figure 3.6). EDTA however imparted a small stabilising effect 
(ΔTm 1.4˚C). This stabilisation was further enhanced in the presence of ATP indicated 
by a statistically significant increase in Tm of His-TRIB2 in the presence of both ATP 
and EDTA compared to EDTA alone (students t-test p=0.00930). EDTA-dependant 
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ATP binding activity was then assessed further by autoradiography (Figure 3.7) where 
there was around a 2 fold increase in His-TRIB2 autophosphorylation, as analysed by 
densitometry, in the presence of ATP and EDTA as compared to ATP and Mg2+ 
(p=0.00110).  
 
Figure 3.6: Analysis of TRIB2 thermal stability in the presence of ATP and EDTA. ΔT
m
 values from 
DSF analysis are shown for 5 μM His-TRIB2 incubated with 10 mM ATP,1 mM EDTA or 1 mM MgCl
2
. 
Mean ΔT
m
 values (±SD) are with reference to a buffer control from 4 separate experiments are shown. 
Students t-test was used to reveal a statistically significant difference between the ΔT
m
 values of EDTA 
and ATP+EDTA (p = 0.00930).   
 
 
Figure 3.7: His-TRIB2 autophosphorylates in the absence of Mg2+ ions. (A) 6 µg of His-TRIB2 was 
assayed in duplicate for 30 minutes at 30°C in a shaking incubator with either 1 mM ATP (2.2 μCi γ-
32P ATP) and 1 mM EDTA or 1 mM ATP with 1 mM MgCl2. The reactions were stopped by the addition 
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of 5 x SDS loading buffer, protein resolved by SDS-PAGE and then transferred to a nitrocellulose 
membrane which was treated to autoradiography by exposure to x-ray film for 1 week. The nitrocellulose 
membrane was stained with ponceau to serve as a loading control. (B) Densitometry analysis of His-
TRIB2 autophosphorylation by γ-
32
P ATP incorporation. Band intensities were normalised to loading 
controls and a student’s t-test was used to assess statistical difference between ATP + EDTA and ATP 
+ Mg
2+
 treated protein (p=0.00110).  
 
3.5.2   Comparison of His-TRIB2 stability with His-PKA and a hyper-stable 
C104Y mutant 
Thermal stability analysis was used to compare ATP binding properties of His-TRIB2 
to the canonical kinase domain of PKA. His-TRIB2 (Tm = 39.54°C) was much less 
thermostable than His-PKA (Tm = 46.84°C) (Figure 3.8). In contrast to TRIB2, 
recombinant His-PKA was not stabilised by either ATP alone or ATP and EDTA 
together. His-PKA was instead stabilised by ATP in a Mg2+ dependent manner (ΔTm 
of 3.36˚C), as expected for a canonical Ser/Thr kinase domain [250]. 
 
Figure 3.8: Thermal denaturation profiles of recombinant His-TRIB2 and His-PKA ± ATP + 
EDTA/Mg
2+
. Representative unfolding profiles are shown for 5 μM His-TRIB2 incubated with/without 10 
mM ATP or 10 mM ATP and 1 mM EDTA. 5 μM His-PKA was incubated with/without 10 mM ATP or 10 
mM ATP and 1 mM MgCl
2
.  T
m
 values (±SD) were obtained from 3 separate fluorescence profiles, each 
point assayed in duplicate.    
 
It was previously reported that TRIB1 is sterically hindered from undergoing 
conformational rearrangement to an active like conformation and, therefore, unable to 
bind ATP [106]. This was in part due to the presence of a Tyr134 residue in the αC-
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helix, the equivalent residue being Cys104 in TRIB2 [106]. WT TRIB2, C104Y TRIB2 
and PKA were purified to homogeneity (Figure 3.9A, left). Sequence alignments of the 
TRIB1, TRIB2, TRIB3 and STK40 β3-Lys to αC-helix residues (Figure 3.9 right) 
reveals that Cys104 of TRIB2 is a Tyr residue in TRIB1 and TRIB3 and an Ile in the 
more distantly related STK40. The elution volumes from Superdex 200 were identical 
for purified WT and C104Y TRIB2, confirming that both proteins were stable and 
monomeric in solution (figure 3.9B), with an estimated Mr of 45.3 kDa. Thermal 
stability based on unfolding profiles were determined for each protein (Figure 3.9C). 
Remarkably, single substitution of Cys 104 with Tyr induced marked stabilisation of 
TRIB2, with the Tm value increasing from 38.6°C for WT TRIB2 to 48.9°C for C104Y 
TRIB2. The increased thermal stability of C104Y TRIB2 is comparable to that 
observed to that of human TRIB1 (Tm ~49˚C) in an independent study [106], 
suggesting an important structural role for this residue in both TRIB1 and TRIB2 
(un)folding dynamics. As demonstrated earlier, TRIB2 did not bind to ATP alone or in 
the presence of Mg2+ (Figure 3.9D), but was stabilised by ATP and EDTA. Interestingly 
C104Y TRIB2 was not stabilised by ATP alone, ATP with EDTA or ATP with Mg2+. 
PKA was only stabilised in the presence of both ATP and Mg2+.    
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Figure 3.9: Thermal stability and ATP binding analysis of a C104Y TRIB2 mutant by DSF. (A) SDS-PAGE of 
recombinant proteins employed for in vitro analysis (left). Amino acid sequence alignment of the β3-Lys to the αC-
helix region of TRIB2, TRIB1, TRIB3 and STK40 pseudokinases. (B) SEC analysis of WT and C104Y TRIB2 each 
purified from 4 litres of E. coli. (C) Thermal denaturation profiles of recombinant WT His-TRIB2, C104Y His-TRIB2 
and His-PKA. (D) DSF analysis for 5 μM His-tagged WT TRIB2, C104Y TRIB2 and PKA incubated with/without 10 
mM ATP or 10 mM ATP and 1 mM EDTA. 5 μM His-PKA incubated with/without 10 mM ATP or 10 mM ATP and 1 
mM MgCl
2
.  T
m
 values (±SD) were obtained from 3 separate fluorescence profiles, each point assayed in duplicate.    
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3.5.3   Comparison of TRIB2 stability with TRIB1 
The thermal stability and ATP binding potential of His-tagged human TRIB1 was also 
analysed. TRIB1 lacking the N-terminal domain was expressed because residues 1-
84 were predicted to be disordered and were absent in biochemical and 
crystallographic studies performed previously [106]. Two TRIB1 proteins were 
analysed, TRIB1 84-372, with an intact C-terminal tail and TRIB1 84-343, which lacked 
the C-terminal tail containing the COP1 binding site. The C-terminal tail was previously 
suggested to increase TRIB1 thermal stability by forming an in cis interaction with the 
pseudokianse domain [106].  
TRIB1 proteins were purified by IMAC and SEC and buffer exchanged into 20 mM Tris 
pH 7.4, 100 mM NaCl and 1 mM DTT (Figure 3.10A). Interestingly TRIB1 84-343, the 
pseudokinase domain alone, eluted from the SEC column more quickly than TRIB1 
84-372 with a calculated mw of 58.2 kDa suggesting dimerization (Figure 3.10B). For 
studies carried out previously [106] TRIB1 proteins were purified by SEC into Hepes 
pH 7.6, 300 mM NaCl, 2 mM DTT. Thus SEC analysis was performed by equilibrating 
an S200/60 gel filtration column with the same buffer before loading and resolving 2 
mg of each TRIB1 protein and TRIB2 1-343 and 54-318 (Figure 3.9C). Interestingly in 
these buffer conditions TRIB1 84-343 no longer appeared to dimerize, the calculated 
Mr being 30.25 kDa.  
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Figure 3.10: Purification and SEC analysis of TRIB1 in Tris pH 7.4 and Hepes pH 7.6. (A) SDS 
PAGE analysis of His-tagged TRIB2 1-343, TRIB1 84-372 and TRIB1 84-343 purified from E. coli. (B) 
SEC analysis TRIB1 84-372 (blue) and TRIB1 84-343 (red) resolved on an S200 column equilibrated 
in 20 mM Tris pH 7.4, 300 mM NaCl and 2 mM DTT. Predicated Mr is shown. (C) 2 mg of each TRIB1 
protein 84-372 (blue) and 84-343 (red), previously purified into Tris, were resolved on an S200 column 
equilibrated in 10 mM Hepes pH 7.6, 300 mM NaCl, 2 mM DTT. Predicted Mr is shown. 
 
Structural analysis of TRIB1 reveals an in cis self-assembly whereby the COP1 
binding site of the C-terminal tail region (containing the conserved DQLVP motif) binds 
directly to the TRIB1 pseudokinase domain adjacent to the short αC-helix [106]. This 
hypothesis was supported by small angle X-ray scattering, DSF and in vitro 
competition assays [106]. Thermal melting curves (Figure 3.11A) reveal that both 
TRIB1 proteins have a greater thermal stability than TRIB2 1-343 and 54-318. 
However unexpectedly, TRIB1 84-372, with a Tm of 41.9°C, was in fact less stable 
than the TRIB1 pseudocatalytic domain alone (84-343), which had a Tm of 44.8°C. The 
TRIB1 DSF experiments were carried out in the same buffer (20 mM Tris pH 7.4, 100 
mM NaCl and 1 mM DTT) as previously used [106]. Although in my experiments the 
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C-terminal tail did not stabilise TRIB1, the obtained Tm values for both TRIB1 proteins 
were markedly different than previously reported [106]. Murphy et al (2015) obtained 
a Tm ~49˚C for TRIB1 84-372 and a Tm of ~47.5˚C for TRIB1 84-343. Consistently, 
neither TRIB1 protein was stabilised by ATP and EDTA (Figure 3.11B).  
 
Figure 3.11: Analysis of TRIB1 thermal stability in the presence of ATP. (A) Thermal denaturation 
profiles of TRIB2 1-343 and TRIB1 proteins (84-372 and 84-343). Average melting temperatures are 
displayed with standard deviation. (B) Thermal shifts of TRIB2 and TRIB1 in the presence of 10 mM 
ATP and 1 mM EDTA. 
 
3.5.4   Stability of TRIB1 in different buffer compositions 
For subsequent analysis, purified TRIB1 proteins were buffer exchanged into either 
20 mM Tris pH 7.4, 10 mM Hepes pH 7.6 or 20 mM bicene pH 9.0 ± 1 mM DTT. All 
buffers also contained 100 mM NaCl. TRIB2 was previously shown to be the most 
stable in Bicene pH.9.0 [60, 251]. In all buffers, Tris pH 7.4, Hepes pH 7.6 and Bicene 
pH 9.0, in the absence of DTT, Tm values for TRIB1 84-372 were similar (40.6°C, 
40.7°C and 41.1°C) (figure 12A). This was also observed for TRIB1 84-343, the Tm 
values being similar in the absence of DTT regardless of buffer or pH (Figure 12B). 
However, TRIB1 84-343 Tm values were comparatively greater than TRIB1 84-372 by 
~2°C. DTT did not influence the stability of TRIB1 in the presence of Tris pH 7.4 or 
Hepes pH 7.6 however, surprisingly, did in the presence of Bicene pH 9.0 and 1 mM 
DTT. There was there a marked increase in the Tm of both proteins. The Tm for TRIB1 
84-372 was 46.9°C and 47.0°C for TRIB1 84-343 in this condition, being relatively 
equal.  
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Figure 3.12: Thermal denaturation profiles of recombinant His-TRIB1 in different buffer 
compositions. (A) Representative unfolding profiles are shown for 5 μM His-TRIB1 (54-372) in buffers 
with differing pH (20 mM bicene pH 9.0, 20 mM Tris pH 7.4 and 20 mM Hepes pH 7.6). All buffers 
contained 150 mM NaCl and 1 mM DTT. (B) Same as for (A) but for the analysis of His-TRIB1 (84-343). 
 
3.6 TRIB2 destabilisation in the absence of the C-terminal tail 
3.6.1   Analysis of truncation mutants and a COP1 binding site mutant 
To investigate whether the C-terminal tail region stabilises TRIB2, a series of point 
and truncation mutants were generated by PCR and recombinant protein expressed 
and purified. These proteins lacked either the N-terminal extension (54-343), predicted 
to be disordered by both I-TASSER [252] and VSL2 [253], the C-terminal tail (1-318) 
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or both regions (54-318). A COP1 binding site triple point DQLVP to AQLAA mutant 
was also generated (Figure 3.13A). SEC analysis from Figure 3.13B reveals that WT 
TRIB2 elutes in agreement to the predicted Mr. However, SEC analysis indicated that 
TRIB2 54-318 (pseudokinase domain alone) eluted with a calculated Mr of 56.2 kDa. 
The predicated molecular weight of TRIB2 54-318 is 32.0 kDa, which suggests that 
this truncation mutant formed a dimer or aggregated. Interestingly, AQLAA TRIB2 had 
a predicted molecular weight of 70.0 kDa, indicative of dimer formation (or potential 
aggregation).  
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Figure 3.15: Purification and SEC analysis of TRIB2 truncation and AQLAA mutants. (A) SDS-
PAGE analysis of TRIB2 proteins purified by IMAC and SEC. (B) SEC analysis of TRIB2 1-343, TRIB2 
54-318 and AQLAA COP1 binding site mutant. (C) SEC analysis of TRIB2 1-343 in Hepes pH 7.6. 
TRIB2 54-318 was also loaded onto the column but no elution profile was detected.  
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It was described in Figure 3.10C that TRIB1 84-343 no longer formed a dimer in Hepes 
pH 7.6, 100 mM NaCl and 1 mM DTT as opposed to Tris pH 7.4, 100 mM NaCl and 1 
mM DTT. Therefore TRIB2 was also analysed by SEC in this buffer Hepes pH 7.6. In 
Hepes pH 7.6 TRIB2 1-343 appeared to be unstable with peaks with very low signals 
appearing at calculated molecular weights of 46.9 and 73.23 kDa (Figure 3.13C). 
TRIB2 54-319 was completely unstable in this buffer and the absence of protein eluting 
in the void volume indicated that protein may have become blocked inside of the 
column.    
In order to investigate these mutants further, DSF was exploited (Figure 3.14). Full-
length (1-343) TRIB2 and TRIB2 lacking only the N-terminal domain (TRIB2 54-343) 
both exhibited similar Tm values of 39-40°C (Figure 3.14). In contrast, deletion of the 
C-tail (residues 318-343), either in the absence (TRIB2 54-318) or presence (TRIB2 
1-318) of the N-terminal region, markedly reduced TRIB2 thermal stability. This could 
be indicative of a destabilised conformation observed in TRIB1, as previously 
described [106]. Indeed, mutation of the DQLVP motif to AQLAA also caused TRIB2 
thermal destabilisation, with a Tm value of ~36°C (Figure 3.14).  
 
Figure 3.14: Thermal stabilisation of TRIB2 by the C-terminal tail. Thermal denaturation profiles of 
truncated TRIB2 proteins and a COP1 binding site DQLVP to AQLAA triple mutant with mean T
m
 values 
± standard deviation. Cartoon diagrams with domain boundaries illustrate TRIB2 proteins analysed.  
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3.6.2   DSF analysis with synthetic C-terminal TRIB2 peptides 
Based on previous work in which the PKA regulatory subunit and AKAP binding were 
competed with using stapled peptides [24], I hypothesised that synthetic stapled C-
terminal peptides (containing the DQLVP COP1 binding motif) could compete for 
binding with the TRIB2 C-terminal tail in TRIB2 pseudocatalytic domain, thus 
influencing TRIB2 thermal stability. Tribbles peptides were synthesised by Dr Eileen 
Kennedy (University of Georgia). A synthetic TRIB2 C-terminal peptide with the 
sequence YKAAYAKESDQLVPDK with a hydrocarbon staple between the residues 
highlighted in red (Figure 3.15A) and the COP1 binding DQLVP was synthesised. A 
control peptide, YKAAYAKEVSAQLVAAD with a mutated COP1 binding motif was 
also prepared and tested (Figure 3.15A). Lastly, a scrambled peptide was synthesised 
with the sequence YKAKSLAADQYDGPVE, which served as an additional negative 
control. 
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Figure 3.15: DSF analysis of TRIB2 1-343 and 54-318 with stapled C-terminal tail peptides. (A) 
Structures and sequences of TRIB2 C-terminal stapled peptide, containing the DQLVP motif, a control 
C-terminal peptide, with a divergent AQLVAA motif and a scrabbled peptide. (B)  5 μM of TRIB2 was 
assayed in the presence of 20 μM peptide and mean ΔT
m
 values are shown from 3 independent 
experiments. ATP + EDTA served as a control. (C) Dose response analysis of C-terminal peptides. 5, 
10, 20, 40, 80 and 160 μM of peptides were analysed by DSF in the presence of 5 μM TRIB2 1-343 
and TRIB2 54-318. The extent of destabilisation induced by the C-terminal peptide was significantly 
greater than that induced by both the control and scrambled peptide as measured by students t-test 
(p<0.0001). 
 
DSF was used to assess the stability of full-length TRIB2 (1-343) and the 
pseudokinase domain alone (54-418) in the presence of the stapled TRIB2 synthetic 
stapled C-terminal peptide containing the DQLVP motif and the control peptide (Figure 
3.15B). Excitingly the TRIB2 C-terminal peptide destabilised 1-343 (ΔTm -2.3 °C) but 
not 54-318 TRIB2 (ΔTm -0.6 °C). This ΔTm for 54-318 TRIB2 could indicate the 
occurrence of a weak destabilising interaction in the pseudokianse domain. It is 
important to note that the C-terminal stapled peptide did not stabilise 54-318 TRIB2, 
supporting the hypothesis that the destabilisation induced in 1-343 TRIB2 was a result 
of C-terminal tail displacement. Furthermore, the destabilisation effect was reduced to 
-0.7˚C and -0.5 ˚C for 1-343 and 54-318 TRIB2 respectively in the presence of the 
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control peptide, which has a divergent AQLVA motif. Similarly, the destabilisation 
effect in the presence of the C-terminal scrambled peptide was markedly reduced 
compared to the TRIB2 C-terminal tail peptide, with ΔTm. values of -0.9 and -0.8 ˚C for 
1-343 and 54-318 TRIB2 respectively. This suggests that the destabilising interaction 
by stapled peptides with full length TRIB2 (1-343) was sequence specific. ATP and 
EDTA stabilised both proteins to a similar extent (~2.7˚C).  
The effect of destabilisation of full length (1-343) TRIB2 by the C-terminal stapled 
peptide was dose-dependent (Figure 3.15C), reaching a maximum ΔTm of -3.9°C at a 
protein to peptide ratio of 1:32. Interestingly, there was a minor destabilisation effect 
on both 1-343 and 54-318 TRIB2 in the presence of the scrambled peptide, which was 
also dose-dependent, reaching a maximum ΔTm of ~-1.5°C. This further evidenced 
that, to a lesser degree, non-specific interactions were instigated between the stapled 
peptides and the TRIB2 pseudokinase domain. Indeed, the more extensive 
destabilisation detected in 1-343 TRIB2 in the presence of the C-terminal tail stapled 
peptide was suggestive of a targeted interaction.    
 
3.7 Small molecule analysis 
It was previously suggested that the TRIB2 pseudokinase domain is ‘druggable’ [60]. 
Both the MLKL and TRIB1 pseudokinases have been screened by DSF using the 367 
small molecule kinase inhibitors in the PKIS1 in order to discover novel drug leads 
[105, 217].  TRIB2 was analysed by DSF in the presence of known small molecule 
kinase inhibitors in order to find potential novel drug leads. 
3.7.1   Staurosporine does not bind to His-TRIB2 
Staurosporine binds to many protein kinases and pseudokinases through various 
binding modes [254, 255]. However, the thermal stability of His-TRIB2, in the presence 
of staurosporine, did not detectably change, even at concentrations as high as 100 
µM (1:20 protein:inhibitor) (Figure 3.16B). His-PKA however was stabilised in a dose 
dependent manner, with 1 µM (5:1) giving no significant shift, 5 µM (1:1) a ΔTm of 
~3.5˚C and a ΔTm obtained at 10 µM (1:2) of ~6.5˚C. In the presence of 100 µM 
staurosporine His-PKA was stabilised by ~6.5˚C. 
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Figure 3.16: His-TRIB2 is not stabilised by staurosporine. (A) SDS-page analysis of recombinant 
His-TRIB2 and His-PKA used for DSF analysis. (B) Varying concentrations of staurosporine (STS) (1-
100 μM) were incubated with 5 µM of either His-TRIB2 or His-PKA and analysed by DSF. ΔTm values 
were calculated with reference to a DMSO (2% v/v) buffer control.   
 
3.7.2 A DSF screen for TRIB2 ligands 
To discover potential ligands for TRIB2 I screened the PKIS1 against recombinant His-
TRIB2 in a protein:compound ratio of 1:4 (Figure 3.17) [242]. Cut off values of ΔTm = 
<-2°C and >+3.5°C were used to define ‘hit’ compounds that possessed the ability to 
either destabilise or stabilise TRIB2, respectively. The top ‘stabilising’ compound 
identified was GW693881A, a dual EGFR/HER2 thienopyrimdine inhibitor exhibiting a 
ΔTm of 4.7°C. The top ‘destabilising’ compound was GW804482X, a thiophene polo-
like kinase (PLK) inhibitor that induced a ΔTm of - 3.4 °C (Figure 3.17, red symbols).  
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Examining the most stabilising hits (>2.5˚C) it was apparent that there was an 
abundance of thienopyrimidine based EGFR/HER2 and benzimidazole based TIE-
2/VEGF2 dual inhibitors (Figure 3.18). The thiophene PLK inhibitor GW804482X was 
the most destabilising. Interestingly a structurally-related thiophene PLK inhibitor 
(GW853609X) also stabilised TRIB2 by 3.2˚C.    
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As there were both stabilising and destabilising compounds belonging to known ATP-
competitive thienopyrimidine EGFR/HER2 chemotypes (Figure 3.18) [256, 257], which 
suggested broad cross-reactivity between TRIB2 and EGFR/HER2, ligands from the 
PKIS 1 were selected and investigated by DSF. The most stabilising compound 
GW693881A (ΔTm ~5°C) (Figure 3.19 top) is structurally similar to GSK969786A and 
GW68426B, which surprisingly did not modulate TRIB2 thermal stability (Figure 3.19 
bottom). Both GSK969786A and GW68426B have a sulphur atom in a different 
position to GW693881A in the five membered ring of the thienopyrimidine scaffold 
(Figure 3.19 bottom Highlighted with red asterisks). In addition, a nitrogen is present 
at the β-position of the adjoining five membered ring in GW693881A, which are oxygen 
and sulphur atoms in GSK969786A and GW68426B (respectively), marked by blue 
asterisks in Figure 3.19 (bottom). Besides these rather subtle differences compounds 
GW693881A, GSK969786A and GW68426B are structurally identical. Some 
EGFR/HER2 dual inhibitors destabilised TRIB2. The second most potent destabiliser 
of TRIB2 in the PKIS1 was the EGFR/HER2 dual Thiazolylquinazoline inhibitor 
GW569530A (Figure 19).  
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Figure 3.19: Comparative DSF analysis of dual EGFR/HER2 PKIS inhibitors as potential TRIB2 
ligands. DSF analysis of selected compounds (TOP) and chemical structures of compounds (bottom). 
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3.7.3   Counter-screen with PKA and a TRIB2 β3 K90M mutant 
The β-3 lysine (K90 in TRIB2) is pivotal for ATP binding in most canonical kinases, 
with mutation to an uncharged Met reducing ATP binding ability [58, 258]. Therefore 
His-TRIB2 K90M was purified sequentially by IMAC and SEC (Figure 3.20A). The yield 
of K90M TRIB2 was far lower than that of WT-TRIB2 (<0.1 mg per L of bacteria) and 
this decreased stability was reflected in the sharply reduced Tm of purified K90M 
TRIB2 (30.2˚C) compared to WT TRIB2 (39.9˚C) (Figure 3.20B).  
Figure 3.20: Comparative DSF analysis between WT TRIB2, a β3 lysine K90M TRIB2 mutant and 
PKA. (A) SDS PAGE analysis of purified WT and K90M His-TRIB2 (5 μg) electrophoresed side by side 
along with 5 μg of BSA. (B) Thermal denaturation profiles of WT and K90M TRIB2. (C) DSF analysis 
comparing binding of selected PKIS thienopyrimidine dual EGFR/HER2 inhibitors and clinical inhibitors 
lapatinib (LAP) (dual EGFR/HER2) and gefitinib (GEF) (EGFR) to WT TRIB2, K90M TRIB2 and PKA. 
ATP + EDTA served as the positive control WT TRIB2 and ATP + Mg2+ served as the positive control 
for PKA.  
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To evaluate the relative specificity of PKIS ‘hit’ TRIB2-binding compounds, a counter-
screen was performed employing PKA and K90M TRIB2 using two of the most highly 
stabilising EGFR/HER2 ligands (GW69388A and GSK300014A) and two non-
stabilising EGFR/HER2 ligands (GSK969786A and GW68426B) (Figure 3.20C). ATP 
and EDTA were used as the positive control for TRIB2 and ATP and Mg2+ was used 
as the positive control for PKA. The clinically approved dual EGFR/HER2 inhibitor 
lapatinib as well as the clinically approved EGFR inhibitor gefitinib were also tested. 
GW69388A strongly stabilised TRIB2 by ~5˚C the effect of which was acutely reduced 
to ~2˚C for K90M TRIB2. On the other hand, GSK300014A induced a ΔTm of ~4˚C for 
WT TRIB2 but did not promote any significant stabilisation of K90M TRIB2. PKA 
exhibited no response to either of these compounds or the two EGFR/HER2 non-
stabilisers (GSK969786A and GW68426B). The clinically approved and commercially 
available thienopyrimidine based dual EGFR/HER2 inhibitor lapatinib did in fact 
stabilise WT TRIB2 (ΔTm 4˚C). The 1.5˚C shift exhibited by K90M TRIB2 indicated a 
reduced affinity for lapatinib. Interestingly, the clinical monovalent EGFR inhibitor 
gefitinib afforded no significant thermal stabilisation or destabilisation for any of the 
proteins tested and would hence forth serve as a negative control for TRIB2.   
 
3.8 DSF screen for TRIB2 interaction with clinically approved 
kinase inhibitors 
In order to build upon the finding that some compounds originally developed to bind to 
the catalytic domain of EGFR, HER2 and PLK tyrosine kinases also influenced TRIB2 
thermal stability, it was hypothesised that the cross reactivity observed could be 
exploited to repurpose clinical inhibitors to target TRIB2. To this end a panel of 
commercially available inhibitors were analysed for their ability to modulate 
recombinant TRIB2 stability by DSF.  
3.8.1   Screen of EGFR, EGFR/HER2 and PLK inhibitors 
Screening a panel of commercial EGFR/HER2 and PLK inhibitors revealed that the 
clinical type I EGFR/HER2 inhibitors TAK-285 and lapatinib potently stabilised TRIB2 
to a greater extent than ATP and EDTA (Figure 3.21A). In addition, the Type IV 
irreversible EGFR/HER2 inhibitors afatinib, neratinib, osimertinib, dacomitinib and 
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canertinib were also tested. The type IV irreversible inhibitor of Bruton’s Tyrosine 
Kinase (BTK) ibrutinib [259] was also tested. EGFR/HER2 type IV inhibitors contain a 
strategically positioned highly electrophilic acrylamide group designed to covalently 
bind to specific thiol functional groups found in target cysteines, such as Cys 797 in 
EGFR, Cys805 in HER2 and Cys803 in HER4 [207]. Remarkably, afatinib, neratinib 
and osimertinib induced a thermal shift in TRIB2 through destabilisation. The extent of 
which was comparable to the most potent destabilising hit from the principal screen 
(PLK1 inhibitor GW804482X), inducing ΔTm values of -3.0˚C, -2.5˚C and -2.3˚C for 
afatinib, neratinib and osimertinib respectfully. Surprisingly, the closely related type IV 
EGFR/HER2 inhibitors dacomitinib and canertinib had no effect on TRIB2 stability. 
Afatinib, neratinib, osimertinib and canertinib share a quinazoline-based scaffold 
(Figure 3.21B) developed from gefitinib [213]. Differential binding properties based on 
compounds with subtle differences in the positions of functional groups were 
highlighted in section 3.7.2 (Figure 3.19). 
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Figure 3.21: Comparative DSF analysis of clinical and preclinical kinase inhibitors as potential 
TRIB2 ligands. (A) DSF of TRIB2 with selected clinical and preclinical kinase inhibitors: lapatinib (LAP), 
BI6727 GW804482X
LAP TAK-285 AFA
NER OSI
IBR
ERL
GEF BI2536
B
DAC
CAN
A
L
A
P
T
A
K
-2
8
5
A
T
P
+
E
D
T
A
A
F
A
N
E
R
O
S
I
D
A
C
C
A
N
G
E
F
E
R
L
B
I2
5
3
6
B
I6
7
2
7
G
W
8
0
4
4
8
2
X
-4
-3
-2
-1
0
1
2
3
4
Type I dual 
EGFR/HER2
Type IV dual EGFR/HER2
Type I 
EGFR
Type I PLK
T
R
IB
2
 Δ
T
m
/⁰
C
128 
 
TAK-285 (TAK), afatinib (AFA), neratinib (NER), osimertinib (OSI), ibrutinib (IBR), erlotinib (ERL), and 
gefitinib (GEF). (B) Structures of listed small molecule kinase inhibitors.   
Ibrutinib, the covalent BTK inhibitor, afforded no thermal stabilisation or destabilisation 
for TRIB2 in the DSF assay as did both type 1 clinically approved EGFR inhibitors 
gefitinib and erlotinib (Figure 3.21A). PLK type 1 inhibitors BI2536 and BI6727, are 
dihydropteridinone derivatives which contain 2-aminopyrimidine (Figure 3.21B). Only 
thiophene based PLK inhibitors appear to modulate TRIB2 stability; GW804482X 
induced a thermal destabilisation of -3.9˚C (Figure 3.21A) and GW853609X a thermal 
stabilisation of +3.2 (Figure 3.18).  
By employing PKA, afatinib, neratinib, osimertinib, erlotinib and lapatinib were counter-
screened at the highest inhibitor to protein ratio (1:32) tested in Figure 3.22. The 
purpose was to elucidate the potential presence of non-specific interactions at high 
inhibitor concentrations. The promiscuous kinase inhibitor Dasatinib, which has 
previously been shown to induce a strong thermal shift for PKA in the DSF assay [250], 
was used as a positive control and gave a ΔTm of 11.08˚C (Figure 3.22). Afatinib, 
neratinib, osimertinib, erlotinib and lapatinib did not result in any discernible thermal 
shift when 5 µM of PKA was analysed with 160 µM compound demonstrating no non-
specific binding.  
Figure 3.22: Screen of EGFR/HER2 inhibitors with PKA. 5 µM His-PKAc thermal shifts were 
analysed in the presence of a panel of dual EGFR/HER2 or EGFR inhibitors (final concentration 160 
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µM), confirming a lack of binding. The PKA-stabilizing compound dasatinib (160 µM) was employed as 
a positive control. Data from N=2 experiments (± SD) for triplicate assays are shown. 
To determine that the extent of TRIB2 thermal stabilisation/destabilisation was 
dependent on kinase inhibitor concentration, a dose-response experiment was 
conducted (Figure 3.23A). At 5 µM (1:1 protein:compound), lapatinib began to induce 
detectable TRIB2 stabilisation (ΔTm 1.6˚C ± 0.04). At 10 µM (2:1) lapatinib induced a 
thermal stabilisation comparable to 10 mM of ATP (ΔTm 2.40˚C ± 0.02). By 20 µM (4:1) 
maximal stabilisation afforded by lapatinib was reached with a ΔTm 3.25˚C, with a 
similar thermal shift observed at 160 µM inhibitor concentration. Destabilisation of 
TRIB2 by all three covalent EGFR/HER2 inhibitors, occurred in a dose-dependent 
manner. Neratinib appeared to have the strongest affect, inducing marked 
destabilisation at 5µM (ΔTm 2.58˚C) and a maximal destabilisation at 160 µM inducing 
a thermal shift of 6.18˚C. Afatinib was the second most potent of the type IV inhibitors, 
influencing TRIB2 stability in a dose dependent manner with a maximal destabilisation 
of 4.57˚C at 160 µM compound concentration. Osimertinib, whilst inducing 
destabilisation in a dose dependent manner (maximal ΔTm of -2.98˚C exhibited at 80 
µM), was least effective. Consistent with our previous findings erlotinib at all 
concentrations tested did not produce a detectable thermal shift in TRIB2.Denaturation 
profiles (Figure 3.23B) show that inhibitors in relation to DMSO (black) induce typical 
thermal shifts.  
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Figure 3.23: Dose-dependent analysis of thermal shifts induced by clinical TRIB2 ligands. (A) 
Thermal shifts of 5 µM TRIB2 in the presence of compounds tested at 5, 10, 20, 40, 80 and 160 μM. 
(B) Thermal denaturation profiles of TRIB2 in the presence of increasing concentrations of inhibitor.  
 
B
3 0 3 5 4 0 4 5 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
L A P
D M S O
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 %
 m
a
x
Temperature /⁰C
lapatinib
2 5 3 0 3 5 4 0 4 5 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
A F A
D M S O
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 %
 m
a
x
Temperature /⁰C
afatinib
3 0 3 5 4 0 4 5
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
N ER
D M S O
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 %
 m
a
x
Temperature /⁰C
neratinib
2 5 3 0 3 5 4 0 4 5 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
O S I
D M S O
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 %
 m
a
x
Temperature /⁰C
osimertinib
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 %
 m
a
x
Temperature /⁰C
2 0 2 5 3 0 3 5 4 0 4 5 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
E R L
D M S O
erlotinib
A
L
A
P
A
F
A
N
E
R
O
S
I
E
R
L
-6
-4
-2
0
2
4
A F A
N ER
O S I
E R L
L A P
AFA
NER
SI
ERL
P
T
R
IB
2
 Δ
T
m
/⁰
C
Compound
T
R
IB
2
 Δ
T
m
/⁰
C
131 
 
3.8.2   Binding analysis of TRIB2 using Microscale Thermophoresis (MST) 
To further evaluate compound interactions with TRIB2, Microscale Thermophoresis 
(MST), a biophysical technique that detects the motion of fluorescent labelled proteins 
along a microscopic temperature gradient in a capillary, was used [260]. By exploiting 
the 6xHis tag, WT TRIB2 was labelled with nitrilotriacetic acid (NTA) conjugated to a 
fluorescent tag. 0.001-100 μM of compounds were titrated into 5μM of labelled TRIB2. 
Due to poor solubility of compounds in Tris pH 7.4, 100 mM NaCl and 1 mM DTT 
accurate data past 100 μM compound concentration could not be obtained. An 
interaction between afatinib and fluorescent NTA-coupled His-TRIB2 was detected, 
which could be fitted to a reversible binding event with a Kd value of ~16 µM (Figure 
3.24A). As MST is designed to evaluate saturated, reversible binding of small 
molecules to proteins, it can be argued that this value reflected the initial (reversible) 
binding before covalent modification [261]. To lend further support to this idea, the 
reversible EGFR/HER2 inhibitor TAK-285 was also tested, resulting in a predicted Kd 
of ~20 µM (Figure 3.24B). For a positive control Myeloid cell leukemia 1 (Mcl-1), a pro-
survival member of the Bcl-2 family (regulators of apoptosis) was assayed by MST in 
the presence of a selective inhibitor, A1210477. A sub-micromolar interaction of 740 
nM between MCL-1 and A1210477 was observed (Figure 3.24C) [262]. Previous TR-
FRET binding affinity assays for MCL-1 and A1210477 revealed a Kd of 430 nM [263]. 
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Figure 3.24: Microscale Thermophoresis (MST) analysis of compound binding. (A) MST analysis 
of reversible binding of afatinib to fluorescently labelled TRIB2. (B) MST analysis of reversible binding 
of TAK-285 to TRIB2. (C) Positve control of high-affinity (sub-micromolar) binding of A-1210477 to MCL-
1. Data for duplicate experiments were plotted. 
3.8.3   Counterscreen employing TRIB1 and C104Y TRIB2 
In order to test the mechanism and selectivity of the TRIB2 ligands discovered from 
DSF screening, TRIB1 84-372, TRIB1 84-343 and the ‘TRIB1-like’ C104Y TRIB2 
mutant were counter-screened. The αC-helix region of TRIB2 possesses distinct Cys 
residues at positions 96, 104 and 106, that are not present in TRIB1, TRIB3 or STK40 
(Figure 3.25B). As TRIB1 and C104Y TRIB2 are not destabilised by afatinib, neratinib 
or osimertinib, these distinct Cys residues could potentially be sites of covalent 
modification by type IV inhibitors.  
 As controls, the type IV inhibitors afatinib, neratinib and osimertinib destabilised 
TRIB2 (ΔTm -2.9, -3.3 and -2.1°C) (Figure 3.25A). Afatinib, neratinib and osimertinib 
did not destabilise either of the TRIB1 proteins analysed. TRIB1 84-372 in fact showed 
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a consistently positive ΔTm of ~1°C in the presence of both afatinib and osimertinib. 
Remarkably, upon mutation of Cys104 to Tyr in TRIB2, neratinib induced a positive 
thermal shift of 2.6˚C, confirming the importance of this TRIB2 residue in compound 
binding. Importantly, the type I PLK inhibitor GW804482X also destabilised C104Y 
TRIB2 and both TRIB1 proteins (Figure 3.25A). Consistently, lapatinib and TAK-285 
strongly stabilised WT-TRIB2 and C104Y TRIB2. Both TRIB1 proteins displayed a 
modest increase in melting temperature in the presence of lapatinib (ΔTm 1.68°C and 
1.54°C respectively) but not TAK-285. The established TRIB2 negative control EGFR 
type I inhibitor gefitinib did not induce a thermal shift in any of the proteins assayed. 
Finally, ATP did not induce a thermal shift in C104Y TRIB2 or either TRIB1 proteins, 
consistent with the TRIB1 crystal structure, which revealed an active site that occludes 
ATP binding due to the Tyr134 (Cys104 in TRIB2) causing the αC-helix and ‘SLE’ motif 
to adopt an inward orientation. The Leu226 residue of the SLE motif in TRIB1 is 
directed towards a binding pocket overlapping with the position usually occupied by 
the gatekeeper residue (Phe160), which is instead displaced towards the hinge region 
of the N- and C-terminal lobes [106]. In this ‘SLE-out’ conformation Leu226 of TRIB1 
stabilises the activation loop which obstructs the ATP binding pocket. The ‘SLE-in’ 
conformation, associated with conformational rearrangement upon C/EBPα substrate 
binding, in TRIB1 opens the a binding pocket that can bind to small molecule ATP 
mimicking inhibitors but not ATP [105].        
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Figure 3.25: Counter-screen of TRIB2 with a TRIB2 C104Y mutant and TRIB1. (A) DSF analysis of 
WT TRIB2, C104Y TRIB2, TRIB1 84-372 and TRIB1 84-343 in the presence of selected compounds. 
(B) Sequence alignment of the TRIB2, TRIB1, TRIB3 and STK40 β3-Lys and ‘αC-Helix’ revealing 
unique perhaps targetable Cys residues in TRIB2.   
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3.9 Mechanistic analysis of destabilisation 
As it was shown in section 3.6 that TRIB2 is stabilised by the C-terminal tail, it was 
next hypothesised that destabilisation of TRIB2 upon binding of type IV EGFR/HER2 
inhibitors resulted in displacement of the TRIB2 C-terminal tail.    
The thermal stability of the previously described TRIB2 truncation and AQLAA mutants 
(Figure 3.14) was assessed in the presence of selected kinase inhibitors, in order to 
interrogate the nature of TRIB2 stabilisation/destabilisation in the context of compound 
binding (Figure 3.26). As observed before, Full-length (1-343) TRIB2 was destabilised 
by covalent type IV EGFR/HER2 inhibitors afatinib and neratinib and the reversible 
type I PLK inhibitor GW804482X. Accordingly, the type I EGFR/HER2 inhibitors 
lapatinib and TAK-285 stabilised TRIB2. Consistently, the EGFR-specific inhibitor 
erlotinib had no discernible effect (Figure 3.26). The N-terminal deletion mutant of 
TRIB2 (54-343) displayed similar behaviour to WT when assayed by DSF; the TRIB2 
N-terminus had no effect on ΔTm values induced by any of the compounds. 
Conversely, in all proteins where the C-terminal tail was deleted (1-318 and 54-318) 
or mutated (AQLAA) afatinib and neratinib induced destabilisation was prevented. 
Interestingly, the C-Terminal deletion had negligible effect on GW804482X binding, 
supporting the hypothesis that type I compound binding modulates TRIB2 stability 
through an alternate mechanism. 
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Destabilisation by afatinib was also completely prevented in the AQLAA triple mutant, 
whereas neratinib effects were reduced by >50% (Figure 3.26). Furthermore, the 
destabilisation/stabilisation effect of GW804482X and lapatinib/TAK-285 was 
analogous to that observed in full-length TRIB2 (1-343).  
Previous ITC studies showed that a fusion protein, containing the C/EBPα recognition 
sequence, had reduced affinity for the pseudocatalytic domain in the presence of the 
C-terminus (Kd 7.2 µM) compared to the C-terminal deletion mutant (Kd 11 µM) [106]. 
This difference in affinity suggested competition between C/EBPα and C-terminal 
peptide binding. Following this, it can be proposed that an equilibrium exists between 
C-terminal peptide binding and dissociation resulting in ‘stabilised/closed’ and 
‘destabilised/open’ states, the latter potentiated by type IV inhibitor binding in TRIB2.   
3.10 Investigating covalent binding of type IV clinical inhibitors to 
TRIB2 
Cysteines are ideal for targeting ‘drug-resistant’ EGFR kinases, because the reactive 
thiol side-chain potentially represent an irreversible covalent target, depending on 
redox state [261], within the ATP-binding site for covalent type IV inhibitors [264, 265]. 
Afatinib, neratinib, osimertinib, dacomitinib and canertinib are type IV inhibitors of 
EGFR and HER2 tyrosine kinases [264], and function by first reversibly binding to the 
catalytic domain of their targets (Cys797, Cys805, or Cys803 for EGFR, HER2, and 
HER4, respectively). The conformational changes associated with initially reversible 
binding to the catalytic domain potentially brings the cysteine residue closer to the β-
carbon of the enamide functional group. Subsequently the sulfhydryl of the Cys 
residue becomes deprotonated by a base and performs an electrophilic attack on the 
β-carbon of the enamide moiety in a Michael 1,4 addition reaction to form a covalent 
adduct [265] (Figure 3.27). This mechanism is hypothesised to instigate covalent 
binding of afatinib and neratinb to distinct cysteines of TRIB2.   
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Figure 3.27: Proposed chemical mechanism of covalent inhibitor binding to cysteine residues 
by a Michael 1-4 addition. 1. The sulphur in the thiol of a cysteine in a polypeptide becomes 
deprotonated by a base and performs electrophilic attack on the β-carbon, which causes an electron 
rearrangement and formation of an enolate. 2. The enolate becomes protonated to form an enol. 3. The 
enol tautomerizes to a more energetically favourable state through bond rearrangement. 
 
3.10.1   Covalent binding of AFA and NER to TRIB2 
In order to confirm whether afatinib and/or neratinib covalently interact with TRIB2, 
mass spectrometry (MS) analysis was performed (Figure 3.28A). As these inhibitors 
possess an electrophilic ‘warhead’ designed to covalently modify target cysteine 
residues, it was hypothesised that afatinib and neratinib covalently bind to TRIB2 at a 
certain solvent exposed cysteine residue(s). As shown in Figure 3.28A the intact mass 
spectrometry (MS1) of 5 µM TRIB2 1-343, incubated with 25 µM of afatinib for 15 
minutes, revealed peaks corresponding to His-tagged TRIB2 1-343 with the added 
mass of either 1 or 2 afatinib molecules. Subsequently a chymotryptic digest and 
Higher-energy collisional dissociation (HCD) mass spectrometry (MS2) revealed a 
product ion representing the TRIB2-derived DISC96Y:afatinib peptide adduct at m/z 
543.2 (Figure 3.28B). Unequivocal evidence that the modification of TRIB2 at Cys96 
was due to afatinib came from the characteristic nature of the measured:theoretical 
isotopic ratio of the 35Cl or 37Cl-containing peptide ions (Figure 3.27C). Evidence of a 
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second site of covalent modification arose from MS2 analysis of 5 μM TRIB2 incubated 
with 25 μM neratinib for 15 minutes. A reducing chemotrypsin digest identified a 
distinct peptide which included Cys96 plus the molecular weight of neratinib (Figure 
3.28D). In addition, another peptide containing Cys104 of TRIB2 was found to be 
modified by neratinib (Figure 3.28E). The MS evidence suggests that afatinib and 
neratinib can bind to TRIB2 and modify Cys residues 96 and 104 located within the 
TRIB2 αC-helix (figure 3.25B).   
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Figure 3.28: Mass spectrometry (MS) analysis of TRIB2 bound to afatinib and neratinib. (A) Intact 
mass spectrum (MS1) for purified TRIB2 pre-incubated with afatinib for 15 minutes at 20°C. (B) MS2 
spectra generated by Higher-energy collisional dissociation (HCD) of chymotryptic peptides derived 
from 5 μM full length His-tagged TRIB2 1-343 incubated with 20 μM afatinib for 15 minutes The doubly 
charged ion at m/z 543.2 confirms covalent binding of afatinb to Cys96 in the diagnostic Asp-Ile-Ser-
Cys96-Tyr tetrapeptide derived from chymotrypsin digestion. (C) The isotopic distribution for the 543.2 
m/z ion precisely matches the theoretical isotopic distribution for an ion containing chlorine isotopes 
35Cl and 37Cl, which are present in the spectrum due to the chlorofluro-benzyl moiety present in afatinib. 
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(D) Binding of neratinib to Cys96 and (E) Cys104 of TRIB2. 5 µM of His-TRIB2 was incubated with 25 
µM of neratinib for 15 minutes at 20 °C before reducing chymotrypsin digest and HCD MS2 analysis. 
Product ion mass spectra revealed two TRIB2 peptides modified with neratinib at Cys96 and 104. MS 
was performed by Samantha Ferries.    
 
3.10.2   Analysis of TRIB2 Cys mutations 
MS analysis had revealed covalent interactions of afatinib and neratinib with αC-helix 
Cys residues 96 and 104. To evaluate this binding mode further, recombinant His-
TRIB2 C96S, C104S and C96/104S were generated by site directed mutagenesis and 
purified from bacteria. Proteins were purified by IMAC and SEC to homogeneity 
(Figure 3.29A). In contrast to the previously described Cys104 to Tyr mutant (Figure 
3.9B), mutation of either one or both Cys96 and 104 residues to the closely related 
amino acid serine did not alter the thermal stability of TRIB2 (Figure 3.29B). DSF 
assays were then used to assess the thermal stability of the Cys mutant TRIB2 
proteins in the presence of selected inhibitors. As demonstrated previously, afatinib 
and neratinib destabilise TRIB2 by 3.1 and -2.7°C respectively (Figure 3.29C). 
Interestingly, mutation of either Cys residues, 96 or 104, was sufficient to preclude 
destabilisation, apparent from the observation of no discernible thermal shift for C96S, 
C104S or C96/104S TRIB2 in the presence of afatinib and neratinib.  
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Figure 3.29: TRIB2 Cys 96 and 104 mutants are not destabilised by type IV EGFR/HER2 
inhibitors. (A) Recombinant TRIB2 cysteine mutant proteins employed for in vitro analysis. 5 μg of the 
indicated purified proteins were resolved by SDS-PAGE. (B) Thermal denaturation profiles of 
recombinant proteins. (C) Comparative DSF thermal shift analysis of TRIB2 Cys-mutated proteins 
measured in the presence of a panel of compounds (20 μM).  
The reversible type I PLK inhibitor GW804482X (Figure 3.29C), which was shown 
previously to destabilise WT TRIB2, has a similar destabilising effect on all TRIB2 Cys 
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TRIB2 destabilisation was prevented when the Cys residues involved in covalent 
binding (elucidated by MS) are mutated, it can be hypothesised that the irreversible 
targeting of these distinct Cys residues induced the destabilisation effect on TRIB2. 
Lapatinib, TAK-285 and ATP+EDTA did indeed stabilise WT TRIB2 and all three 
cysteine mutants. This lends credence to the idea that mutation of residues 96 and 
104 to serine was not detrimental to global protein integrity, as the binding of ATP 
competitive ligands and ATP was not impacted. 
3.10.3   Computation model of afatinib and neratinib binding to TRIB2 
To examine the potential interaction of afatinib and neratinib with the TRIB2 
pseudokinase and C-terminal domain (41-343) in silico, a model was generated by Dr 
Natarajan Kannan (University of Georgia), using the crystal structure of TRIB1 as a 
template in PyMOL. The AutoDock Vina plugin was used in studies to assess 
compound binding in silico [266]. An unbiased search of TRIB2 (41-343) revealed 
putative binding-pockets close to Cys96 and the potential binding modes for afatinib 
and neratinib using a covalent docking approach were assessed [267]. Figure 30 
shows that the compounds were flexibly docked to the protein by covalently linking the 
electrophilic enamide to the sulfhydryl Cys. Docking of covalent inhibitors revealed a 
putative binding pocket formed by residues from the vestigial TRIB2 C-helix, including 
Cys96, the P-loop and the activation loop.  
 
 
144 
 
 
Figure 3.30: Molecular model of TRIB2 bound to afatinib (A) and neratinib (B). The TRIB2 
pseudokinase domain was modelled based on an ‘SLE-in’ TRIB1 crystallographic conformation and 
subjected to energy minimization followed by docking of compounds revealing the enamine moiety 
situated next to Cys96. Distinct solvent exposed Cys residues 104 and 106 are also highlighted. (C) 
Analysis of afatinib binding to the EGFR hinge region (PDB ID: 4G5J) with the tyrosine kinase domain 
in an active ‘DFG-in’ conformation. The enamine moiety was revealed to be in close proximity to Cys797 
of EGFR. Computational analysis was performed by Safal Shrestha (University of Georgia, USA).  
 
In contrast to the known structure of EGFR bound to afatinib, it was revealed that 
TRIB2 adopts a unique binding mode that is both structurally and energetically-
feasible. In a molecular dynamics simulation (Figure 3.31) both afatinib and neratinib 
remained stably bound to TRIB2 for ~17 ns. Interestingly a similar time for afatinib and 
EGFR interaction was reported, giving confidence in this model of TRIB2 covalent 
modifications. Additionally the enamide β-carbon remained within 3-5 Å of the Cys96 
sulphur atom during the simulation, which is a viable distance for covalent adduct 
formation [213].  
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Figure 3.31: Molecular dynamics simulation of afatinib and neratinib binding to TRIB2 and EGFR. 
A 20 nanoseconds (ns) molecular dynamics simulation was employed to analyse binding of afatinib and 
neratinib in the binding modes modelled in figure 3.30. Interactions of afatinib and neratinib adjacent to 
EGFR Cys797 and TRIB2 Cys96 were stable for ~17 ns with predicted distance of the sulphur atom to 
the enamide β-carbon in Å. Analysis was performed by Safal Shrestha (University of Georgia, USA).   
 
The binding surface for the TRIB1 C-terminal tail forms when the activation loop folds 
away from the αC-helix and the pseudokinase domain is sustained in an ‘SLE-out 
conformation’ [105], blocking the putative ATP-binding pocket. Upon substrate 
binding, and speculatively for TRIB2 upon covalent kinase inhibitor binding (Figure 
3.32), the activation loop becomes fully ordered and folds between the N and C lobes 
of the pseudokinase domain and movement of the αC-helix completes the regulatory 
spine. Thus, compound binding is proposed to induce an open ‘destabilised’ 
conformation in TRIB2 (Figure 3.32).   
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Figure 3.32: Proposed modulation of TRIB2 conformation upon compound binding. The crystal 
structures of TRIB1 in the SLE-in and SLE-out conformation were used to illustrate the proposed 
conformational change that occurs in TRIB2 upon binding of covalent inhibitors afatinib and neratinib. 
Data was obtained from Jamieson and colleagues (2018) [105]. 
 
3.11 Discussion  
3.11.1   Biochemical characterisation of recombinant TRIB proteins 
The aim of the studies carried out in this chapter was to discover novel small molecule 
ligands that bind to TRIB2 using an unbiased TSA [58, 60]. To this end, functional and 
folded monomeric recombinant His-tagged human TRIB2, expressed in E. coli was 
purified into a buffer composed of 20 mM Tris pH 7.4, 100 mM NaCl, 1 mM DTT and 
10% glycerol. The presence of TRIB2 was confirmed using a combination of SDS-
PAGE, MS and immunoblotting. Recombinant TRIB2 had the propensity to aggregate 
if at a concentration over 5 mg/mL (>100 μM). The instability of monomeric soluble 
TRIB2 is perhaps a primary factor as to why there is yet no structural information 
available. Consistent with previous findings TRIB2 was more stable in Bicine pH 9.0 
[60] than Tris pH 7.4 and least stable in Hepes pH 7.6, which was incidentally the 
optimal buffer for TRIB1 purification reported previously [106]. Although TRIB2 was 
more stable in the presence of reducing agent there was no significant difference 
between 3 reducing agents tested (TCEP, DTT and BME) (Figure 3.3). Importantly, 
with DTT as the reducing agent in Tris pH 7.4 buffer, TRIB2 was found to bind to a 
physiological target, C/EBPα p42 in vitro (Figure 3.5).   
‘SLE-out’ ‘SLE-in’
+ afatinib/neratinib
Activation loop
Activation loop
αC-helix
αC-helix
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In agreement with previous findings [60] TRIB2 was thermally stabilised by ATP and 
EDTA. In contrast to the canonical kinase PKA [250], binding was inhibited in the 
presence of magnesium ions. Indeed, TRIB2 did autophosphorylate weakly in the 
presence of ATP and EDTA, but not ATP and magnesium, the canonical co-factor 
complex in most kinases. Due to the apparent thermal stabilisation in the presence of 
EDTA alone, and no destabilisation in the presence of magnesium ions alone, it seems 
logical that EDTA was not only acting as a metal ion chelator but also interacting with 
TRIB2 (Figure 3.6). Conceivably this interaction allowed TRIB2 to take on a 
conformation more amenable to ATP binding. As hyper-stable C104Y TRIB2 was not 
stabilised by either EDTA or ATP (Figure 3.9C), nor was TRIB1 (Figure 3.11B), it is 
plausible that these proteins were stabilised in an ‘SLE-out’ conformation. Structural 
analysis of TRIB1 and TRIB1 co-crystallised with C/EBPα [105, 106], reveals a Tyr 
residue in the αC-helix at the equivalent (134) position causing TRIB1 to adopt an 
inactive conformation, consistent with my findings.  
Chromatography analysis suggested that the pseudokinase domains of TRIB1 (Figure 
3.10) and TRIB2 and the TRIB2 COP1 binding site AQLAA mutant can dimerize 
(Figure 3.13). This could be indicative of a yet unknown regulatory function of tribbles 
upon uncoupling of the C-terminal tail. Where TRIB2 was more thermally stable in the 
presence of the C-terminal tail (Figure 3.14), suggestive of a functional interaction 
between the C-terminal tail and pseudocatalytic domain, TRIB1 was not (Figure 
3.11A). This was surprising since this was not reported previously [106], although this 
could be explained by an apparent decreased TRIB1 stability with buffer exchange 
and the protein concentration steps employed. Purified and buffer exchanged TRIB1 
84-372 Tm was measured at 41.9˚C (Figure 3.11A). However previous studies 
reported a TRIB1 84-372 Tm of 49˚C [106]. Strikingly the thermal stability of both the 
TRIB1 catalytic domain alone (84-343) and with the C-terminal tail (84-372) had a 
considerably increased melting temperature (~5˚C) in alkaline Bicine pH 9.0 only in 
the presence of reducing agent (DTT) (Figure 3.12). Understanding potential structural 
changes in the presence of different buffers would be interesting to elucidate in future 
experiments. 
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3.11.2   Can the TRIB2 C-tail be uncoupled with stapled peptides? 
Previous studies revealed an interaction between C/EBPα and the TRIB1 αC-helix 
[105, 106], and that competition for binding with the TRIB1 C-terminal tail can take 
place. Compounds and peptides that compete for binding in the unusual αC-helix 
region of TRIB2 could modulate binding and signalling outputs of known TRIB2 
interactors, for instance C/EBPα, CDC25C and AKT [102, 103, 109]. TRIB2 is involved 
in a plethora of signalling pathways so, therefore, it may be difficult to decipher TRIB2 
outputs with repurposed small molecule inhibitors. In this chapter it was also 
discovered that a synthetic stapled TRIB2 C-terminal peptide also had the ability to 
destabilise TRIB2 in vitro (Figure 3.15), in a manner that was dependent on the C-
terminal region, but did not occur with a scrambled peptide. The TRIB2 catalytic 
domain alone (54-318) was not as potently destabilised by the TRIB2 C-terminal 
stapled peptide, indicating that destabilisation results from uncoupling of the TRIB2 C-
terminal tail. In contrast, and in a dose-dependent manner, full length TRIB2 was 
destabilised by such peptides, indicating that peptides can be used to target this 
unique feature tribbles pseudokinases.   
Cell-permeable TRIB2 ‘specific' stapled peptides might therefore be used to 
investigate signalling in cellulo, potentially reducing complication of factoring-in 
targeted (and off targeted) effects of kinase inhibitors that appear inevitable.  
Stapled peptides based on a helix from the Ras exchange factor Son of Sevenless 
(SOS) have been used to target KRAS [268]. Although successfully inhibiting ERK-
MAP kinase phosphosignalling the Ras-binding peptides described by Leshchiner et 
al (2015) are not selective for the GTP-bound form of the Ras protein [268]. In fact, 
Thomas et al (2016) were able to target GTP-bound Ral with a single helix stapled 
peptide, providing proof-of-principle for the maturation to therapeutically useful 
antagonists of Ras signalling [269]. Targeting scaffolding functions of TRIB2 with 
stapled peptides might also modulate interactions with C/EBPα or AKT [103, 109] and 
have consequences on downstream signalling. The hypothesis that stapled peptides 
could abrogate PPIs is also supported by studies carried out by Fulton et al (2018) 
who showed that targeting the H-helix of EGFR could prevent dimerization, inhibit 
phosphorylation and downstream signalling in MDA-MB-231 cell based assays [270].  
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3.11.3 ATP binding and targeting with ATP-competitive inhibitors 
The majority of kinase inhibitors are reversible and ATP-competitive, and interact with 
the ATP binding site in a stereotypical fashion [207, 271]. The mechanism by which 
most canonical kinases bind and hydrolyse ATP is also highly conserved, therefore, 
achieving selectivity with small molecules has proven extremely challenging [271]. 
However, the promiscuity of such inhibitors may be exploited to discover new drug 
targets, and indeed, targeting of multiple kinase family members in some therapeutic 
circumstances could be beneficial. Dasatinib, a highly promiscuous type I inhibitor, is 
approved for the treatment of imatinib-resistant chronic myeloid leukaemia (CML). 
Kinome wide profiling shows that dasatinib inhibits all nine members of the Src family 
of kinases (and numerous other kinases) [271, 272]. Despite this lack of selectivity, 
dasatinib exhibits a more favourable side effect profile than conventional cytotoxic 
chemotherapy. Indeed compounds have the potential to not only be repurposed as 
selective TRIB2 ligands, but be used for polypharmacological therapy where TRIB2 is 
a driver of disease or drug resistance [103, 104, 109]. This, together with previous 
studies suggesting that TRIB2 is ‘druggable’ [60], formed the rational to screen TRIB2 
using PKIS1 [273].   
From screening a library of known small molecule kinase inhibitors (PKIS1) it was 
discovered that distinct classes of ATP-competitive dual EGFR/HER2 ligands, 
including thienopyrimidines [257] and thiazolylquianazolines [256] modulated TRIB2 
stability when analysed by DSF (Figure 3.17). Several EGFR/HER2 inhibitors are 
commercially available and a panel was created to analyse alongside TRIB2 by DSF 
(Figure 3.21). It was discovered that lapatinib and the pyrrolo[3,2-d]pyrimidine 
EGFR/HER compound TAK-285 strongly stabilised TRIB2. TRIB2 stabilisation could 
be informative of conformational changes upon inhibitor binding as lapatinib and TAK-
285 both bind to HER2 in an active ‘DFG in’ conformation. In the absence of a high-
resolution TRIB2 pseudokinase crystal structure, conformation(s) relevant for small 
molecule interaction are not yet known. However, there is ~71% sequence similarity 
between TRIB2 and TRIB1. Critically, TRIB1 can adopt two conformations, ‘SLE-in’ 
and ‘SLE-out’, the former vulnerable to small molecule compounds [105]. Therefore, 
it is conceivable that an ‘SLE-in’ conformation in TRIB2 is targeted by small molecule 
inhibitors. Analysis of a β3 lysine mutant, which suggested that compound binding was 
in the atypical TRIB2 nucleotide-binding site, offers further support to this conclusion 
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[258]. Binding of lapatinib was abolished upon mutation of the TRIB2 β3 lysine. This 
Lys is not only important for interaction with the α and β ATP phosphates, but can also 
form a salt bridge with a conserved Glu residue in the αC-helix which maintains the 
kinase domain in an active conformation [37]. However, the melting temperature of 
TRIB2 K90M was reduced compared to WT (Figure 3.20), suggesting an important 
role for this residue in global protein stability. Therefore, it is difficult to definitively 
conclude that these inhibitors are stabilising TRIB2 by binding to the active site or 
inducing an ‘SLE-in’ conformation, as K90M may be too dissimilar to WT to glean 
mechanistic information. The TRIB2 ‘SLE-out’ conformer may also be amenable to 
inhibitor targeting that bind in an allosteric mode. In an inactive conformation, the 
positioning of the αC-helix results in exposure of a targetable allosteric binding pocket 
present in kinases such as ERK1/2, which are targeted by inhibitors including 
SCH772984 [274].  
As well as thienoyrimidine base EGFR/HER2 dual inhibitors, an abundance of 
benzimidazole based inhibitors, originally designed to target both TIE-2 and VEGFR-
2 kinase domains, were discovered. However, due to the availability of various clinical 
inhibitors with well characterised mechanisms of binding, attention was focused 
towards EGFR/HER2 clinical type inhibitors. These included type IV irreversible 
inhibitors afatinib, neratinib and osimertinib, which although initially unexpected, 
induced a decrease in TRIB2 thermal stability in vitro (Figure 3.21).  
3.11.4 Targeting TRIB2 with type IV EGFR/HER2 inhibitors 
Type IV ‘third generation’ EGFR inhibitors contain well-established kinase inhibitor 
chemotypes that have been modified to include an electrophilic ‘warhead’ to react with 
nucleophilic thiol groups of cysteine residues found in their targets. Structure guided 
design of type IV from type I inhibitors owes fruition to the availability of high resolution 
crystal structures. Afatinib, neratinib, osimertinib, dacomitinib and canertinib all 
possess the same quinazoline-based scaffold as gefitinib with a strategically 
positioned enamide moiety [213]. Co-crystal structures of gefitinib and afatinib in 
complex with EGFR confirmed formation of the non-covalent instigated through 
interaction of nitrogen, on the quinazoline ring in the hinge binding motif, which is 
required to stabilise compound orientation and give sufficient time for covalent bond 
formation [213].  
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Irreversible binding poses serval distinct advantages, including enhanced selectivity, 
long-lasting cellular inhibition and lower concentrations required at site of action [207, 
213]. As it was demonstrated from the PKIS1 DSF screen that EGFR/HER2 dual type 
I inhibitors seemed to have broad cross reactivity with TRIB2, type IV EGFR/HER2 
inhibitors were also tested. Despite being developed from gefitinib, which had no effect 
on TRIB2 thermal stability, TRIB2 thermal stability was in fact decreased in the 
presence of afatinib, neratinib and osimertinib but not dacomitinib or canertinib. 
Interestingly, afatinib, neratinib and osimertinib destabilised TRIB2 but not TRIB1 or 
C104Y TRIB2 (Figure 3.25) in a dose dependent-manner (Figure 3.23). Although like 
TRIB2, destabilisation of TRIB1 was evident in the presence of GW804482X, which is 
perhaps indicative of an alternative targetable conformation in both these Tribbles 
pseudokinases.  
Using MS, it was possible to detect covalent binding of afatinib and neratinib to TRIB2 
at residues Cys 96 and 104 (Figure 3.28), mutation of which to Ser residues abolished 
destabilisation detected by DSF (Figure 3.29). Moreover, these Cys residues are 
absent in TRIB1, TRIB3 and STK40, which may lead to selectivity to evaluate TRIB2 
signalling in cellular contexts. Consistent with this hypothesis, only WT TRIB2 was 
destabilised by afatinib, neratinib or osimertinib (Figure 3.25) when analysed by DSF. 
Targeting pseudokinase domains with covalent compounds to investigate signalling 
builds upon Xie et al (2014) who found that the ligand TX1-85-1 was able to covalently 
bind to HER3 at Cys721 in the roof of the ATP binding pocket, leading to HER3 
degradation in cells and in turn inhibited HER3-mediated signalling [62].   
In EGFR, binding of afatinib to HER2 induces repositioning of the αC-helix bringing 
the enamide moiety closer to Cys797. Afatinib and neratinib covalently bind to EGFR, 
HER2 and HER4 (at Cys 797 in EGFR, Cys805 in HER2 and Cys803 in HER4) [213]. 
The equivalent residue in HER3 is Ser794, which results in reversible binding of 
afatinib and conformational change giving rise to an active state with low catalytic 
activity [131]. The kinetics of reversible interactions of type IV covalent inhibitors were 
explored by Schwartz et al (2014), using nonreactive compound analogues and 
biochemically by analysing recombinant EGFR with sulfinylated and glutathiolated 
cysteine residues [261]. MST was used to measure reversible binding of afatinib to 
TRIB2 with a Kd of 16 µM (Figure 3.23). Molecular modelling and simulation suggest 
that the enamide of both afatinib and neratinib and the sulfhydryl of Cys96 in TRIB2 
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remain ~5 Å apart for ~17 ns, which is thought to be sufficient for covalent bond 
formation [267].  
When the key TRIB2 cysteine residues involved in covalent binding of afatinib and 
neratinib were mutated, there was no longer any destabilisation (Figure 3.29), 
supporting the hypothesis that destabilisation results from covalent binding. 
Presumably there was transient reversible binding event, which did not result in a 
change in TRIB2 thermal stability. Further biophysical analysis of compound binding 
to TRIB2 Cys mutants should be considered using ITC and NMR, although poor 
compound solubility and low protein stability thus far has limited such studies. 
3.11.5 Mechanistic analysis of TRIB2 destabilisation with covalent compounds 
Similar to effects previously observed for TRIB1 [265], when the C-terminal tail 
(containing the DQLVP motif) of TRIB2 (1-318 and 54-318) was deleted or mutated 
(AQLAA), protein stability was reduced. These data supports the hypothesis that 
pseudokinase-domain docking to the C-terminal tail generates a thermally-stable 
conformation TRIB2. The functional divergence of C-tail interactions, in-cis, within the 
kinase domain has also been observed in AGC kinases PKA, PKB and PKC [24]. The 
C-terminal tail of AGC kinases possess three separate regions that interact with the 
kinase domain: the N-lobe tether (NLT), the active-site tether (AST), and the C-lobe 
tether (CLT).  Conservation of the C-tail was also found in AGC kinase family members 
across diverse organisms, suggesting an evolutionary mode of regulation. The 
conservation of residues within the kinase domain of AGC kinases that directly interact 
with the C-tail suggests that the catalytic core may have coevolved with the C-tail [24]. 
In Tribbles pseudokinases, TRIB2 being the ancestor [104], co-evolution of the 
pseudokinase domain and regulatory interaction with the C-terminal tail is also 
apparent. Interestingly, certain TRIB2 orthologues (for instance in the pathogenic 
thread worm) lack both sequence similarity in the C-terminal tail COP1 binding site 
and the normally complementary docking region for the tail in the pseudokinase N-
lobe [104].   
When assayed in the presence of compounds, destabilisation of TRIB2, induced by 
covalent inhibitors afatinib and neratinib, occurred only in the presence of an intact C-
terminal tail (Figure 3.26). This indicated that compound-induced destabilisation 
resulted from the TRIB2 pseudokinase domain becoming uncoupled from the C-tail. 
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The orientation of the ‘SLE’ motif which creates a binding pocket for the E3 ubiquitin 
ligase binding motif (DQLVP) in the C-terminal tail could be a unique feature of Tribbles 
pseudokinases [105, 106]. The dynamic interaction between the TRIB2 C-terminal tail 
and pseudokianse domain could potentially be targeted with small molecule inhibitors.  
In Chapter 4 I address the use of small molecules to target exogenous and 
endogenous TRIB2 in human cells. By using mutagenesis and cellular thermal shift 
assays (CETSAs) as validation approaches, and by analysing TRIB2 signalling 
outputs in intact cells, I have begun to elucidate targeted interactions of compounds 
with TRIB2. Such an initial analysis is important to determine whether or not small 
molecule kinase inhibitors can be used as chemical probes to evaluate cellular 
functions of TRIB2 and to furnish the first potential therapeutic leads for evaluation of 
diseases associated with TRIB2 (over)expression [275].   
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Chapter 4: Investigating TRIB2 with small molecule kinase 
inhibitors in human cells 
Introduction  
In chapter 3, I demonstrated that TRIB2 pseudokinase-domain intramolecular docking 
to the C-terminal tail generated a thermally-stable conformation in TRIB2, and that 
covalent binding of several type IV (covalent) dual EGFR/HER2 inhibitors disturbed 
this interaction, causing TRIB2 to adopt a destabilised conformation. In this chapter I 
address whether small molecules that bind to TRIB2 in vitro can be used to interrogate 
the functions of exogenous and endogenous TRIB2 in human cells. 
TRIB and STK40 proteins are thought to exert their cellular signalling roles by acting 
as scaffolds to bridge (and regulate) components of AKT signalling networks or 
functioning as adaptors that recruit ubiquitin E3 ligases, such as COP1, resulting in 
ubiquitination and subsequent proteasome-mediated degradation of substrates, such 
as C/EBPα, CDC25C and Acetyl Coenzyme A carboxylase (ACC) [276-278]. Tribbles 
family members are differentially expressed in numerous tissues where they have 
been reported to have context specific roles [279]. For instance, TRIB3 has been 
shown to negatively regulate AKT in the liver [124], TRIB1 and TRIB2 are proposed to 
serve scaffolding roles to modulate MAPK kinase signalling [279, 280] and recently 
TRIB2 overexpression has been shown to induce AKT phosphorylation at Ser473, 
contributing to clinical resistance to inhibitors of the PI3K signalling network [103].  
In order to better understand the roles of TRIB2 in cellular signalling, the effects of the 
repurposed EGFR/HER2 ligands, described in the previous chapter, were analysed in 
exogenous TRIB2 expressing stable cell models and in a leukaemia cell model, where 
endogenous TRIB2 overexpression is linked to pathogenicity. It was hypothesised that 
if selected reversible and irreversible EGFR/HER2 inhibitors could bind to TRIB2 in 
cells, then it may be possible to probe and gain insights into TRIB2 functions in cellular 
signalling. If small molecule kinase inhibitors can modulate TRIB2 activity in cells, they 
may provide a foundation for the development of therapeutic strategies where TRIB2 
overexpression or mutation is a contributor to disease aetiology. The objectives of the 
work described in this chapter were to: 
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1. Generate tetracycline (TET) inducible isogenic stable human cell lines and 
evaluate cellular expression of (exogenous) TRIB2.  
2. Discover whether or not small molecule kinase inhibitors can modulate the 
stability of TRIB2 in stable human cells, with targeted validation approaches 
such as cellular thermal shift assays (CETSAs) and mutational analysis.   
3. Analyse the effects of TRIB2 expression on cellular signalling with the 
application of potential repurposed inhibitors.  
4. Discover whether or not ‘repurposed’ inhibitors can be used to interrogate 
endogenous TRIB2 functions in a human leukaemia cell model.  
 
Results 
4.1 Detection of FLAG-tagged TRIB2 in transfected HeLa cells and 
development of inducible TRIB2 expressing stable cell line 
4.1.1 Transient transfection of HeLa cells for FLAG-TRIB2 expression 
In order to generate a positive control for immunoblotting with an anti-FLAG antibody, 
recombinant TRIB2 with an N-terminal 6His tag followed by a single FLAG peptide 
sequence (DYKDDDDK) was purified from E. coli (Figure 4.1A). As well as serving as 
a control, varying amounts of E. coli purified His-FLAG-TRIB2 were analysed by 
immunoblotting to generate a standard curve to estimate levels of FLAG-TRIB2 
expression in HeLa cells [281, 282] (Figure 4.1B). Immunoblot analysis utilising a 
commercial anti-FLAG (Sigma Aldrich) antibody revealed that 50 ng of recombinant 
His-FLAG-TRIB2 could be detected after a short exposure of 10 seconds using ECL 
reagent (Figure 4.1B). Up to 500 ng of recombinant FLAG-TRIB2 could be detected 
before signal saturation. In the final lane (Figure 4.1B left) whole cell lysate obtained 
from TET induced transiently transfected HeLa Flp-In T-Rex (with pcDNA5/FRT/TO 
encoding FLAG-TRIB2) was analysed. FLAG-TRIB2 was only observed in the 
presence of TET, levels of which were calculated by plotting a standard curve of the 
relative densitometry values (ImageJ software) from recombinant FLAG-TRIB2 signal 
(Figure 4.1B right). The predicted amount of FLAG-TRIB2 expressed in HeLa cells 
was ~7.5 ng FLAG-TRIB2 per µg of whole cell lysate.  
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To optimise lysate loading for immunoblot analysis increasing amounts (between 10-
160 µg) of lysate from TET induced transiently transfected HeLa cells were analysed 
by immunoblotting with anti-FLAG and anti-Histone H3 (loading control) (Figure 4.1C). 
Detection of Histone H3 also provided evidence that the nuclear components of the 
HeLa cells were obtained during lysis [283]. Detection of FLAG-TRIB2 was clear in 40, 
but not, 20 µg lysate at an exposure of 10 seconds, although a longer exposure was 
not tested. Incomplete transfer of lysate proteins from SDS-PAGE gels to 
nitrocellulose was observed when 160 µg of lysate was subjected to electrophoresis, 
with a substantial amount of protein still visible in the coomassie-stained gel post 
transfer (data not shown). Therefore, 40 µg of whole cell lysate, which was well within 
the limit of linear detection for TRIB2, was used for immunoblot analysis.  
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Figure 4.1: Detection of recombinant FLAG-TRIB2 and comparison of expression levels in stable 
and transient HeLa Flp-In T-Rex cells. (A) SDS-PAGE analysis of 5 μg IMAC and SEC purified His-
TRIB2 and His-FLAG-TRIB2.(B) Western blot of increasing amounts of recombinant His-FLAG-TRIB2 
and by 40 µg of whole cell lysate from pcDNA5/FRT/TO FLAG-TRIB2 lipofectamine transiently 
transfected TET induced parental HeLa Flp-In T-Rex cells. Normal ECL reagent was used for a 
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detection time of 10 seconds (left). Densitometry analysis of recombinant FLAG-His-TRIB2 standards 
and estimated amount of FLAG-TRIB2 observed in 40 µg of transient whole cell lysate (right). (C) Flp-
In T-REx-HeLa cells were transiently transfected and induced with TET to express FLAG-TRIB2. 
Varying quantities of lysate were subjected to electrophoresis and analysed by immunoblotting. (D) 
Establishment of stably expressing FLAG-TRIB2 HeLa cells and optimisation of loading. Stable Flp-In 
T-REx-HeLa cells that expressed FLAG-TRIB2 upon incubation with tetracycline (TET) were incubated 
with 1 μg/mL of TET for 16 hours. Whole cell extracts were then obtained and the indicated amount of 
loaded into lanes on an SDS-PAGE gel followed by immunoblotting to detect FLAG-TRIB2. Histone H3 
served as the loading control. ECL select reagent with an exposure time of 15 seconds. (E) Western 
blot of TET induced and non-induced lysates from a WT FLAG-tagged TRIB2 stably expressing HeLa 
cell line followed by increasing amounts of recombinant His-FLAG-tagged TRIB2 standards. ECL select 
reagent was used for a detection time of 15 seconds (left). Densitometry analysis of recombinant His-
FLAG-TRIB2 standards and estimated amount of FLAG-TRIB2 observed in 40 µg of stable whole cell 
lysate (right). (F) Stable FLAG-TRIB2 Flp-In T-REx-HEK293 cells were generated. Transfected FLAG-
TRIB2 Flp-In T-REx-HEK293 cells were seeded in 10 cm dishes at a density 2.2 x 106 for 24 hours then 
incubated +/- 1 μg/ml of tetracycline (TET) for 16 hours. Whole cell lysates were prepared followed by 
western blot analysis using ECL select reagent for detection. An exposure time exposure time of 20 
minutes was used to attempt detection of FLAG-TRIB2.  
 
4.1.2 Establishment of an inducible FLAG-TRIB2 expressing stable HeLa cell 
line 
In order to generate stable FLAG-TRIB2 expressing cell lines, parental HeLa Flp-In T-
Rex cells had been co-transfected with pcDNA5/FRT/TO (encoding FLAG-TRIB2) and 
pOG44 plasmids to insert the FLAG-TRIB2 gene into the FLP-recombinase site, which 
was under control of a tetracycline-regulated CMV/TetO2 promoter [284]. Cell that had 
successfully integrated the TRIB2 transgene were selected using 200 μg/mL of 
hygromycin (chapter 2, section 2.19).  
Stable isogenic HeLa cells were cultured in 10 cm dishes to ~70% confluence, 1 μg/mL 
of TET added directly to the medium and the cells incubated for a further 16 hours. 
Whole cell lysates were obtained by lysis of cells (after washing) in RIPA buffer, 
followed by SDS-PAGE and immunoblot analysis with an anti-FLAG antibody (Figure 
4.1D). Histone H3 served as the loading control [283]. The more potent detection 
reagent ECL select (Amersham) had to be utilised to observe FLAG-TRIB2 in stable 
HeLa lysate, consistent with the lower levels of expression. TET induced HeLa cells 
(Figure 4.1D) had detectable levels of FLAG-TRIB2 with little to no detectable protein 
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at this molecular weight in the absence of TET. In lane 2 (-TET) there was a faint band 
that corresponded to the FLAG-TRIB2 molecular weight, which could have been due 
to either the α-FLAG antibody binding to cross reactive protein(s) or to low levels of 
leaked expression. In the repeat experiment (Figure 4.1D lane 3 and 4) had no 
detectable protein at this molecular weight. Consistently, another potential non-
specific band was observed between the molecular weights of 25 and 32 kDa 
throughout all experiments regardless of whether or not cells had been incubated with 
TET.  
In order to estimate the amount of FLAG-TRIB2 present, 40 μg of whole cell lysate, 
from both induced (+TET) and non-induced (-TET) isogenic HeLa cells along with 
varying amounts (between 0.5 and 10 ng) of purified recombinant His-FLAG-TRIB2 
were western blotted with an α-FLAG antibody (Figure 4.1E, left). The more potent 
ECL select regent was again used for a detection time of 10 seconds to observe FLAG-
TRIB2. Recombinant His-FLAG-TRIB2 signal increased in linear proportion between 
0.5 and 2 ng, evident from densitometry analysis (Figure 4.1E, right). Based on the 
signal output, it was estimated that there was ~60 pg of FLAG-TRIB2 present in 1 µg 
of whole cell lysate from isogenic TET induced HeLa cells, far lower than the amount 
of FLAG-TRIB2 expressed in transiently transfected parental HeLa cells (~7.5 ng).  
4.1.3 FLAG-TRIB2 was not detected in stable HEK293 cells 
In order to analyse FLAG-TRIB2 in an independent stable cell line, Flp-In T-Rex HEK 
293 cells were generated as previously described for HeLa cells. However, no FLAG-
TRIB2 was detected in these cells on induction with TET (Figure 4.1F), perhaps due 
to expression levels that were below the limits of detection. ECL select reagent was 
used for 10 minutes in order to maximise detection of FLAG-TRIB2. Very faint bands 
corresponding to the expected molecular weight of FLAG-TRIB2 were observed 
across all lysates regardless of TET exposure, therefore indicating the presence of a 
cross reactive band. In addition, there was a strong contaminant observed just above 
46 kDa as well as various other more faint non-specific bands. It was therefore decided 
that future experiments would proceed using only the isogenic HeLa cells.  
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4.2 Analysis of cellular FLAG-TRIB2 stability and potential phosphorylation 
4.2.1 TRIB2 is degraded by the proteasome in HeLa cells 
As TRIB2 turnover was previously established to be regulated by the ubiquitin 
proteasome system [113, 285], FLAG-TRIB2 expression in stable HeLa cells was 
assessed in the presence of the proteasome inhibitor MG132. Consistent with this 
finding, FLAG-TRIB2 was shown to be stabilised in the presence of proteasome 
inhibitor MG132 (Figure 4.2). A brief 4-hour exposure of TRIB2-expressing cells to the 
proteasome inhibitor MG132 led to an increase in TRIB2 protein expression (Figure 
4.2A). A titration of increasing concentrations of MG132 revealed that 10 µM was 
sufficient to observe maximal increase in exogenous TRIB2 levels for 4 hours 
exposure (Figure 4.2B). 
 
 
Figure 4.2: FLAG-TRIB2 is stabilised by MG132 and destabilised by geldanamycin. (A) Stable 
isogenic HeLa cells were induced to express FLAG-tagged TRIB2 with TET for 16 hours and then 
incubated with DMSO (0.1% v/v) or 10 μM of MG132 for the indicated number of hours before lysis and 
immunoblotting with an anti-FLAG antibody. α-tubulin served as the loading control. (B) HeLa cells were 
induced to express FLAG-tagged TRIB2 with TET for 16 hours and then incubated with DMSO (0.1% 
v/v), 10, 25 or 100 μM of MG132 for 4 hours prior to lysis and immunoblot analysis. (C) HeLa cells were 
induced to express FLAG-tagged TRIB2 with TET for 16 hours and then incubated with DMSO (0.1% 
161 
 
v/v), 10 μM geldanamycin or 10 μM of both geldanamycin and MG132 for 4 hours prior to lysis and 
immunoblot analysis.  
To provide further evidence that FLAG-TRIB2 was regulated by proteasome turnover, 
expression was assessed in the presence of heat shock protein 90 (HSP90) inhibitor 
geldanamycin. HSP90 is a molecular chaperone that contributes to folding and 
regulation of many cytosolic proteins [286]. Ubiquitination of human Hsp90 has been 
reported to induce degradation of several client proteins, including p53, CDK4 (cyclin-
dependent kinase 4), PLK1 (Polo-like kinase 1) and AKT1 via the proteasome [287, 
288]. After only 4 hours of incubating TET-induced HeLa cells with geldanamycin, 
there was a marked decrease in the amount of TRIB2 detected (Figure 4.2C). 
Remarkably co-incubation of geldanamycin with MG132 completely reversed this 
effect, with levels of TRIB2 even greater than DMSO exposed cells. As well as 
confirming that TRIB2 turnover is regulated partially by the proteasome this finding 
suggests that heat shock proteins are important for TRIB2 stability.   
4.2.2 FLAG TRIB2 is phosphorylated in stable HeLa cells 
It was intriguing to observe that there was a fainter and smeared second band above 
the band corresponding to FLAG-TRIB2 in cell extracts. Interestingly, this band 
became intensified in the presence of MG132 (Figure 4.2). The higher band 
corresponding to TRIB2, with a lower electrophoretic mobility, was potentially a 
phospho-form. To investigate this specifically, a lambda phosphatase (λPP) assay was 
developed [289]. Accordingly, 40 μg of lysate from TET induced HeLa cells that had 
been incubated with 10 μM MG132 for 1 and 16 hours were incubated with 10 ng of 
λPP for 30 minutes at 37˚C. Without λPP a faint smeared band was observed above 
the dominant FLAG-TRIB2 corresponding band (Figure 4.3A). As hypothesised, the 
smeared bands above FLAG-TRIB2 were no longer present upon incubation with λPP 
(Figure 4.3A). In order to offer further support to this assertion, a FLAG-
immunoprecipitation was performed to enrich and isolate FLAG-TRIB2 from the HeLa 
extract (Figure 4.3B). Two separate elutions, using FLAG peptide, were obtained and 
incubated for 30 minutes at 37˚C ± λPP. The samples were resolved by 
electrophoresis for an extended period in order to further resolve the proteins. After 
immunoblot analysis with anti-FLAG antibody, it was observed that the upper FLAG-
TRIB2 bands had disappeared, suggesting dephosphorylation by λPP. Moreover, in 
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the absence of λPP various other faint smeared bands became visible, potentially 
indicating the presence of multiple TRIB2 phosphosites.  
 
Figure 4.3: FLAG-TRIB2 is phosphorylated in HeLa cells. (A) Stable isogenic HeLa cells were 
induced to express FLAG-TRIB2 by addition of TET for 16 hours at which point whole cell lysates were 
obtained. 40 µg of whole cell lysate was incubated +/- 10 ng of λ phosphatase (λPP) at 37˚C for 1 hour 
prior to western blot analysis. (B) TET induced HeLa cells was lysed followed by FLAG 
immunoprecipitation. Bound FLAG-TRIB2 was eluted with FLAG peptide. 500 ng of each elution (1 and 
2) were incubated +/- 10 ng of λ phosphatase (λPP) at 37˚C for 1 hour prior to western blot analysis. 
 
4.3 Validation of novel TRIB2 antibodies and detection of 
endogenous TRIB2 in U937 cells 
U937 cells are widely used as an in vitro model to analyse haematological malignancy 
and were isolated from a 37 year old male with histiocytic lymphoma [290]. The 
regulation of TRIB2 expression and its various roles in pathogenesis, through targeted 
degradation of substrate proteins (including the p42 isoform of C/EBPα) in U937 cells 
has previously been well-characterised [109, 113]. To evaluate and compare 
endogenous TRIB2 expression in U937 cells to exogenous FLAG-TRIB2 expression 
in stable HeLa, three novel polyclonal TRIB2 antibodies and a commercial TRIB2 
antibody was tested by immunoblotting cellular lysates.  
4.3.1 Comparison of novel and commercial TRIB2 antibodies 
In order to support the assertion that FLAG-TRIB2 was indeed being expressed and 
detected in stable HeLa cells, and to analyse endogenous TRIB2 in U937 cells, three 
polyclonal TRIB2 antibodies were generated in rabbits (Figure 4.4A). Lysate from TET 
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induced and non-induced HeLa cells were assessed alongside 10 ng His-FLAG-TRIB2 
purified from E. coli. Immunoblot analysis α-TRIB2 1 produced a crisp signal with very 
little background noise. TRIB2 antibodies were generated from 3 separate immunised 
rabbits. The α-TRIB2 1 and the commercial anti-FLAG antibodies appeared to be 
equally effective at recognising cellular FLAG-TRIB2 and recombinant His-FLAG-
TRIB2. The α-TRIB2 2 and 3 antibodies were able to detect cellular FLAG-TRIB2 and 
bacterial His-FLAG-TRIB2 but with an increased abundance of cross reactive bands 
and background noise. Analysis with the CST commercial TRIB2 antibody resulted in 
high levels of background noise and signals from cross reactive bands. Furthermore, 
immunoreactive bands appeared at the predicted molecular weight of FLAG-TRIB2 in 
the absence of TET, which could potentially lead to a ‘false-positive’ detection of 
TRIB2. The clear signal using α-TRIB2 1 and indecisive results achieved with the 
commercially available TRIB2 antibody highlights the importance in taking careful 
measures to collaboratively share reagents to support new research into TRIB2 
cellular signalling. Interestingly, the levels of endogenous TRIB2 in HeLa Flp-In T-REx 
were too low to be detected with any of the TRIB2 antibodies, indicated by no TRIB2 
signal in the absence of TET. This finding explains the need for inducible HeLa cells 
to mechanistically analyse TRIB2, as it would be expected that the extremely low 
background levels of endogenous TRIB2 might not significantly contribute to signalling 
outputs. It was further demonstrated that the α-TRIB2 1 antibody could detect 
recombinant His-FLAG-TRIB2 purified from E. coli in a dose dependent manner and 
detect FLAG-TRIB2 expressed in transiently transfected HeLa cells (Figure 4.2B). The 
commercial α-FLAG and novel α-TRIB2 1 antibodies appeared to be equally effective 
at detecting FLAG-TRIB2, which supports the idea for their use to comparatively 
analyse both endogenous and exogenous TRIB2 expression in different cell lines.   
4.3.2 Comparison of exogenous and endogenous TRIB2 in HeLa and U937 cells 
U937 cells were a gift from Karen Keeshan (University of Glasgow). In order to 
compare TRIB2 expression in TET induced HeLa and U937 cells, 40 µg of lysate from 
each cell line was analysed side by side (Figure 4.4C). Exogenous FLAG-TRIB2 from 
HeLa cells was observed to be at a similar level to endogenous TRIB2 in U937 cells, 
both with ~60 pg of TRIB2 per µg of cellular lysate. This finding supports the idea that 
stable HeLa cells, with similar expression levels of TRIB2 to U937, is a reasonable 
exogenous TRIB2 expressing model to comparatively analyse TRIB2 related 
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signalling outputs. It was also established that TRIB2 in U937 cells was stabilised after 
4 hours incubation with MG132 (Figure 4.4D), consistent with protein turnover by the 
proteasome [113]. 
 
Figure 4.4: Comparison of novel polyclonal and commercial TRIB2 antibodies. Three novel 
polyclonal rabbit α-TRIB2 antibodies (α-TRIB2 1, 2 and 3) were raised towards a unique N-terminal 
TRIB2 sequence in human TRIB2, affinity purified, and used to immunoblot for FLAG-TRIB2 (in stable 
isogenic TET induced HeLa cells) and 10 ng of recombinant His-FLAG-TRIB2 protein. These antibodies 
were compared alongside a commercial TRIB2 antibody (α-TRIB2 C) and a commercial α-FLAG 
antibody. ECL select reagent was used for an exposure time of 15 seconds. (B) Detection of His-FLAG-
TRIB2 standards and exogenous FLAG-TRIB2 in transiently transfected HeLa cells: Increasing 
amounts of recombinant His-FLAG-TRIB2 and 40 µg of whole lysate from transiently transfected HeLa 
cells were analysed by immunoblotting with the α-TRIB2 1 antibody. Normal ECL regent was used for 
an exposure time of 15 seconds. (C) Analysis of endogenous TRIB2 expression in U937 cells and 
exogenous FLAG-TRIB2 in stable HeLa cells. Whole lysates were obtained for U937 cells and TET 
induced stable FLAG-TRIB2 expressing HeLa cells. 40 µg of protein was loaded and resolved by SDS-
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PAGE before western blot analysis with α-TRIB2 1 and α-tubulin. (D) Endogenous TRIB2 in U937 cells 
is stabilised by MG132. U937 cells were incubated for 4 hours with either DMSO or 10 μM MG132.  
 
4.4 Evaluation of small molecule inhibitors in stable HeLa cells 
In Chapter 3, it was discussed that covalent EGFR/HER2 dual inhibitors had the ability 
to both stabilise and destabilise recombinant TRIB2 in vitro. I wished to investigate 
whether these compounds interact with FLAG-TRIB2 in the inducible HeLa model 
discussed above. As proof of concept, covalent binding of the hydrophobic compound 
TX2-121-1 to HER3 at Cys721 [291], causes proteasomal mediated degradation of 
the HER3 pseudokinase [62]. It was hypothesised that repurposed EGFR/HER2 
ligands could bind to intracellular TRIB2 and modulate its stability, which could be 
evaluated by immunoblot analysis.   
4.4.1 Analysis of EGFR/HER2 inhibitors in HeLa cells 
ERK western blots were initially optimised in the absence of TRIB2. Varying amounts 
of un-induced HeLa lysate were analysed by immunoblotting for total ERK1/2 and 
activated pERK1/2 (phosphorylated at Thr202 and Tyr204) (Figure 4.5A). At 40 μg 
both non-phosphorylated ERK1 and ERK2 isoforms could be detected. However, 
pERK1 was barely visible, with pERK2 not detectable whatsoever. The signal for 
pERK1 was far stronger when 80 µg of total HeLa lysate was analysed, although still 
the presence of pERK2 was not apparent. Only when 160 or 320 µg of lysate was 
resolved by electrophoresis could both phosphorylated isoforms of ERK be detected. 
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Figure 4.5: Analysis of EGFR/HER2 clinical inhibitors in HeLa cells and effect on exogenous 
FLAG-TRIB2. (A) Optimisation of pERK detection. Parental HeLa cells were grown to 70% confluence 
at which point whole cell lysates were obtained. Increasing amounts of lysate were resolved by SDS-
PAGE before western blot detection of total ERK1/2 and phosphorylated ERK1/2 (pERK) at Thr202 and 
Tyr204. GAPDH served as a loading control. (B) A screen of clinically approved EGFR/HER2 inhibitors 
in FLAG-tagged TRIB2 expressing stable HeLa cells. HeLa cells were induced to express FLAG-tagged 
TRIB2 with tetracycline for 16 hours and then incubated with DMSO (0.1% v/v) or 10 μM of inhibitor for 
4 hours prior to lysis and western blot analysis. AFA (afatinib), NER (neratinib), OSI (osimertinib), IBR 
(ibrutinib), LAP (lapatinib), ERL (erlotinib), GEF (gefitinib). (C) Parental HeLa cells were incubated with 
0.1% DMSO (v/v) or the indicated concentration of afatinib for 4 hours prior to immunoblot analysis of 
total ERK1/2 and phosphorylated ERK1/2 (pERK) at Thr202 and Tyr204. GAPDH served as a loading 
control.  
 
The ability of a panel of EGFR/HER2 inhibitors to inhibit ERK phosphorylation was 
assessed in FLAG-TRIB2 expressing (TET induced) HeLa cells. The effects of these 
compounds on FLAG-TRIB2 expression was also analysed. In the presence of DMSO 
both ERK1 and 2 were phosphorylated. Interestingly, there was a greater abundance 
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of ERK2 but higher levels of ERK1 phosphorylation in the un-induced HeLa cells 
treated with DMSO (Figure 4.5B). Upon incubation with 10 µM inhibitor total ERK1/2 
levels remained constant but ERK phosphorylation was completely inhibited, for all 
EGFR/HER2 inhibitors tested, confirming inhibition of their canonical (EGFR-family) 
targets. The Type IV dual EGFR/HER2 small molecule kinase inhibitors afatinib, 
neratinib and osimertinib were shown in Chapter 3 (section 3.8.1) to destabilise TRIB2 
in vitro. The dual EGFR/HER2 inhibitor lapatinib stabilised TRIB2 with monovalent 
EGFR inhibitors gefitinib and erlotinib having no discernible effect. The type IV BTK 
inhibitor ibrutinib that did not affect TRIB2 stability in vitro, was also assessed as a 
control alongside gefitinib and erlotinib. Interestingly, levels of FLAG-TRIB2 decreased 
in the presence of afatinib (Figure 4.5B). However, in this experiment, neratinib and 
osimertinib did not appear to have any major effect on TRIB2 levels. The in vitro TRIB2 
stabilising ligand lapatinib did not appear to have any effect on TRIB2 protein levels in 
HeLa cells at this concentration, and neither did the EGFR inhibitors gefitinib or 
erlotinib.  
A dose response experiment was performed using afatinib in un-induced 
(undetectable TRIB2) HeLa cells to analyse concentration dependent inhibition of 
pERK. Varying concentrations of afatinib (between 1 and 20 µM) were incubated with 
un-induced HeLa cells for 4 hours prior to immunoblot analysis. In DMSO treated and 
for all concentrations of afatinib tested the total amount of ERK remained constant. 
However, pERK was only detected in lysate from cells exposed to DMSO, indicated 
by total inhibition of pERK at 1 µM afatinib, the lowest concentration tested. This 
information was important as subsequent experiments evaluated the effects of 
inhibitors within this concentration range with unique effects of drugs on TRIB2 
therefore likely to be ‘off-target’ to EGFR/HER2.   
4.4.2 Analysing the effect of EGFR/HER2 inhibitors on TRIB2 in stable HeLa 
cells 
To understand the effect of TRIB2 destabilisation in the presence of afatinib, a dose 
response experiment was performed on TET induced isogenic HeLa cells (Figure 
4.6A). The amount of TRIB2 was markedly reduced at the concentration of 10 µM, 
with a maximum observed affect at 15 µM. This finding supports the hypothesis that 
levels of TRIB2 were directly responsive to afatinib in a dose-dependent manner. 
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Gefitinib at a concentration of 10 µM was employed as a negative control and did not 
have an observable effect on the amount of TRIB2 detected.  
Although it was previously demonstrated that 10 µM of the covalent inhibitor neratinib 
had no observable effect on TRIB2 after 4 hours (Figure 4.5B), a dose response 
experiment revealed that, as for afatinib, TRIB2 was destabilised in a dose-dependent 
manner after an extended incubation (Figure 4.6B). 5 µM of the type IV EGFR/HER2 
kinase inhibitor neratinib was insufficient to induce a convincing TRIB2 destabilisation 
effect in HeLa cells. However, TRIB2 was clearly destabilised in the presence of 10 
µM neratinib, albeit not as extensively as in the presence of 10 µM afatinib (the positive 
control). Finally, at a concentration of 20 µM neratinib, the extent of TRIB2 
destabilisation was essentially complete (Figure 4.6B). 
As lapatinib was previously shown by DSF to stabilise TRIB2 (section 3.8.1), it was 
hypothesised that intracellular lapatinib binding might result in increased levels of 
TRIB2 in stable TET-induced HeLa cells. Varying concentrations of lapatinib (between 
2-20 µM) were incubated with TET induced HeLa cells for 4 hours, however no effect 
on TRIB2 stability was observed (Figure 4.6C), which suggested that either lapatinib 
did not engage TRIB2 in the HeLa cells, or binding of lapatinib could not confer an 
effect on TRIB2 protein levels.    
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Figure 4.6: Dose dependent analysis of EGFR/HER2 clinical inhibitors in FLAG-TRIB2 
expressing stable HeLa cells. (A) Stable HeLa flp-in TRIB2 cells, induced for 16 hours with TET, were 
incubated with DMSO (0.1% v/v), increasing concentrations of AFA or 10 μM gefitinib for 4 hours 
followed by whole cell lysis and immunoblot analysis. (B) Stable HeLa flp-in TRIB2 cells, induced for 16 
hours with TET, were incubated with DMSO (0.1% v/v), increasing concentrations of neratinib (NER) or 
10 μM afatinib for 4 hours followed by whole cell lysis and immunoblot analysis. (C) Stable HeLa flp-in 
TRIB2 cells, induced for 16 hours with TET, were incubated with DMSO (0.1% v/v) or increasing 
concentrations of lapatinib for 4 hours followed by whole cell lysis and immunoblot analysis.  
 
4.5 Investigating the mechanism of TRIB2 destabilisation in the 
presence of afatinib 
4.5.1 Time dependent destabilisation of TRIB2 by afatinib 
In order to elucidate the time at which afatinib begins to induce TRIB2 destabilisation, 
TET induced HeLa cells were incubated with afatinb for varying lengths of time. A rapid 
time-dependent elimination of TRIB2 protein was evident (Figure 4.7B), in contrast to 
DMSO controls in which TRIB2 levels remained observably stable throughout the 
experiment (Figure 4.7A). In the presence of afatinib, after only a 2 hour incubation, 
there was substantial loss of TRIB2 and the maximal effect of destabilisation was 
observed by 4 hours. Incubation with the proteasome inhibitor MG132 induced 
stabilisation of TRIB2 (Figure 4.7C), consistent with previous findings that TRIB2 
turnover is proteasome-dependent [113]. In the presence of both afatinib and MG132, 
TRIB2 levels remained stable for a longer period of time than in the presence of 
afatinib alone (Figure 4.7D). However, TRIB2 was eventually destabilised, indicating 
that perhaps the proteasome was not completely inhibited. By employing λPP assays 
it was again shown that TRIB2 is potentially phosphorylated in HeLa cells.   
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Figure 4.7: Afatinib induces FLAG-TRIB2 degradation in a time-dependent manner in HeLa cells. 
(A) HeLa cells were induced to express FLAG-TRIB2 for 16 hours with TET, incubated with either 0.1% 
(v/v) DMSO (A), 10 µM afatinib (B), 10 µM MG132 (C) or both 10 µM afatinib and 10 µM MG132 (D) 
and then lysed at the indicated time points prior to immunoblot analysis. A λPP was performed on 40 
µg of lysate from time points 1 and 16 hours for each condition.   
 
4.5.2 Proteasome inhibition in the presence of afatinib 
After a 4-hour incubation, TRIB2 levels were acutely decreased in the presence of 
afatinib and stabilised by proteasome inhibition with MG132. Incubation of TET 
induced stable HeLa cells with both afatinib and MG132 reversed TRIB2 degradation 
(Figure 4.8A). However, the total amount of TRIB2 in the MG132 treated cells 
exceeded the total amount of TRIB2 in the cells that had been treated with afatinib 
and MG132. This indicated that either degradation of TRIB2 in the presence of afatinib 
was not solely dependent on the proteasome, or the proteasome was not completely 
inhibited.     
Subsequently, TET-induced HeLa cells were incubated with afatinib, MG132 or both 
afatinib and MG132 together for 1 and 16 hours to observe effects on TRIB2 levels. In 
the presence of DMSO, between 1 and 16 hours, TRIB2 levels remained constant 
(Figure 4.8B). After 1 hour incubation with afatinib, TRIB2 levels were similar to the 
amount observed in the presence of MG132 over the same time, suggesting that 
changes to TRIB2 levels were gradual. After 16 hours, however, in the presence of 
afatinib, TRIB2 levels were markedly reduced.  
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Figure 4.8: FLAG-TRIB2 is degraded partially by the proteasome in the presence of afatinib. (A) 
Stable HeLa cells induced for 16 hours with TET were incubated with DMSO (0.1% v/v) 10 µM afatinib 
or 10 µM afatinib and 10 µM MG1312. (B) Stable HeLa cells induced for 16 hours with TET then treated 
for either 1 or 16 hours with 10 μM afatinib, 10 µM MG132 or both 10 µM AFA and MG132 followed by 
lysis and immunoblot analysis. (C) Stable HeLa cells induced for 16 hours with TET then incubated with 
increasing concentrations of MG132 ± 10 µM AFA for 4 hours.   
 
Interestingly, there was an apparent ‘laddering effect’ of higher molecular weight 
bands, which potentially corresponded to (poly)ubiquitinated TRIB2 (Figure 4.8B). 
After 16 hours incubation with MG132 alone there was substantial TRIB2 stabilisation 
along with extensive laddering. Between 1 and 16 hours treatment with both afatinib 
and MG123 there was a substantial increase in the amount of observed TRIB2 (Figure 
4.8B), which was also accompanied by increased levels of laddering. Although, again 
the amount of TRIB2 in the presence of both MG132 and afatinib was less than in the 
presence of MG132 alone. It could have been that either afatinib induced a rapid 
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proteasome-mediated turnover of TRIB2 prior to complete inhibition of the proteasome 
by MG132, or an alternate degradation pathway was also involved.  
In order to investigate whether or not the decrease in TRIB2 levels in the presence of 
both afatinib and MG132 (relative to MG132 treatment alone) was due to only partial 
inhibition of the proteasome, TET induced HeLa cells were incubated with increasing 
concentrations of MG132 in the presence of afatinib (Figure 4.8C). In the presence of 
MG132 alone the amount of TRIB2 was increased to similar extents, regardless of 
MG132 concentration. As expected, TRIB2 was destabilised by afatinib but was 
rescued in the presence of MG132 to an extent similar to MG132 alone, when the 
MG132 concentration was increased to 100 μM. This result suggested that MG132 
concentrations of 100 μM were required to sufficiently inhibit the proteasome and 
prevent degradation of TRIB2 in the presence of afatinib.  
4.5.3 Analysis of lysosome inhibitors in the presence of afatinib 
In order to determine whether TRIB2 was exclusively degraded via the proteasome 
upon incubation with afatinib, the levels of TRIB2 were also assessed in the presence 
of autophagy and autophagy/lysosomal inhibitors AICAR and chloroquine. AICAR and 
chloroquine had no effect on TRIB2 stability (Figure 4.9A), in contrast to MG132 which 
stabilised TRIB2. In comparison to afatinib treatment, stabilisation was apparent when 
MG132 and afatinib were used in combination. When AICAR or chloroquine were 
incubated together with afatinib, there was no detectable rescue of TRIB2 
destabilisation. Autophagy, lysosomal and proteasome inhibitors where then pre-
incubated for 1 hour with TET induced HeLa cells prior to the addition of afatinib 
(Figure 4.9B). Consistently, TRIB2 decrease in the presence of afatinib was not 
mitigated in the presence of AICAR or chloroquine. Employing another proteasome 
inhibitor bortezomib (Figure 4.9C), it was shown that there is a clear rescue of TRIB2 
degradation when afatinib exposed HeLa cells were incubated with either MG132 or 
bortezomib.   
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Figure 4.9: Analysis of FLAG-TRIB2 stability in the presence of AFA with proteasome and 
lysosome inhibitors. (A) TET induced HeLa cells were incubated with 10 µM MG132 and lysosome 
inhibitors 1 mM ACAR (AIC) and/or 50 µM chloroquine (CLQ) ± 10 μM afatinib for 4 hours followed by 
western blot analysis. (B) FLAG-TRIB2 expressing stable cells were incubated with 10 µM MG132, 1 
mM AIC and/or 50 µM CLQ for 1 hour prior to 4 hour incubation ± 10 µM afatinib followed by western 
blot analysis. (C) HeLa cells were induced to express FLAG-tagged TRIB2 with TET for 16 hours and 
then for 1 hour with10 µM MG132, 10 µM bortezomib, 1 mM AIC and/or 50 µM CLQ. Subsequently 10 
µM or 0.1% (v/v) DMSO was added for a further 4 hours prior to western blot analysis. 
 
4.5.4 Analysis of COP1 binding site and N-terminal truncation TRIB2 mutants 
In chapter 3 it was established that afatinib binding to TRIB2 induced a thermally-
destabilised conformation, in which the C-terminal tail likely became uncoupled from 
the pseudokinase domain. Here, I show that afatinib induces degradation of TRIB2 in 
isogenic HeLa cells via the proteasome. In order to investigate whether or not TRIB2 
degradation, in the presence of afatinib, occurred through the C-terminal tail, a HeLa 
cell line expressing FLAG-TRIB2 with a COP1-binding motif mutation (DQLVP to 
AQLAA) was generated. As the N-terminus (residues 1-54) were predicted to be 
disordered (section 3.6.1) and contain a PEST region, which might regulate TRIB2 
turnover [104], a HeLa cell line expressing an N-terminal truncation (54-343) FLAG-
TRIB2 mutant was also generated.  
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Stable HeLa cell lines were generated to express FLAG-tagged TRIB2 lacking the N-
terminal domain (54-343) and a full length (1-343) C-terminal tail AQLAA TRIB2 
mutant on induction with tetracycline (Figure 4.10A). After 4 hours incubation with 
afatinib all TRIB2 proteins were destabilised (Figure 4.10B), indicating that 
degradation of TRIB2 was independent of the N-terminus and an intact E3 ubiquitin 
ligase binding motif in the C-terminal tail.  Moreover, after 4 hours treatment of TET 
induced HeLa cells with MG132, there was a marked increase of all TRIB2 proteins, 
suggesting that neither the N-terminal domain nor the DQLVP E3 ligase binding motif 
are required for TRIB2 turnover by the proteasome. 
   
Figure 4.10: Degradation of FLAG-TRIB2 through in the presence of the pseudokinase domain. 
(A) Cartoon representation of FLAG-TRIB2 proteins; full length TRIB2 (residues 1-343) (top), the N-
terminus with pseudokinase domain (residues 1-318) (middle) and full length TRIB2 with a COP1 
binding site DQLVP to AQLAA mutation (bottom). (B) (Left) Immunoblot analysis of stable HeLa cell 
lines expressing full length FLAG-TRIB2 and a truncation mutant lacking the N-terminal domain (1-53) 
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incubated with either 0.1% DMSO (v/v), 10 µM afatinib or 10 µM MG132 for 4 hours. (Right) Immunoblot 
analysis of stable HeLa cells expressing full length FLAG-TRIB2 with a C-tail AQLAA mutation 
incubated with 0.1% DMSO (v/v), 10 µM afatinib or 10 µM MG132 for 4 hours. 
 
4.6 Investigating targeted interactions of TRIB2 ligands using 
CETSA 
To investigate whether or not small molecule inhibitors that bound to TRIB2 in vitro 
had intracellular engagement with exogenous TRIB2 expressed in HeLa cells, cellular 
thermal shift assays (CETSAs) were employed [292, 293]. Biophysical ligand-induced 
changes in protein thermal stability can be detected by treatment of cells with 
compounds that bind to and modulate thermal stability of target proteins [293]. 
Engagement of compounds can either increase or decrease the melting temperature 
of the target protein, causing protein aggregation which can be separated from the 
soluble lysate. TRIB2 expressing HeLa cells were incubated with compounds for 1 
hour followed by aliquoting, heating to different temperatures for 3 minutes, lysis by 
sonication, centrifugation and finally immunoblot analysis for FLAG-TRIB2. The 
cellular lysate was centrifuged to separate soluble proteins from precipitated proteins.   
4.6.1 Establishing the melting temperature of FLAG-TRIB2 in HeLa cells 
Before analysing TRIB2 thermal stability in the presence of compounds the melting 
temperature of FLAG-TRIB2 in HeLa cells had to be elucidated. This was completed 
in order to establish the temperature range at which exogenous TRIB2 becomes 
aggregated with no compound present [294]. Firstly, a narrow temperature range, 
between 38 °C and 46 °C, was employed, however FLAG-TRIB2 remained stable 
under these conditions and did not become denatured (Figure 4.11A). Thus an 
extended temperature range up to 70°C was investigated (Figure 4.11B). TRIB2 
expressed in stable HeLa cells remained stable until cells were heated to a 
temperature of 50°C, at which point levels of TRIB2 began to decrease, probably 
marking the onset of protein aggregation. At 60°C the majority of FLAG-TRIB2 had 
become insoluble and by 70°C TRIB2 protein was no longer detectable in the soluble 
fraction of the cellular lysate. The loading control α-tubulin was observed to be 
destabilised steadily throughout the experiment, demonstrating aggregation as a 
function of temperature increase.    
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Figure 4.11: Optimisation of whole cell cellular thermal shift assay (CETSA). (A) Stable isogenic 
HeLa cells were induced to express FLAG-TRIB2 with TET for 16 hours with cells reaching 90% 
confluence. Cells were thereafter incubated with 0.1% (v/v) DMSO for 1 h and subsequently collected 
and re-suspended in PBS. The re-suspended cells were sub-aliquoted into PCR tubes and heated in a 
series of 2⁰C increments between 38 and 46⁰C. The cells were subsequently lysed by sonication, 
centrifuged for 20 minutes at 18,000 g and analysed by western blot for FLAG-TRIB2 and alpha tubulin. 
(B) Same as for (A) but with an extended temperature range of 5 ⁰C increments between 40⁰C and 60⁰C 
with a final temperature of 70⁰C.  
 
4.6.2 Analysing the effect of small molecule inhibitors on cellular TRIB2 
thermal stability 
Lapatinib was previously shown to increase the thermal stability of recombinant TRIB2 
in vitro by DSF (section 3.8.1). Although, lapatinib did not induce detectable changes 
in the amounts of TRIB2 in HeLa cells incubated with lapatinib (Figure 4.6B). It is still 
possible, however, that lapatinib bound to cellular TRIB2 without changing the total 
amount protein present. To test this hypothesis CETSAs were performed employing 
lapatinib with DMSO as a control (Figure 4.12A). Consistently, in the presence of 
DMSO TRIB2 was thermally stable up to 50 °C before beginning to aggregate, 
indicated by a decrease in total TRIB2 protein at 56 °C. Interestingly, after 1 hour 
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incubation of lapatinib with TET induced stable HeLa cells, TRIB2 became less 
affected by temperature increase and remained soluble at a heating temperature of 
58 °C. In addition, overall TRIB2 signal intensity was greater for lapatinib treated cells, 
as opposed to DMSO treated, across the temperatures range of 50-58 °C, the onset 
of TRIB2 aggregation (Figure 4.12B). By employing densitometry analysis (Figure 
4.12B), it was elucidated that the Tm of TRIB2 in the presence of DMSO was ~49 °C 
and ~51 °C in the presence of lapatinib. 
Next the effects of lapatinib, afatinib and erlotinib on intracellular TRIB2 thermal 
stability were tested (Figure 4.13A). TRIB2 in HeLa cells that had been exposed to 
lapatinib as opposed to DMSO was again more stable. Remarkably, when HeLa cells 
were exposed to afatinib TRIB2 was less thermally stable with no TRIB2 being 
detected at a temperature of 45 °C, giving an estimated Tm of ~40 °C (Figure 4.13B). 
This result provided evidence of a direct intracellular interaction between afatinib and 
TRIB2 and furthermore, consistent with DSF analysis (section 3.8.1), TRIB2 had a 
lower melting temperature in the presence of afatinib. Erlotinib, which had no 
detectable interaction with TRIB2 when assayed by DSF, did not have any influence 
on intracellular TRIB2 thermal stability compared to DMSO (Figure 4.13A).  
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Figure 4.12: CETSA analysis of lapatinib in FLAG-TRIB2 expressing HeLa cells. (A) Stable 
isogenic HeLa cells were induced to express FLAG-TRIB2 with TET for 16 hours with cells reaching 
90% confluence at which point they were incubated with 0.1% (v/v) DMSO or 100 µM lapatinib for 1 h. 
Cells were subsequently trypsinised and re-suspended in PBS. The re-suspended cells were sub-
aliquoted into PCR tubes and heated in a series of 2⁰C increments between 46 and 64⁰C. The cells 
were subsequently lysed by sonication, centrifuged for 20 minutes at 18,000 g and analysed by western 
blot for FLAG-TRIB2 and α-tubulin. (B) Densitometry analysis data from (A). Percentage is relative to 
the densitometry value obtained at 46°C.  
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Figure 4.13: CETSA suggests intracellular engagement of afatinib and Lapatinib. TET induced 
HeLa cells were gown to 90% confluence and treated with either (A) DMSO or 100 μM of (B) lapatinib, 
(C) afatinib or (D) erlotinib for 1 hour. Cells were subsequently collected and re-suspended in PBS. The 
re-suspended cells were aliquoted into PCR tubes and heated at 5 ⁰C increments from 40 to 70⁰C 
followed by lysis by sonication, centrifugation for 20 minutes at 18,000 g and immunoblot analysis. (E) 
Densitometry analysis of CETSA. Bands were normalised relative to the DMSO control.  
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4.7 Compound binding analysis with TRIB2 cysteine mutants 
In Chapter 3 mass spectrometry was used to demonstrate that afatinib covalently 
bound to TRIB2 at two distinct cysteine residues in the αC-helix, Cys96 and Cys104. 
CETSA analysis revealed that afatinib binding reduced TRIB2 thermal stability. 
Destabilisation of TRIB2 in HeLa cells could have been driven through similar 
mechanisms of covalent binding identified by in vitro analysis (section 3.10.2, Figure 
3.29). It was hypothesised that afatinib covalently bound to cellular TRIB2, in turn 
inducing destabilisation. For this reason, HeLa cells lines expressing Cys 96 and Cys 
104 Ser residues, were generated.  
4.7.1 Stability of WT, C96S and C96/104S-TRIB2 in the presence of EGFR/HER2 
kinase inhibitors 
PCR was performed to introduce C96S and double cysteine to serine C96/104S 
mutants into TRIB2 encoded within the pcDNA5/FRT/TO plasmid. Parental HeLa Flp-
In T-Rex were transfected, as previously described, generate stable TRIB2 Cys 
mutant expressing cell lines. On TET induction all full length TRIB2 proteins (WT, 
C96S, C96/104S and AQLAA) were expressed to similar levels (Figure 4.14) and total 
TRIB2 levels were increased after 4 hours incubation with MG132. In the absence of 
TET there appeared to be either a faint cross-reactive band or a slight degree of 
expression leakage, which was consistent regardless of the cell line.  
 
Figure 4.14: FLAG-TRIB2 cysteine mutants and COP1 binding site AQLAA mutants express at 
similar levels to WT TRIB2. Stable HeLa cell lines were induced with TET for 16 hours to express 
either WT, C96S, C96/104S or AQLAA FLAG-TRIB2 followed by incubation with either 0.1% DMSO 
(v/v) or 10 µM MG132 for 4 hours prior to lysis and immunoblot analysis. 
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Firstly, with comparison to WT TRIB2, the effect of selected EGFR/HER2 inhibitors on 
cellular C96S TRIB2 was assessed in TET induced HeLa cells. As expected, after 4 
hours incubation, afatinib induced extensive destabilisation of WT TRIB2 (Figure 
4.15). Excitingly, the destabilisation effect was diminished for C96S TRIB2. Neratinib 
induced partial degradation of WT TRIB2 but C96S TRIB2 remained more stable. In 
this experiment, there was less WT TRIB2 in the presence of lapatinib, but this was 
not seen consistently and such a decrease in TRIB2 expression in the presence of 
lapatinib was not apparent in previous or subsequent experiments. Moreover, levels 
of C96S TRIB2 did not seem to be influenced by lapatinib. Lapatinib gave an identical 
stabilising thermal shift profile for both WT and C96S TRIB2 when recombinant 
proteins were assayed in vitro by DSF (section 3.10.2, Figure 3.29). In chapter 3 it was 
also demonstrated that the thienopyrimidine EGFR/HER2 dual type I inhibitor TAK-
285 also stabilised recombinant WT and C96S TRIB2 when assayed by DSF. 
However, in TET induced HeLa cells, TAK-285 did not appear to have a significant 
effect on WT or C96S-TRIB2 stability. Erlotinib, as expected, did not observably affect 
the amount of WT or C96S-TRIB2.      
 
 
Figure 4.15. Comparison of WT and C96S TRIB2 in HeLa cells in the presence of EGFR/HER2 
inhibitors. HeLa flp-in cells expressing either WT or C96S full length FLAG-tagged TRIB2 were induced 
with TET for 16 hours. Cells were subsequently treated with either DMSO, 10 μM afatinib, neratinib, 
lapatinib, TAK-285 or erlotinib for 4 hours. Whole cell extracts were obtained followed by immunoblot 
analysis.  
Next the effect of inhibitors were tested on the double C96/104S mutant in inducible 
HeLa cells. Erlotinib had no discernible effect on WT or C96/104S TRIB2 (Figure 4.16). 
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It was interesting to observe that, unlike WT, C96/104S was only partially destabilised 
in the presence of afatinib and almost completely resistant to degradation in the 
presence of neratinib (Figure 4.16). As demonstrated from my previous DSF TRIB2 
analysis (Chapter 3), both C96S and C96/104S TRIB2 were resistant to destabilisation 
to the covalent EGFR inhibitors afatinib and neratinib. However, as deduced from 
cellular analysis, the double Cys TRIB2 mutant was the most resistant to 
destabilisation induced by afatinib and neratnib in HeLa cells.  
 
Figure 4.16: Comparison of WT and C96/104S TRIB2 in HeLa cells in the presence of EGFR/HER2 
inhibitors. HeLa flp-in cells expressing either WT or C96/104S full length FLAG-tagged TRIB2 were 
induced with TET for 16 hours. Cells were subsequently treated with either DMSO, 10 μM afatinib, 
neratinib or erlotinib for 4 hours. Whole cell extracts were obtained followed by immunoblot analysis.  
 
4.7.2 Afatinib dose response analysis of C96S and C96/104S-TRIB2 mutants in 
HeLa cells 
TET-inducible WT, C96S or C96/104S TRIB2 mutant stable cell lines were evaluated 
in the presence of varying concentrations of afatinib. To determine the effect on 
exogenous TRIB2 stability, immunoblotting and densitometry analysis was employed. 
Afatinib induced dose-dependent loss of TRIB2 in WT-TRIB2 cells, which was partially 
prevented for C96S, and completely abolished in C96/104S TRIB2-expressing cells 
(Figure 4.17A). Densitometry analysis from three separate dose response 
experiments confirmed that differences in WT-TRIB2 and Cys mutant TRIB2 levels 
were statistically significant (Figure4.17B). Interestingly, for WT TRIB2 the greatest 
degree of destabilisation took place between concentrations of 10 and 20 µM of 
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afatinib. A Kd, between afatinib and WT TRIB2 previously measured at 16 µM (section 
3.8.2, Figure 3.24) is in agreement with these results and supports the hypothesis that 
there is a direct interaction between afatinib and TRIB2 in HeLa cells, with subsequent 
covalent modification of TRIB2 by afatinib leading to TRIB2 degradation. 
 
 
Figure 4.17: Dose response of afatinib versus WT, C96S and C96/104S. (A) The indicated 
concentration of afatinib, 10 μM lapatinib or 10 μM TAK-285 were incubated for 4 hours with isogenic 
stable HeLa cells expressing WT-TRIB2, C96S or C96/104S TRIB2 (induced by TET exposure for 16h). 
After lysis, whole cell extracts were immunblotted with the indicated antibodies. (B) FLAG-TRIB2 levels 
were quantified after exposure to 10, 15 and 20 µM afatinib relative to DMSO controls using 
densitometry, with a representative experiment shown (significance assessed using data from three 
independent experiments and students t-tests p < 0.05* and p=0.01 **).  
 
4.7.3 Analysis of AQLAA-TRIB2 destabilisation in the presence of afatinib 
From in vitro DSF analysis, it was suggested that binding of afatinib to TRIB2 caused 
the C-terminal tail to uncouple from the pseudokinse domain. To explore and better 
understand what effect this might have on cellular TRIB2, an afatinib dose response 
analysis of WT and AQLAA TRIB2 was carried out in HeLa cells. The C-terminal tail 
AQLAA-TRIB2 mutant was indeed destabilised in a dose dependent manner (Figure 
4.18). In side by side analysis, AQLAA-TRIB2 was more sensitive to afatinib mediated 
degradation than WT-TRIB2 (Figure 4.18A). WT-TRIB2 had greater stability than 
AQLAA-TRIB2 at afatinib concentrations of 2.5 and 5 µM. In a repeat experiment it 
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was clear that AQLAA was pointedly destabilised at an afatinib concentration as low 
as 2.5 µM (Figure 4.18B). Previous thermal profiling analysis (section 3.6.1, Figure 
3.14) along with biochemical and crystal structure analysis of TRIB1 [105, 106], 
suggested that absence of an in-cis interaction between the E3 ligase binding motif 
(DQLVP) and binding pocket in the αC-helix causes TRIB1 and TRIB2 to adopt an 
open ‘destabilised’ conformation. It could be hypothesised that this open conformation 
predisposes AQLAA-TRIB2 to afatinib binding and subsequent degradation. As 
AQLAA-TRIB2 was expressed at similar levels to WT-TRIB2 and was degraded in the 
presence of afatinib, it can be argued that AQLAA-TRIB2, in the open ‘destabilised’ 
conformation, is not degraded until covalently modified by afatinib.    
 
 
Figure 4.18: AQLAA TRIB2 is more sensitive to afatinib mediated degradation. (A) The indicated 
concentration of afatinib, 10 μM lapatinib or 10 μM TAK-285 were incubated for 4 hours with isogenic 
stable HeLa cells expressing WT-TRIB2 (top) or AQLAA-TRIB2 (bottom). After lysis, whole cell extracts 
were immunoblotted with the indicated antibodies. (B) The indicated concentration of afatinib was 
incubated for 4 hours with isogenic stable HeLa cells expressing AQLAA-TRIB2 prior to immunoblot 
analysis. 
4.8 Effects of TRIB2 signalling in transiently transfected HeLa cells 
In order to investigate the effects of TRIB2 overexpression on certain signalling 
pathways, previously established to be influenced by TRIB2 expression, transiently 
transfected HeLa cells were TET induced and analysed by western blotting. As shown 
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in section 4.1.1, transiently transfected HeLa Flp-In T-Rex cells expressed ~7.5 ng per 
µg of lysate after 16 hours induction with TET. With high expression it was expected 
that effects of TRIB2 on various signalling pathways associated with normal TRIB2 
function would be amplified.      
4.8.1 Investigating TRIB2 dependent regulation of AKT, CDC25C and ACC in 
transiently transfected HeLa 
A previous study found that TRIB2 could directly interact with AKT leading to AKT 
phosphorylation, through an unknown mechanism, at Ser473 but not Thr308 [103]. 
The effects of high FLAG-TRIB2 expression on cell signalling outputs was assessed 
(Figure 4.19). In the absence of TET There was no detectable TRIB2 expression and 
a very faint band corresponding to phosphorylated AKT at Ser473. When TRIB2 
expression was induced with TET there was an unequivocal increase in AKT 
phosphorylation at Ser473. This result was consistent with previous findings [103], 
whereby transfection and expression of TRIB2 in HeLa cells induced phosphorylation 
of AKT at Ser473 but not Thr308. AKT phosphorylated at Thr308 was not detected in 
HeLa Flp-In T-Rex cells (data not shown).  
 
Figure 4.19: Activation of AKT in transiently transfected parental HeLa cells. (A) HeLa parental 
cells were transiently transfected with pcDNA5/FRT/TO encoding the full length WT human TRIB2 gene 
with a C-terminal FLAG-tag using lipofectamine. Cells were then incubated with TET for 16 hours 
followed by whole cell lysis and immunoblotting with the indicated antibodies.  
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CDC25C is an established effector of TRIB2, which becomes targeted for 
ubiquitination and subsequently degraded via the proteasome [102]. TRIB3 targets 
acetyl Coenzyme A carboxylase (ACC) for proteasome mediated degradation, via 
association with the E3 ligase COP1, in adipocytes [107]. To examine the effects of 
TRIB2 expression on levels of CDC25C and ACC in HeLa cells, immunoblot analysis 
was performed on lysates from TET induced transiently transfected HeLa cells (Figure 
4.19).  It was hypothesised that expression of TRIB2 in HeLa cells would result in a 
decreased observable amounts by immunoblotting due to ubiquitination and 
degradation of these target proteins. On the contrary, levels of ACC in transiently 
transfected HeLa cells did not perceivably change (Figure 4.19). CDC25C levels did 
not decrease in the presence of TRIB2 either.  
4.8.2 Analysis of the effect of hyper stable C104Y TRIB2 mutant on AKT 
signalling 
The TRIB2 C104Y mutant was established to have a thermal stability far greater than 
WT-TRIB2 when analysed by DSF (Figure 4.20A). The cartoon diagrams represent 
the amino acid Tyr for Cys substitution. Steric hindrance due to the Tyr134 in TRIB1 
(Cys104 in TRIB2) is proposed to reduce freedom of movement in the αC-helix and 
thus maintain TRIB1 in the SLE-out ‘stabilised’ conformation [105, 106]. Consistent 
with this finding, upon mutation of Cys104 to a Tyr, TRIB2 had the same Tm (~49 °C) 
as previously observed for TRIB1 by Murphy and colleagues (2015) [106], suggesting 
that TRIB2 was stabilised in the SLE-out conformation. Remarkably, this increased 
thermal stability resulted in greater expression levels of C104Y compared to WT-
TRIB2 in HeLa cells (Figure 4.20B). Furthermore this increase in TRIB2 correlated 
with enhanced levels of AKT phosphorylation at Ser473.  
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Figure 4.20: C104Y FLAG-TRIB2 is more stable than WT in HeLa cells. (A) Thermal melting profiles 
of WT and C104Y TRIB2 analysed by DSF. (B) HeLa parental cells were transiently transfected with 
pcDNA5/FRT/TO encoding either WT or C104Y FLAG-TRIB2 using lipofectamine. Cells were TET 
induced for 16 hours followed by immunoblotting with the indicated antibodies.  
 
4.8.3 Analysing the effect of afatinib on TRIB2 and AKT in transiently 
transfected HeLa cells 
Overexpression of TRIB2 activated pSer473 AKT. Afatinib was proposed to covalently 
bind to TRIB2, exploiting the thiol functional group of Cys96 and Cys104, resulting in 
conformational rearrangement towards an SLE-in ‘destabilised’ state (section 3.10.3, 
Figure 3.32) before cellular degradation. I therefore hypothesised that exposure of 
afatinib to transiently transfected TET induced TRIB2 expressing HeLa cells would 
destabilise TRIB2 in turn leading to abrogated AKT phosphorylation at Ser473. 
Consistently, TET induced transiently transfected HeLa cells with WT-TRIB2 and 
C96/104S-TRIB2 had a higher levels of detectable pSer473 AKT in the presence of 
DMSO, as opposed to un-induced transfected HeLa (Figure 4.21). This finding 
demonstrated that mutation of both Cys96 and 104 residues to Ser did not block the 
ability of TRIB2 to induce Ser473 phosphorylation in AKT. After 4 hours incubation 
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with afatinib, however, the amount of observable WT, but not C96/104S-TRIB2, 
decreased. Remarkably, the destabilisation of WT-TRIB2 accorded with less pSer473 
AKT. Conversely, AKT phosphorylation at Ser473 in the presence of C96/104S-TRIB2 
and afatinib remained consistent relative to DMSO exposed HeLa cells. This finding 
supports the hypothesis that TRIB2 is targeted by afatinib, which directly influences 
AKT phosphorylation at Ser473. Although in the presence of afatinib WT-TRIB2 was 
destabilised in transiently transfected HeLa cells, this was not tantamount to the extent 
TRIB2 destabilisation in stable HeLa cells. An explanation could be that the greater 
quantity of TRIB2 expressed in transiently transfected HeLa cells (~7.5 ng/µg) relative 
to stable HeLa cells (0.06 ng/ µg) was not fully destabilised within the 4 hours of 
afatinib incubation. Therefore the effects of TRIB2 cellular signalling were assessed in 
stable HeLa cell lines.  
 
 
Figure 4.21: Partial degradation of WT FLAG-TRIB2 followed by decreased AKT activation in 
transiently transfected parental HeLa cells. (A) HeLa parental cells were transiently transfected with 
pcDNA5/FRT/TO encoding the full length WT or C96/104S FLAG-TRIB2 using lipofectamine. Cells 
were TET induced for 16 hours followed by incubation with either DMSO (0.1% v/v) or 10 μM afatinib 
prior to lysis and immunoblotting with the indicated antibodies. 
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4.9 Analysis of TRIB2 signalling using kinase inhibitors in stable 
HeLa cells 
I was interested to explore the effects of kinase inhibitors on TRIB2 stability and AKT 
signalling in the stable TRIB2 expressing HeLa cell lines, because levels of TRIB2 
expression were deduced to be closer to those of the disease U937 cell model. The 
high degree of TRIB2 overexpression in transient HeLa cells (~7.5 ng/µg) is likely not 
reflective of physiological TRIB2 signalling nor of pathological TRIB2 expression in 
U937 cells.  Moreover, the destabilisation of WT-TRIB2 in transiently transfected HeLa 
cells by afatinib was not equivalent to that observed in stable induced HeLa, with a 
significant amount of TRIB2 still remaining after afatinib incubation (Figure 4.21). The 
effects of TRIB2 expression in stable HeLa cells on levels of total and phosphorylated 
ACC and CDC25C were also investigated. The main aim of this section was establish 
whether or not a targeted interaction between WT-TRIB2 and afatinib leads to 
diminished AKT phosphorylation by analysing the afatinib resistant C96/104-TRIB2 
mutant and by employing a panel of various other EGFR/HER2 kinase inhibitors as 
controls.  
4.9.1 Effect of TRIB2 expression on levels ACC and CDC25C in stable HeLa 
cells 
In TET induced stable HeLa cells, as opposed to transiently transfected HeLa, there 
was a decrease in the total amount of ACC observed, compared to un-induced HeLa 
(Figure 4.22). Interestingly, phospho ACC was detected in un-induced cells but not 
when TRIB2 was expressed. This finding suggest that phosphorylation might have a 
role in regulating targeted ACC degradation in the presence of TRIB2. Upon incubation 
of TET induced stable HeLa with afatinib TRIB2 was destabilised and levels of both 
total and phosphorylated ACC increased. The increased signal was, however, far 
greater than from those from the un-induced HeLa cell lysate, suggesting that afatinib 
influenced ACC and phospho ACC levels through off targeted compound induced 
effects. Therefore it would not be possible to come to any conclusions about the effect 
of TRIB2 on ACC, in the presence of afatinib.  
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Figure 4.22: Expression of FLAG-TRIB2 correlates with decreased levels of acetyl Coenzyme A 
carboxylase (ACC) in stable HeLa cells. (A) Stable HeLa cells were incubated ± TET for 16 hours 
followed by a further 4 hour incubation with DMSO (0.1% v/v) or 10 µM afatinib prior to whole cell lysis 
and immunoblot analysis. 
 
Despite the fact that TRIB2 expression led to a decrease in the quantity of total ACC 
and abolition of phospho ACC, matters were complicated by the presence of afatinib, 
which appeared to induce a sharp rise in both total and phospho ACC levels (Figure 
4.22). Therefore, as a potential alternative, TRIB2 mediated effects on CDC25C were 
explored. Although afatinib and neratinib destabilised TRIB2 in TET induced stable 
HeLa cells, there was no apparent change in the quantity of CDC25C observed (Figure 
4.23). The employed EGFR and dual EGFR/HER2 kinase inhibitor controls geftinib 
and lapatinib, previously demonstrated to not influence TRIB2 stability in the stable 
HeLa cell model, did not modulate the amount of CDC25C observed either. Hence 
CDC25C levels did not appear to be modulated by the potential off target effects of 
the EGFR/HER2 inhibitors tested, however, targeted degradation of CDC25C in the 
presence of TRIB2 could not be evidenced in this experiment.           
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Figure 4.23: Expression of FLAG-TRIB2 does not affect CDC25C levels in stable HeLa cells. (A) 
Stable HeLa cells were incubated ± TET for 16 hours followed by a further 4 hour incubation with DMSO 
(0.1% v/v) or 10 µM of indicated inhibitor prior to whole cell lysis and immunoblot analysis. 
 
4.9.2 Development of a serum block and release procedure to observe the 
effect of TRIB2 expression and degradation on AKT activation 
Unfortunately, no AKT pSer473 could be detected in induced or un-induced stable 
HeLa cells under standard cellular conditions (data not shown). This was presumably 
due to low levels of AKT activation, which were below the limits of detection by 
immunoblotting. However, by utilising a serum block and release procedure, pSer473 
AKT levels became much more readily detectable (Figure 4.24). After serum starvation 
for 16 hours, stable HeLa cells were incubated ± TET. Interestingly, in the absence of 
TET, AKT became phosphorylated at Ser473 at 4 hours after serum addition and 
remained phosphorylated for the next 4 hours before being totally undetectable once 
again. Excitingly at 4 hours, in the presence of TRIB2, AKT phosphorylation was 
evident and lasted for 24 hours. After 48 hours, with subsided TRIB2 expression, 
phospho AKT signal was no longer detected. This experiment showed that the 
presence of TRIB2 could stimulate AKT phosphorylation. In a stable HeLa cell line, at 
24 hours there was clear phosphorylation of AKT in the TET induced HeLa cells; this 
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would provide a time framework from which to investigate the effects of repurposed 
kinase inhibitors on TRIB2 signalling in stable HeLa cells.  
 
 
Figure 4.24: TRIB2 induces AKT phosphorylation in stable HeLa cells after serum block and 
release. Uninduced (-Tet) or Tetracycline-induced (+Tet) FLAG-TRIB2 stable HeLa cells were serum 
starved for 12 h prior to the addition of serum, and lysed at the indicated times. Whole cell extracts were 
blotted with FLAG antibody to detect TRIB2, pSer 473 AKT antibody or total AKT and total GAPDH as 
loading controls.  
 
4.9.3 Analysing the effect of inhibitors on WT and C96/104S-TRIB2 and AKT 
signalling in stable HeLa cells 
HeLa cells were serum starved for 16 hours prior to the addition of TET and fully 
supplemented medium for 20 hours. Thereupon selected EGFR/HER2 inhibitors were 
added for a further 4 hours before lysis and immunoblotting (Figure 4.25). In the 
presence of afatinib WT-TRIB2 was completely destabilised, which in turn resulted in 
a large decrease in AKT phosphorylation. In support of this assertion, C96/104S-
TRIB2, as before, was completely resistant to degradation in the presence of afatinib, 
which caused levels of Ser473 phosphorylated AKT to be unaffected.  The important 
controls TAK-285 (EGFR/HER2 dual type I inhibitor) and erlotinib (monovalent EGFR 
type I inhibitor) had no effect on TRIB2 expression or AKT phosphorylation, but both 
completely abolished ERK phosphorylation.  Importantly, all of the EGFR or 
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EGFR/HER2 signalling pathway inhibitors consistently blocked ERK phosphorylation 
(Figure 4.25); any unique effects of drugs amongst this panel are therefore likely to be 
‘off-target’ to EGFR/HER2. 
 
 
Figure 4.25: C96/104S TRIB2 is resistant to afatinib mediated degradation and maintains AKT 
phosphorylation at Ser473. WT and C96/104S stable HeLa cell lines were subjected to a serum block-
and-release protocol (materials and methods). Subsequently, the indicated compounds (10 µM) were 
added for 4 h prior to cell lysis and immunoblotting with the indicated antibodies.  
 
4.10 Analysis of novel TRIB2 inhibitors in U937 cells 
TRIB2 expression has only previously been analysed in a few cell types, in large part 
due to a lack of reliable TRIB2 reagents. Using the previously described novel in-
house TRIB2 antibody (Figure 4.4), the effects of endogenous TRIB2 stability and 
signalling outputs in U937 cells were explored in the presence of kinase inhibitors. 
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High levels of TRIB2 expression drive AML in vivo by inhibiting myeloid differentiation 
and promoting proliferation [109, 112]. TRIB2 expression is required for U937 survival, 
with loss of viability after knockdown of TRIB2 with siRNA [113].I therefore 
hypothesised that kinase inhibitors that induced degradation of endogenous TRIB2 
would have enhanced cytotoxicity in U937. To this end Trypan blue and MTT cell 
viability assays were carried out on U937 cells in the presence of selected small 
molecule kinase inhibitors.  
4.10.1 Investigating endogenous TRIB2 stability and AKT signalling in U937 
cells using EGFR/HER2 kinase inhibitors   
Incubation of afatinib with U937 cells for 4 hours induced destabilisation of 
endogenous TRIB2 (Figure 4.26). Erlotinib, as previously shown in HeLa cells, had no 
effect on levels of TRIB2. MG132 induced an increase in TRIB2 levels, consistent with 
previous findings that describe the regulation of TRIB2 turnover through the ubiquitin-
proteasome system and my observations in HeLa cells.  
 
Figure 4.26: Analysis of endogenous TRIB2 expression U937 cells. Stable isogenic HeLa cells 
were incubated +/- TET for 16 hours followed by a 4 hour incubation with DMSO (0.1% v/v) then 
immunoblotted with α-TRIB2 antibody. U937 cells incubated with either DMSO (0.1% v/v) or 10 µM of 
afatinib, afatinib with MG132, erlotinib or MG132 alone followed by immunoblotting with α-TRIB2.  
 
Following on from this promising result, varying concentrations of afatinib were 
incubated with U937 cells for 4 and 24 hours (Figure 4.27A) to observe the effects on 
endogenous TRIB2 expression and AKT signalling. Endogenous TRIB2 was 
eliminated in U937 cells in a dose dependent manner. The quantity of detectable 
TRIB2 was acutely diminished at 10 µM and completely abolished at 20 µM afatinib, 
which was consistent with that observed for exogenous TRIB2 levels in HeLa cells in 
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the presence of afatinib (Figure 4.6A). Remarkably, this decrease in endogenous 
TRIB2 correlated with a decrease in AKT phosphorylation at Ser473, with none being 
detected at afatinib concentrations where TRIB2 had been extensively destabilised. 
ERK phosphorylation was totally inhibited at the lowest concentration of afatinib tested 
(0.5 µM). Therefore, it is likely that the reduction in pSer473 AKT, at the increased 
afatinib concentrations, was not due to a targeted inhibition of EGFR and HER2. 
Furthermore, lapatinib and erlotinib did not influence TRIB2 stability or modulate AKT 
phosphorylation but did inhibit pERK (Figure 4.27A). Cleavage of caspase-3 marks 
the onset of apoptosis and is an indicator of cell viability and was detected in the 
presence of compounds. At high concentrations of afatinib, when TRIB2 was 
extensively destabilised and AKT phosphorylation was inhibited, the cleavage 
products of caspase-3 could be observed (Figure 4.27A), the intensity of which rose 
with increasing afatinb concentration and TRIB2 elimination. The protesomal inhibitor 
bortezomib is a clinical agent in the treatment of some haematological malignancies 
and is highly cytotoxic to U937 cells [278]. Bortezomib was therefore employed as the 
positive control, which induced caspase-3 cleavage in U937 cells (Figure 4.27A).  
An extended period of 24 hours incubation with compounds was next used to explore 
the effects on endogenous TRIB2, pSer473 AKT and caspase-3 cleavage (Figure 
4.27B). Interestingly, with 24 hours exposure to afatinib, endogenous TRIB2 was 
cleared from U937 cells at lower concentrations than observed for 4 hours incubation. 
It was again observed that phosphorylation of AKT at Ser473 concomitantly decreased 
with TRIB2 degradation, which correlated with caspase-3 cleavage. Both lapatinib and 
erlotinib had no effect on pSer473 AKT phosphorylation during the 4 hour incubation. 
However, lapatinib, but not erlotinib caused a decrease in pSer473 AKT levels after 
24 hours incubation, but this led to a very slight increase in caspase-3 cleavage.       
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Figure 4.27: Afatinib destabilises endogenous TRIB2 and induces caspase-3 cleavage in U937 
cells. (A) U937 cells were incubated with either DMSO (0.1% v/v), varying concentrations of afatinib or 
10 μM of lapatinib, erlotinib or bortezomib for 4 hours prior to lysis and western blot analysis of 
endogenous TRIB2, AKT, ERK and cleaved caspase 3. GAPDH served as a loading control. (B) U937 
cells were incubated with either DMSO (0.1% v/v), varying concentrations of afatinib or 10 μM of 
erlotinib or bortezomib for 24 hours prior to lysis and western blot analysis of endogenous TRIB2, ATK 
and cleaved caspase 3. GAPDH served as a loading control.  
 
4.10.2 Exploring the effects of repurposed EGFR/HER2 inhibitors on U937 cell 
viability      
To determine the impact of afatinib treatment on U937 cell viability, cellular cytotoxicity 
after 4 and 24 hour exposure was measured by employing a Trypan blue assay (Figure 
4.28). The untreated cells (DMSO) were calculated to be ~90% viable. After brief 4 
hour exposure to varying concentrations of afatinib (between 0.5 and 20 µM), cell 
viability seemed unaffected (Figure 4.28A). Lapatinib and erlotinib had no effect during 
this time period and neither did the clinical proteasome inhibitor bortezomib, which 
was utilised as a positive control for a later exposure (see below). This result could 
suggest that the destabilisation of TRIB2 and inactivation of pSer473 AKT in the 
presence of afatinib (Figure 4.27A) at this time point (4 hours) reflected an acute 
response to compound binding prior to cell death. After 24 hours incubation with 
compounds cell viability, as measured by Trypan blue, was proportionally affected as 
a function of increasing afatinib concentration (Figure 4.28B). At an afatinib 
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concentration of 2.5 µM the percentage of viable cells had decreased slightly from 
90% to 77%. After 24 hour incubation with 5 µM afatinib, at which point there was 
considerable caspase-3 cleavage (Figure 4.27B), cell viability had decreased to 69% 
(Figure 4.28B). In the presence of 10 µM afatinib cell viability was calculated to be 
41%. Bortezomib had enhanced cytotoxicity in U937 cells (26% cell viability) when 
incubated with the same concentration for 24 hours. The dose dependent effect of 
afatinib on U937 cell viability was consistent right up to the final concentration tested 
(20 µM) at which point only 6% of cells were deduced to be viable by Trypan blue 
assay. Consistent with no apparent caspase-3 cleavage (Figure 4.27), erlotinib had 
no discernible effect on U937 cell viability after 24 hours (Figure 4.28B). Despite have 
no apparent cytotoxic effect, as measured by Trypan blue, lapatinib induced small 
degree of caspase-3 cleavage.   
 
Figure 4.28: AFA reduces U937 cell viability after 24 hours. (A) U937 cells were incubated with 
DMSO (0.1% v/v), the indicated concentration of afatinib or 10 µM of either erlotinib, lapatinib or 
bortezomib for 4 hours. Cells were then assayed with Trypan blue to assess viability. (B) Same as in 
(A) except compounds were incubated for 24 hours prior to Trypan blue assay and immunoblot analysis.  
 
Trypan blue analysis revealed that even in the short window of 24 hours, albeit with 
high inhibitor concentration, there was a marked effect on U937 viability. Interestingly 
the concentrations at which afatinib began to be cytotoxic (5-20 µM) were the 
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concentrations that caused TRIB2 destabilisation. It is also fascinating that these 
concentrations are proximate to the previously reported Kd for reversible binding (prior 
to covalent modification) of afatinib to TRIB2, which was 16 µM (section 3.8.2, Figure 
3.24A).  
To further understand the cytotoxicity of EGFR/HER2 kinase inhibitors in U937 cells 
and to obtain reliable IC50 values (with reference to the positive control bortezomib), 
MTT assays were completed after incubation with compounds for 72 hours. Afatinib 
and neratinib reduced cell viability with sub-micromolar IC50 values, whereas EGFR 
inhibitors erlotinib and gefitinib and the dual EGFR/HER2 inhibitor TAK-285, were 10-
20 fold less effective when compared side-by-side (Figure 4.29). As these compounds 
did not induce cellular TRIB2 destabilisation, AKT activation or caspase-3 cleavage, 
this data suggests that the TRIB2-destabilising ligands afatinib and neratinib possess 
an enhanced ability to kill AML-derived cells [103]. Interestingly lapatinib, whilst still 
having a far greater IC50 than afatinib and neratinib, was still more potent than gefitinib, 
erlotinib and TAK-285. It could be hypothesised that lapatinib influenced TRIB2 
function and in turn cell viability through a binding mode that did not modulate TRIB2 
stability.          
 
Figure 4.29: TRIB2 selective inhibitors potently reduce cell viability in U937 cells. MTT assays 
comparing the cytotoxicity of a panel of TRIB2 binding and non-binding EGFR/Her2 kinase inhibitors in 
U937 cells. U937 cells were dispensed in 96 well plates prior to the addition of varying concentrations 
of inhibitors the following day (0.1% DMSO v/v). The MTT assay was performed subsequent to 72 hours 
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exposure to inhibitors. IC50 values in nM ± SD derived from 3 independent experiments are shown. 
Statistical analysis confirmed a significant difference in cytotoxicity between afatinib and erlotinib 
(students t-test p value = 0.0104) bortezomib and erlotinib (p value = 0.0072), neratinib and elotinib (p 
value = 0.0104) and lapatinib and erlotinib (p value = 0.04). 
 
4.11 Discussion 
4.11.1 Characterised expression of TRIB2 in HeLa and U937 cells  
Stable HeLa cells that expressed FLAG-tagged TRIB2 protein after induction with TET 
were generated, and TRIB2 expression was analysed by western blotting. Importantly, 
a novel polyclonal TRIB2 antibody allowed comparison of exogenous FLAG-tagged 
TRIB2 expressed in HeLa cells to endogenous TRIB2 expressed in U937 cells. 
Serendipitously, the quantity of TRIB2 expressed by TET induction in stable HeLa cells 
was similar to the amount observed in U937 cells (Figure 4.4C), which is useful for 
comparative purposes. Interestingly FLAG-TRIB2 was phosphorylated in HeLa cells, 
which was confirmed by incubation of the cellular lysate with lambda phosphatase 
(Figure 4.3). Indeed, from immunoblot analysis, a similar second band faint smeared 
band could also be observed just above the band corresponding to endogenous TRIB2 
in U937 cells (Figure 4.4C). Speculatively, this could have indicated the presence of a 
TRIB2 phosphorylated form in U937 cells, although unfortunately this was not 
confirmed with a lambda phosphatase assay due to experimental time constraints.   
In AGC kinases, including AKT, repositioning of the αC-helix to permit an active 
conformation is mediated by an in cis docking interaction between the C-terminal tail 
containing the HF motif and a hydrophobic groove between the αC-helix and β4 strand 
known as the PIF pocket [24, 295]. Both the HM motif and the αC-helix are disordered 
when AKT is in an inactive conformation, however, phosphorylation of Ser473 in HF 
motif of AKT helps to stabilise this active conformation, activating the kinase [42]. It 
would be interesting to use mass spectrometry analysis to elucidate potential TRIB2 
phosphosites, as phosphorylation could serve a similar regulatory purpose. A 
regulatory interaction between the C-terminal tail and binding pocket near the αC-helix 
of TRIB1 has recently been elucidated. Biochemical analysis from Chapter 3 suggests 
that the TRIB2 C-terminal tail also forms interactions within the pseudokianse domain. 
It would be interesting to observe whether or not mutation of potential TRIB2 
phosphosites disrupts or stabilises the interaction of C-terminal tail with the 
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pseudokinase domain. It was also previously reported that p70S6K, a member of the 
AGC kinase superfamily, phosphorylates TRIB2 causing degradation via Smurf1 [120] 
and mutation of Ser83 prevented degradation of TRIB2. 
4.11.2 Regulation of TRIB2 stability by the proteasome  
The turnover of both exogenous FLAG-TRIB2 expressed in HeLa cells and 
endogenous TRIB2 expressed in U937 cells was dependent on the proteasome 
(Figure 4.2 and 4.4). It was discovered that TRIB2 was rapidly degraded in the 
presence of the HSP90 inhibitor geldanamycin. In the presence of both geldanamycin 
and MG132 TRIB2 was stabilised (Figure 4.2). Inhibition of heat shock proteins has 
been a major focus of cancer research [296]. Association with the chaperone protein 
HSP90 can enhance the stability of many cellular proteins, including AKT and EGFR 
[297, 298]. The HSP90 inhibitor 17-allylamino-geldanamycin inhibited myeloma cell 
growth by destabilising AKT [297]. Upon HSP90 inhibition by geldanamycin, HER2 is 
polyubiquitinated and rapidly degraded [299], whereas EGFR is more slowly 
ubiquitinated with catalytic activity inhibited due to stabilisation of the EGFR monomer. 
It would be interesting to investigate the effects of heat shock protein inhibition in cell 
models where TRIB2 is a driver of disease.   
In various cell lines, TRIB1 and TRIB2 have been reported to be unstable, which was 
suggested to be due to conserved destabilising motifs present in the small N-terminal 
PEST region [104, 120, 300]. However, when the N-terminal domain of TRIB2 was 
truncated and TRIB2 54-343 was expressed in HeLa cells, protein stability did not 
increase. Furthermore, TRIB2 54-343 was still stabilised by the proteasome inhibitor 
MG132 to a similar extent as WT-TRIB2 (Figure 4.10). These data suggest that the N-
terminal domain of TRIB2 is not required for protein stability in these cell lines.  
When the DQLVP E3 ligase-binding motif of TRIB2 was mutated to AQLAA, 
expression was similar to WT-TRIB2 and was still stabilised in the presence of 
proteasome inhibitors. An intact DQLVP motif was previously shown to be required for 
TRIB2 to target substrates for ubiquitination [112]. Mutation of the DQLVP motif to 
AQLAA stabilised C/EBPα in vitro and in vivo [112]. However, these data suggest that 
turnover of TRIB2 itself is unlikely to be directed through the binding of E3 ubiquitin 
ligases to the DQLVP motif.  
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4.11.3 Targeting of TRIB2 with the reversible dual EGFR/HER2 inhibitor lapatinib  
Although the type I dual EGFR/HER2 kinase inhibitors lapatinib and TAK-285 
stabilised TRIB2 in vitro when analysed by DSF, there did not seem to be a direct 
consequence on TRIB2 stability when analysed in HeLa cells. This does not, however, 
rule out intracellular binding. Compounds were exposed to TRIB2 expressing HeLa 
cells for only 4 hours. Perhaps an extended period of incubation is required to observe 
significant changes in levels of TRIB2. Ji and colleagues (2018) [301] discovered, by 
employing surface plasmon resonance (SPR), that the compound rutacecarpine 
bound to the active site of VEGF-2 with a Kd of 0.4706 μM. However, it was only after 
48 hours incubation with 5 and 10 μM of inhibitor with HUVEC cells that there was a 
modest detectable increase in levels of total VEGF-2. Unfortunately, the levels of 
TRIB2 in TET-induced HeLa cells begin to decrease after 24 hours (Figure 4.24). This 
is consistent with previous findings that TET has a half-life of around 24 hours in cell 
culture [302]. To circumvent this issue, CETSA analysis was used to elucidate 
intracellular compound binding. CETSA revealed that lapatinib did in fact convincingly 
increase the thermal stability of cellular TRIB2 by ~2 °C. This change in melting 
temperature is close to the thermal shift induced by lapatinib for E. coli purified TRIB2 
in vitro (~3 °C) (section 3.8.1 Figure 3.23). It has been previously noted that 
conventional in vitro thermal shift assays with recombinant proteins purified from E. 
coli correlate with thermal shifts generated by CETSAs [292]. Thermal shifts generated 
from the purified poly (ADP-ribose) polymerase domain of PARP-1 analysed by 
differential static light scattering (DSLS), in the presence of cognate inhibitors (~10 
°C), were replicated when analysed by CETSA [292].  
In U937 cells, the amount of endogenous TRIB2 was not affected by lapatinib or the 
type I EGFR inhibitor erlotinib after 4 and 24 hours incubation at 10 µM. However, after 
24 hours exposure, lapatinib caused a reduction in the amount of pSer473 AKT in 
U937 lysate. Perhaps, during this time the effects of an interaction between lapatinib 
and TRIB2 began to become apparent. In U937 cells 24 hour incubation with lapatinib 
did not lead to caspase-3 cleavage and the cell viability, assessed by Typan blue, was 
not affected. However after 72 hours, MTT assay analysis did reveal that lapatinib had 
enhanced cytotoxicity compared to control EGFR/HER2 inhibitors, which suggests 
that prolonged exposure of lapatinib had an effect on cell viability, perhaps mediated 
through interaction with TRIB2.   
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4.11.4 Targeting TRIB2 for proteasomal degradation with covalent kinase 
inhibitors 
These studies focused on electrophilic type IV kinase inhibitors, and since they were 
likely to bind to TRIB2 via a covalent mechanism, comparative chemical and 
mutational analysis was amenable [303, 304]. At nanomolar concentrations, afatinib 
is a specific inhibitor of EGFR and HER2 in cells, however at low micromolar 
concentrations various other canonical kinases are inhibited due to off-target activity 
[11]. Moreover, osimertinib has off-targeted effects on both kinases [11] as well as 
non-kinases [305], including the lysosomal cathepsin proteases.  In this chapter the 
cross-reactivity of afatinib had been exploited to target TRIB2 in cells. CETSA analysis 
revealed that TRIB2 was thermally destabilised in the presence of afatinib by between 
2-3 °C (Figure 4.13), which was similar to thermal shifts observed by DSF. In whole 
cell assays TRIB2 was rapidly degraded in the presence of afatinib after 4 hours 
incubation. Interestingly, the dose dependent elimination of TRIB2 had a maximal 
effect between 10-15 µM, which is remarkably close to the reversible binding of Kd of 
afatinib (16 µM) elucidated in chapter 3. The related inhibitor neratinib also induced 
TRIB2 degradation in HeLa cells. 
The cellular mechanism by which TRIB2 stability is regulated is proteasome-based. 
Unlike lapatinib, covalent compounds such as afatinib binding caused degradation of 
TRIB2, the effect of which was reversed in the presence of proteasome but not 
lysosome/autophagy inhibitors. TRIB2 levels were also depleted in the presence of 
geldanamycin, the effect of which was also reversed in the presence of proteasome 
inhibitor, indicating a potential stabilising roles of a geldanamycin target on TRIB2. It 
was previously demonstrated that the binding of lapatinib and vemurafenib to HER2 
can deprive the kinase of an interaction with the HSP90-CDC37 system, leading to 
time-dependent HER2 degradation at micromolar concentrations [306]. It can be 
speculated that an afatinib-induced conformational change might induce TRIB2 
ubiquitination, or negatively regulate interaction with an unknown stabilising factor(s), 
such as heat shock protein chaperones [286, 307]. It was previously demonstrated 
that HSP90 does not bind to particular sequence motifs, but in fact associates with 
intrinsically unstable kinases [308]. TRIB1, TRIB2 and TRIB3 have been reported to 
be unstable [104, 120, 300], which has been a major challenge in understanding roles 
of Tribbles in cellular signalling. Therefore, exploring the potential mechanisms of 
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stabilisation of Tribbles pseudokinases through the HSP90 system could be a valuable 
endeavour.  
4.11.5 A chemical genetics approach to elucidate on targeted binding of afatinib 
to TRIB2 
It was hypothesised that mutation of Cys96 and 104 would negate the ability of afatinib 
to covalently bind to TRIB2. A THZ-derived covalent CDK inhibitor was found to bind 
covalently to Cys1039 of CDK12 resulting in protein destabilisation and cellular 
cytotoxicity [304]. HAP1 chronic myeloid leukaemia cells engineered to express a 
C1039S CDK12 mutation, using clustered regularly interspaced short palindromic 
repeats- (CRISPR)-cas9 technology, stabilised CDK12 and reversed compound 
induced cytotoxic effects. Similarly mutation of Cys96 and Cys104 to Ser in TRIB2 
abolished destabilisation induced by afatinib. Both TRIB2 Cys-residues, targeted by 
afatinib, are uniquely located within the distorted αC-helix, which make it vulnerable to 
certain type IV inhibitors that were originally developed as nanomolar covalent 
inhibitors of the tyrosine kinases EGFR and HER2. Such dual-targeting suggests 
shared features between signalling-relevant (‘active’) conformations in the ATP-site of 
both TRIB2 (SLE-in) and EGFR/HER2 (DFG-in).  
It can be asserted that C96/104S-TRIB2 reversibly binds to afatinib but covalent 
modification of Cys96 and 104 are necessary to induce degradation of TRIB2. Indeed, 
MST analysis, (see Section 3.8.2), confirmed a reversible binding Kd of 16 µM to WT 
TRIB2. Further to this afatinib, has the potential to be developed as a TRIB2 specific 
ligand as the lack of equivalent Cys residues in other pseudokinases, including the 
related TRIB1, TRIB3 and STK40, likely prevents them from covalent modification. It 
was recently discovered that MLKL activity could also be regulated by a covalent 
compound that exerted its function by binding to a region distal to the active site. The 
compound necrosulfonamide targeted a unique Cys86 on the N-terminal coiled coil 
domain of MLKL, in turn preventing necroptosis in human cells [309]. This discovery 
presents the opportunity to exploit unique Cys residues both within and outside the 
ATP-binding site to develop target specific pseudokinase irreversible inhibitors.  
HER3 was the first pseudokinase to be targeted by irreversible inhibitors. Afatinib has 
also been shown to bind to HER3, although the binding is reversible due to the 
presence of a Ser794 residue at the equivalent Cys797 in EGFR. However, an 
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alternate, unique, Cys721 residue in the roof of the ATP binding pocket has been 
exploited to which the compound TX2-121-1 irreversibly binds [62]. As well as inducing 
proteasomal degradation of HER3, TX2-121-1 perturbed the hetero-dimerization of 
HER3 with HER2 leading to reduced AKT and ERK phosphorylation. The covalent 
HER3 compound TX2-121-1 was generated by structure-guided hybridization 
between the most potent hits discovered from initial screening [310]. Alas, in the 
absence of a high-resolution TRIB2 pseudokinase crystal structure, the 
conformation(s) relevant for small molecule interaction are not yet known and structure 
guided design of novel TRIB2 ligands is not yet possible.  
The TRIB2 COP1-binding site DQLVP to AQLAA mutant was proposed to be 
maintained in the ‘SLE-in’ conformation and destabilised due to the absence of the 
regulatory interaction between the C-terminal tail and pseudokinase domain in vitro 
(section 3.6). However, AQLAA and WT-TRIB2 had similar stability and expression 
levels in HeLa cells (Figure 4.14). Remarkably, AQLAA-TRIB2 was more sensitive to 
destabilisation in the presence of afatinib, suggesting that in the absence of the C-
terminal tail, the Cys96 and 104 residues in the αC-helix are more readily primed for 
covalent modification. It would be interesting to mutate the Cys96 and 104 residues in 
the AQLAA-TRIB2 mutant to test this hypothesis.   
4.11.6 Kinase inhibitors to investigate the roles of TRIB2 in cellular signalling 
TRIB3 was previously shown to be able to target endogenous ACC for proteasomal-
mediated degradation in vivo in adipose tissue [107]. In transiently transfected HeLa 
cells there was no evidence for degradation of ACC in the presence of TRIB2 (Figure 
4.19). It was previously observed that TRIB3 had the ability to induce ACC degradation 
in HeLa cells but only when TRIB3 cDNA was co-transfected with the gene encoding 
the E3 ligase COP1 [285]. Perhaps in order to observe TRIB2 mediated effects on 
levels of ACC in HeLa, TET induced cells must also be transfected to express COP1. 
TET induced stable HeLa cells had lower levels of phosphorylated ACC than un-
induced cells, suggestive of perhaps a preferential targeted ubiquitination of 
phosphorylated ACC (Figure 4.22). Conversely, it was previously demonstrated in vitro 
that the ability of TRIB1 to bind to C/EBPβ was negated when C/EBPβ was 
phosphorylated at Ser77 or Tyr79, which are within the Tribbles degron [105]. 
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The effects of TRIB2 in U937 cells, in the context of targeted ubiquitination of C/EBPα 
and CDC25C, have been documented [102, 113]. TRIB2 in TET induced HeLa cells 
did not induce degradation of either C/EBPα or CDC25C (Figure 4.19). Again, perhaps 
this was due to the requirement of co-transfection to induce expression of both TRIB2 
and the E3 ligase COP1 [285].  
It was recently demonstrated that TRIB2 overexpression in various transiently 
transfected cell lines induced AKT phosphorylation at Ser473 but not Thr308 [103]. In 
this chapter I demonstrated that transiently transfected HeLa cells expressing TRIB2 
had increased levels of pSer473 AKT (Figure 4.19). Stable TET induced HeLa cells 
also had increased levels of pSer473 AKT after a serum block and release procedure 
(Figure 4.24).WT-TRIB2 was degraded in the presence of afatinib which lead to 
decreased levels of pSer473 AKT. Conversely, using chemical genetics it was 
revealed that the C96/104S-TRIB2 mutant was completely resistant to afatinib, which 
resulted in maintained levels of pSer473 AKT in the presence of afatinib. This provides 
strong evidence for targeted activity of afatinib against TRIB2.     
 
4.11.7 Targeting TRIB2 in a myeloid leukaemia cell model 
The work in this chapter describes the use of novel ligands to elucidate TRIB2 
functions in human cells and potential leads for the development of therapeutics where 
TRIB2 overexpression is a driver of disease [104]. Overexpression of TRIB1 and 
TRIB2 are associated with hematopoietic malignancies, as well as various solid 
cancers [104]. Levels of TRIB1 were found to be elevated in AML and myelodysplastic 
syndrome clinical samples due to gene amplifications and TRIB2 expression was 
shown to be increased in subsets of AML clinical samples characterised by abrogated 
C/EBPα function [311, 312]. These findings are supported by in vivo murine models, 
where TRIB2 overexpression in bone marrow progenitors caused fully penetrant and 
lethal AML [109].  
A previous study established that a K177R TRIB2 mutant, that was not able to promote 
p42-C/EBPα degradation, was able to inhibit granulocyte differentiation in 32D cells 
[112], suggesting that other functions may be exerted by TRIB2 in haematological 
malignancies. Although there are reports that TRIB2 may regulate MAPK signalling, 
no differences in phopho-p44/42 MAPK activity in TRIB2 expressing 32D cells were 
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observed [112]. This result corroborates previous reports that TRIB1, TRIB2 and 
TRIB3 could not influence MAPK activation in hematopoietic cells [285]. 
U937 cells are highly sensitive to knockdown of TRIB2, making them a suitable model 
to probe TRIB2 function with small molecule inhibitors. The effects of TRIB2 on AKT 
signalling in U937 cells have not yet been described. In this chapter I have 
demonstrated that the rapid degradation of endogenous TRIB2 in the presence of 
afatinib resulted in concomitant loss of pSer473 AKT followed by caspase-3 cleavage. 
The covalent EGFR/HER2 inhibitor afatinib may represent a promising basis for the 
development of TRIB2 therapeutics in haematological malignancies where TRIB2 is 
overexpressed. Afatinib and neratinib exhibited submicromolar cytotoxicity in U937 
cells, where other EFGR/HER2 inhibitors were 10-20 fold less potent, despite the fact 
that all compounds tested completely inhibited pERK. Only afatinib, and to a lesser 
extent lapatinib (only after 24 hours), caused a reduction in pSer473 AKT, which was 
proposed to be mediated through binding to TRIB2. Unfortunately dose response 
assays and immunoblot analyses were not performed in the presence of neratinib, but 
it can be argued that a reduction in the amount of TRIB2 and pSer473 AKT might be 
observed. No caspase-3 cleavage was observed after 24 hours incubation of U937 
cells with lapatinib. However, of the reversible inhibitors, lapatinib was the most 
cytotoxic in MTT assay analyses.  
Trypan blue assays revealed that afatinib and the clinical leukaemia therapeutic 
bortezomib had similar cytotoxicity after 24 hours, whereas other EGFR/HER2 
inhibitors had no apparent effect. At 24 hours 10 µM afatinib completely eliminated 
TRIB2 in U937 cells, which coincided with caspase-3 cleavage, giving credence to the 
assertion that TRIB2 is a rate limiting factor in U937 cell survival. Although it cannot 
be ruled out that simultaneous effects of afatinib on both TRIB2 destabilisation and 
ERK/AKT pathway inhibition may be contributing to cellular phenotypes, there is a 
strong case that afatinib-binding is required for TRIB2 destabilisation and AKT 
regulation in HeLa and U937 cells. Indeed simultaneous elimination of TRIB2 and 
inhibition of the ERK-signalling pathway could be a polypharmacological asset, 
especially in TRIB2-dependent drug-resistance in tumour cells [103, 239].  
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Chapter 5:  Conclusions and Future investigations 
 
Conclusions 
It is widely accepted that non-enzymatic components can control signalling outputs in 
normal physiology and disease, exemplified by the cellular activities of pseudokinases 
[313]. In chapter 3 of this thesis, I sought to target the cancer-associated pseudokinase 
TRIB2 with small molecules, initially with the aim of evaluating their biochemical 
properties in vitro. In order to discover novel TRIB2 chemical ligands, a relatively 
simple DSF thermal shift assay was employed [58]. Multiple chemical classes of small 
molecules originally reported to be specific dual EGFR/HER2 kinase inhibitors (but not 
monovalent EGFR inhibitors), were discovered to modulate TRIB2 thermal stability in 
vitro. One group of thienopyrimidine based type I ATP-competitive small molecule 
inhibitors were found to induce a stereotypical (positive) thermal shift by interacting 
with the pseudo-ATP binding site. A second group of quinazoline-based type IV 
EGFR/HER2 inhibitors were found to destabilise TRIB2, leading to the opposite 
(negative) thermal shift. Although initially unexpected, this was mechanistically 
explained by a Cys-based covalent binding mode, which caused the C-terminal tail of 
TRIB2 to become uncoupled from its own pseudokinase domain. Consistently, a more 
thermally-stable conformation of TRIB2, generated by intramolecular interaction 
between the C-terminal tail and the pseudokianse domain, was targeted by three 
clinically-approved type IV EGFR/HER2 inhibitors afatinib, neratinib and osimertinib in 
vitro. Synthetic stapled C-terminal tail peptides that compete with the TRIB2 C-terminal 
tail DQLVP sequence were also found to destabilise TRIB2, again likely by competing 
with the C-terminal tail for binding in the pseudokinase domain.    
A combination of techniques presented in chapter 3 went on to confirm that afatinib 
and neratinib covalently bound to TRIB2 at Cys96 and Cys104 in the αC-helix. These 
two distinct Cys residues are not conserved in TRIB1, TRIB3 or the more distantly 
related pseudokinase STK40. Consistently, afatinib and neratinib did not modulate 
TRIB1 stability when analysed by DSF, or TRIB2 in which these Cys residues were 
mutated to Ser. It can, therefore, be argued that the occurrence of the two unique 
TRIB2 Cys residues exert a selectivity filter, which permits targeting of TRIB2 but not 
208 
 
TRIB1, TRIB3 or STK40, by covalent EGFR/HER2 inhibitors. If this is the case, then 
the differential effects of TRIB2 versus TRIB1 and TRIB3 in cellular signalling could 
potentially be analysed in appropriate experimental circumstances. As discussed in 
chapter 4, the electrophilic type IV EGFR/HER2 chemical ligands, which were 
amenable to comparative and mutational analysis were found to induce destabilisation 
and proteasome-mediated degradation of TRIB2 in human cells. Elimination of WT-
TRIB2, in the presence of afatinib, correlated with decreased phosphorylation of AKT 
at Ser473, which correlates with AKT activity, in an inducible exogenous FLAG-TRIB2 
expressing HeLa cell model. Conversely, the FLAG-C96/104S-TRIB2 mutant was 
significantly more resistant to afatinib-mediated degradation, and in turn, 
phosphorylation of pSer473 AKT was not inhibited. Analysis in a U937 leukaemia 
disease model revealed that endogenous TRIB2 was also destabilised, and the levels 
of pSer473 AKT decreased in-line with afatinib degradation, supporting the case that 
TRIB2 is targeted directly by afatinib in human cells. Furthermore, in U937 cells, upon 
depletion of TRIB2 and concomitant with a decrease in levels pSer473 AKT, afatinib 
also induced caspase-3-cleavge, suggestive of apoptosis. The viability of U937 cells 
also was assessed by MTT assays in the presence of selected EGFR/HER2 inhibitors 
and the leukaemia chemical therapeutic bortezomib. Afatinib and neratinib were nearly 
as effective as the clinical proteasome inhibitor bortezomib and were some 10-20 fold 
more effective than other EGFR and EGFR/HER2 inhibitors.  
 
5.1    In vitro analysis of TRIB2 with small molecule kinase inhibitors 
In this thesis I have employed various techniques, including DSF, MST and MS to 
establish that compounds from distinct designated chemical classes bind to TRIB2 in 
vitro. TRIB2 stabilising and destabilising cell-permeable compounds were initially 
discovered by DSF profiling, supporting the use of this technique to study compounds 
that target this, and other, pseudokinases with unusual nucleotide-binding sites [58]. I 
also attempted to establish TRIB2 compound binding affinity using ITC, but this was 
problematic because TRIB2 was not stable above 100 µM, and the compounds 
remained soluble under these conditions, to ~20 µM, as measured by UV-Vis 
spectroscopy (see Appendix). However, using MST I was able to establish an 
apparent the Kd in the micromolar range for reversible binding of afatinib and TAK-
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285. To corroborate these findings, molecular dynamics simulations revealed that the 
docked enamide moieties of both afatinib and neratinib were positioned between 3-5 
Å from the Cys thiol functional groups specific to TRIB2, and remained stably bound 
for ~17 ns, which is believed to be favourable for covalent bond formation and is similar 
to the experimental parameters calculated for EGFR covalent modification [213]. By 
using mutational analysis in vitro, it was confirmed that covalent EGFR/HER2 
inhibitors, including afatinib and neratinib, caused TRIB2 destabilisation by uncoupling 
the C-terminal tail from the pseudokinase domain upon covalent modification of Cys96 
and Cys104 in the αC-helix. The strongest destabilising agent discovered from initial 
screening was a reversible PLK inhibitor (GW804482X), which induced destabilisation 
through an alternate mechanism that has yet to be elucidated. However, analysis of 
various truncation proteins and a TRIB2 K90M mutant suggested that reversibly 
binding compounds (both stabilising and destabilising) modulate TRIB2 stability by an 
interaction with pseudo-active site, although conformations relevant for binding remain 
unknown.  
Allosteric release of the DQLVP motif occurs on C/EBPα substrate-binding in TRIB1 
[105]. Analysis of TRIB1 revealed that binding of the substrate C/EBPα causes the C-
terminal tail to uncouple from the pseudokinase domain, in turn causing the 
pseudokinase domain to adopt an SLE-in conformation, whereby the activation loop 
folds towards the ɑC-helix and forms a binding site for the C/EBPɑ degron. Isothermal 
titration calorimetry (ITC) revealed that maltose binding protein (MBP)-fused C/EBPα 
and C/EBPβ tribbles degron sequence peptides bound to TRIB1 with Kd values of 11 
and 15 µM respectfully [106]. Interestingly, phosphorylation of C/EBPβ at Ser77 and 
Tyr79, within the Tribbles degron, negatively regulated binding, as measured by 
fluorescence polarisation experiments [105]. This observation suggests that 
phosphorylation of C/EBP transcription factors might regulate their binding to TRIB1, 
depending on cell type or developmental stage. It would be interesting to repeat these 
experiments with TRIB2 to establish whether or not there is an analogous mechanism 
of regulation.  
Interestingly, TRIB1 was not stabilised by the C/EBPα Tribbles degron peptide when 
assayed by DSF [105], perhaps because the global stability of TRIB1 did not change 
with binding to either the C/EBPα peptide or its own C-terminal tail. It would be 
interesting to see whether or not the pseudokinase domain alone of TRIB1 and TRIB2 
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can be stabilised by the C/EBPα peptide. Interestingly, Jamieson and colleagues  
(2018) [105] very recently demonstrated that some PKIS1 compounds stabilised 
TRIB1 in the presence of C/EBPα peptide, and that the stabilisation afforded by 
compound GW607049C, a previously described benzimidazole-based TIE-2/VEGF2 
inhibitor,  was prevented in the presence of C/EBPα peptide, potentially indicative of 
different binding conformations. I speculate that ‘stabilising’ compounds, such as 
lapatinib and TAK-285, might permit, or strengthen, an interaction between the C-
terminal tail and the pseudokinase domain, therefore preventing TRIB2 from binding 
to substrates, or perhaps compete with substrates for binding in the pseudokinase 
domain. There are several crystal structures of TRIB1 in different conformations (and 
in complex with C/EBPα peptide substrate), which have recently been solved [105, 
106]. Therefore, it seems feasible that in the near future TRIB1 (or TRIB2)-compound 
co-crystal structures will begin to emerge. This would give valuable insight into TRIB 
conformations relevant to compound binding for stabilising and destabilising ligands. 
It is worthy to note that the second most prominent class of TRIB2 stabilisers, 
discovered by DSF in my analysis, were benzimidazole TIE-2/VEGF2 inhibitors, which 
included the TRIB1 stabilising compound GW607049C. A relevant experiment, to be 
considered in the future, could employ TRIB2, and C/EBPα and/or C/EBPβ peptides 
to evaluate the structural effects, or dynamics, in the presence of selected inhibitors. 
It could be speculated that binding of afatinib/neratinib would uncouple the C-terminal 
tail from the pseudokinase domain and will either (1) enhance the binding of 
C/EBPα/C/EBPβ peptides or (2) cause binding of the C/EBPα/C/EBPβ peptides to be 
prevented. The former should result in no global change in protein stability and 
therefore no thermal shift in the presence of both compound and C/EBP peptide. In 
the latter case, there will be compound induced destabilisation. Florescence 
polarization experiments to observe whether or not titration of certain inhibitors can 
outcompete the binding of Fluorescence isothiocyanate- (FITC)-C/EBPα to TRIB2 
would additionally be interesting to evaluate [105].  
5.2 Investigation of TRIB2 protein-protein interactions in vitro 
In Chapter 3 I confirmed that recombinant purified TRIB2 interacted with C/EBPα using 
GST pull down assays. A next logical future step will be to investigate the TRIB2-
C/EBPα interaction in the presence of small molecule compounds, perhaps also using 
NMR or cryo-EM to probe the structure of the complexes. Perhaps different 
211 
 
compounds that offer alternate modes of binding will agonise or antagonise TRIB2 
interaction with C/EBPα. Surface plasmon resonance (SPR) might be an alternative 
approach to determine Kd values for C/EBP peptide binding. It would also be 
interesting to investigate binding between the TRIB2 C-tail containing the DQLVP motif 
and αC-helix using SPR in the presence of compounds. The pseudokinase domain 
(54-318) of TRIB2 could be immobilised by exploiting the 6His N-terminal tag and the 
affinity for purified TRIB2 C-terminal peptide (residues 319-343) could be elucidated.  
It might be possible to assess C/EBPα degron peptide binding or C-terminal tail 
binding to TRIB2 in the presence/absence of compounds by using Alphascreen 
(Amplified Luminescent Proximity Homogeneous Assay Screen) technology. The 
AlphaScreen is an interaction based assay, which relies on the use of ‘donor’ and 
‘acceptor’ beads that can bioconjugated. An interaction between the molecules leads 
to a proximity induced cascade of chemical reactions. On laser excitation of the donor 
bead, a reaction causes ambient oxygen to form the unstable singlet species, which 
can diffuse a maximum of 200 nm before conversion to back O2.  The generated 
singlet state oxygen molecules react with a chemiluminescer in the acceptor bead in 
turn activating fluorophores, which emit light at 520–620 nm [314]. For example, 
AlphaScreen was used to screen 14,500 compounds to find inhibitors which 
allosterically modulated the binding of a synthetic PRK2 hydrophobic motif peptide 
(conjugated to the donor bead) to the PIF-pocket of PDK1, which was bioconjugated 
to the Nickel acceptor beads via exploitation of a 6His tag [39]. 
Aside from C/EBPα, another substrate that TRIB2 has been reported to be a target for 
proteasome-mediated degradation in human cells is CDC25C, a dual phosphatase 
that activates CDK1 by specifically dephosphorylating residues Thr14 and Tyr15 [315]. 
TRIB2 was shown to bind to C/EBPα in pull down experiments. It would be interesting 
to repeat this experiment to observe whether or not TRIB2 can interact with 
recombinant CDC25C. Although, it has been reported that the majority of CDC25C, 
purified from E. coli resolved at around 220 kDa and was not present as 55 kDa 
monomer [316]. Additionally endogenous CDC25C immunoprecipitated from HeLa 
cells was observed at a complex above 200 kDa [316]. It would be interesting to 
observe whether or not TRIB2 interacted with the CDC25C tetramer in vitro. Indeed, 
CDC25C is differentially phosphorylated and activated by CDK1/cyclin B1, 
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CDK2/cyclin A2 and CDK2/cyclin E complexes [315, 317], which could potentially 
regulate interaction with TRIB2.     
Size exclusion chromatography analysis of the pseudokinase domain of TRIB2 and 
the E3 ligase-binding site AQLAA-TRIB2 mutant suggested that these proteins form 
dimers. It is postulated that uncoupling of the C-terminal tail from the pseudokinase 
domain, in the absence of substrate, causes dimerization and serves as a regulatory 
function. Size exclusion chromatography coupled to multiangle light scattering (SEC-
MALS) analysis could be used to help deduce whether or not the pseudokinase 
domain of TRIB2 dimerises after uncoupling of the C-terminal tail.   C-related protein 
kinases (PRKs), of the AGC kinase superfamily, possess a HM motif in their C-terminal 
tail that does not form an intramolecular interaction with the PIF-pocket when the 
kinase domain forms an inactive homodimer [49]. Phosphorylation of the turn motif 
within the C-terminal tail promotes zipper-like association of the tail with the kinase 
domain, which results in HM binding to the PIF-pocket and stabilisation of the PRK2 
active monomer [318]. Antibodies that bind to and sequester the HM motif in the C-
terminal tail of PRK2 result in stabilisation of the inactive dimer [49].  
5.2.1 Biophysical approaches for studying TRIB2 
Circular dichroism (CD) can be used to help elucidate conformational changes, by 
observing changes in α-helical and β-sheet composition in the protein secondary 
structure that become modulated upon compound binding [319]. Drawing on the 
biophysical principles of thermal shift assays, compound binding to TRIB2 could be 
investigated using temperature-dependent CD (TdCD) profiling [320]. Measuring the 
temperature-dependent unfolding of proteins by TdCD in the absence and presence 
of inhibitors might lend additional support to conclusions derived from DSF analysis. 
For example, alterations in TRIB2 secondary structure would be more sensitive to 
temperature increase in the presence of destabilising agents such as afatinib and less 
sensitive in the presence of stabilising agents such as lapatinib. It would also be 
interesting observe the potential secondary structure changes upon dimerization of 
the TRIB2 pseudokinase domain. 
An important aspect of future studies will be to chemically modify covalent 
EGFR/HER2 inhibitors such as afatinib, so that they have reduced affinity for their 
original targets, whilst ideally engineering a TRIB2 affinity in the nM region. Then, 
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synthesised compounds that eliminate or preserve interaction with EGFR/HER2 can 
be compared side-by-side in cells. In the latter case, simultaneous elimination of 
TRIB2 and inhibition of EGFR/HER2 signalling could be a polypharmacological asset, 
especially if TRIB2 expression is a contributing factor to drug-resistance, as reported 
for tumour cells [103]. In order to facilitate structure guided design for the development 
of potential TRIB2 inhibitors, structural information of TRIB2 bound to compounds 
would need to be generated. To date there is no NMR or crystallographic structural 
information available for TRIB2 and this is foremost due to the challenging nature of 
recombinant TRIB2 stability and propensity to aggregate in vitro. Previous endeavours 
to crystallise TRIB2 have met with failure. Nanobodies may potentially be used in 
future applications to stabilise WT TRIB2 and aid crystallisation [321]. Perhaps there 
might be more success in crystallising the hyper stable TRIB2 C104Y mutant, or fusing 
TRIB2 to C/EBPα, as reported recently for TRIB1 [105]. Thereupon molecular models 
replacing the Tyr back to a Cys in silico could be informative and produce a more 
accurate WT TRIB2 model and form the basis for the future structure guided design 
of potential ligands.  
 
5.3 Small molecule kinase inhibitors for analysis of TRIB2 in human cells and in 
vivo 
Type II EGFR/HER2 inhibitors such as lapatinib and TAK-285 stabilised the 
pseudokianse domain of TRIB2 in the presence and absence of the C-terminal tail. 
Type IV EGFR/HER2 inhibitors, including afatinib, neratinib and osimertinib, 
destabilised TRIB2 only in the presence of an intact DQLVP motif. On the other hand 
the PLK inhibitor GW804482X destabilised the pseudokianse domain of TRIB2, 
regardless of whether or not the C-terminal tail was present. Alternate modes of 
binding could stabilise different conformations and have versatile effects on TRIB2 
signalling outputs in human cells. In the absence of PIP3 the N-terminal domain of AKT 
containing the PH domain forms intramolecular interactions with the catalytic domain, 
stabilising an inactive conformation that sterically prevents it binding to and being 
phosphorylated at the activation loop Thr308 by PDK1 [322]. The compounds MK-
2206 exploits this intramolecular inhibitory interaction within AKT and allosterically 
stabilises the interaction of the PH domain with catalytic domain [211]. This prevents 
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the PH domain form being sequestered by PIP3. MK-2206, which is currently in 
numerous clinical trials for diverse types of cancers, was developed from compounds 
AKTi1 and AKTi2 [323]. AKTi-1 and AKTi-2 were discovered from screening to be 
selective for AKT1 and AKT2 and allosterically stabilise PH domain binding to the 
catalytic domain [323]. This inactive form of AKT also inhibits the intramolecular 
interaction of the C-terminal HM with the PIF-pocket in the αC-helix [211]. It is 
expected that future structural analysis will reveal detailed mechanisms of TRIB2 
stabilisation and destabilisation and lead to the synthesis of inhibitors that specifically 
target various TRIB2 functions in human cells. The key effects of the AKT signalling 
pathway could be extended beyond pSer473, and the effects assessed on the 
downstream components TSC2 and mTORC1 . 
Inhibitors afatinib and neratinib stimulate TRIB2 degradation in human cells at 
micromolar concentrations. Despite the high concentration required for TRIB2 
degradation and signalling perturbation, covalent drugs have the potential to 
accumulate to relatively high concentrations in cells, which may be of physiological 
relevance for TRIB2 signalling in clinical circumstances. For example osimertinib has 
previously been shown to accumulate in lysosomes [214]. 
The effect of various compounds on C/EBPα stability in U937 cells could not be 
assessed due to time constraints, though it is expected that a loss of TRIB2 will be 
reflected by changes in C/EBPα stability. There are many other haematological cancer 
cell lines that could be employed to explore TRIB2 substrate ubiquitination in the 
presence of small molecule TRIB2 inhibitors. In U937 cells CRISPR/Cas9 technology 
could be utilised to mutate Cys96 and Cys104 of endogenously expressed TRIB2. It 
is hypothesised that C96/104S endogenous TRIB2 would not be as readily degraded 
in the presence of afatinib and neratinib, and therefore would result in levels of C/EBPα 
and pSer473 AKT being analogous to untreated cells. A role for TRIB2 in C/EBPα 
ubiquitination has been described in 32D cells [112]. It will be interesting to test 
whether or not TRIB2 destabilisation modulated C/EBPα stability in this cell line. 
Similarly TRIB2 was discovered to promote ubiquitination of CDC25C leading to 
proteasome-mediated degradation in these cells [324], which could be assessed in 
the presence of afatinib and neratinib. Mice that retrovirally express TRIB2 in 
hematopoietic stem cells develop fully penetrant, lethal AML [109]. It would be 
interesting to analyse the effects of various TRIB2 binding/non-binding EGFR/HER2 
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inhibitors in mice that have been reconstituted with hematopoietic stem cells 
retrovirally expressing either WT or C96/104S-TRIB2.   
Finally, it will be interesting to obtain clinical samples from patients, for instance from 
the Lux-lung trials comparing afatinib and erlotinib in NSCLC with EGFR/HER2 
activating mutations, and quantify TRIB2 expression levels after drug exposure in vivo. 
For example, levels of TRIB2 could be correlated with levels of C/EBPα and pSer473 
AKT signalling in afatinib versus erlotinib treated NSCLC. ELISA-based procedures 
could be developed to quantify effects of these drugs on TRIB2 protein stability, as 
part of broader proteomics approaches to establish all of the intracellular targets of 
these compounds.  
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Appendix 
The following tables contain data from the TRIB2 PKIS1 DSF screen. Table 1 
discloses all of the compounds tested, revealing average ΔTm values. The most 
destabilising compounds along with information about their chemical structures and 
originally intended targets are disclosed in Table 2. Table 3 contains the same data 
as Table 2 but for the top TRIB2 stabilising compounds.  
Plate position Compound code ΔTm 1 ΔTm 2 average st.dev 
JMP-A1 SB-630812 -0.3 -0.27 -0.285 0.015 
JMP-A2 GW831091X -0.09 0 -0.045 0.045 
JMP-A3 GW700494X 2.83 2.06 2.445 0.385 
JMP-A4 GW461104B 1.2 1.51 1.355 0.155 
JMP-A5 GW796920X -0.12 0.07 -0.025 0.095 
JMP-A6 GW632046X 0.6 0.43 0.515 0.085 
JMP-A7 GW627834A 1.27 1.71 1.49 0.22 
JMP-A8 GSK561866B -0.03 0.24 0.105 0.135 
JMP-A9 GW352430A 0.21 0.25 0.23 0.02 
JMP-A10 SB-734117 0.63 0.64 0.635 0.005 
JMP-B1 GW620972X -0.93 -0.19 -0.56 0.37 
JMP-B2 SB-686709-A 0.1 0.13 0.115 0.015 
JMP-B3 GW578748X 0.29 0.13 0.21 0.08 
JMP-B4 GW572399X 1.81 2.06 1.935 0.125 
JMP-B5 GSK2163632A -2.96 -0.38 -1.67 1.29 
JMP-B6 GSK953913A -0.01 0.22 0.105 0.115 
JMP-B7 GSK180736A 0.27 0.32 0.295 0.025 
JMP-B8 SB-264866 0.32 0.29 0.305 0.015 
JMP-B9 GW809897X 1.63 1 1.315 0.315 
JMP-B10 SB-361058 0.44 0.47 0.455 0.015 
JMP-C1 GW829055X 1.43 1.68 1.555 0.125 
JMP-C2 GW434756X -0.12 0.11 -0.005 0.115 
JMP-C3 GSK237700A -0.36 -0.55 -0.455 0.095 
JMP-C4 GW577921A 0.77 0.03 0.4 0.37 
JMP-C5 GW621970A 0.3 0.36 0.33 0.03 
JMP-C6 SB-741905 0.06 0.22 0.14 0.08 
JMP-C7 SB-736290 0.11 0.03 0.07 0.04 
JMP-C8 SB-742865 1.01 0.83 0.92 0.09 
JMP-C9 GW874091X 0.27 0.26 0.265 0.005 
JMP-C10 SB-738561 -1.22 0.34 -0.44 0.78 
JMP-D1 GW829115X 0.05 0.28 0.165 0.115 
JMP-D2 GW856804X 0.96 1.15 1.055 0.095 
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JMP-D3 GW833373X 1.05 0.91 0.98 0.07 
JMP-D4 GW796921X -0.02 0.28 0.13 0.15 
JMP-D5 GSK586581B 0 0.21 0.105 0.105 
JMP-D6 SB-390527 0.24 0.42 0.33 0.09 
JMP-D7 GSK571989A -0.33 0.05 -0.14 0.19 
JMP-D8 GW784684X 3.58 2.88 3.23 0.35 
JMP-D9 GSK204925A 0.22 0.72 0.47 0.25 
JMP-D10 SB-236687 0.45 -0.93 -0.24 0.69 
JMP-E1 GW829906X 0.52 1.29 0.905 0.385 
JMP-E2 GW813360X 0.04 0.15 0.095 0.055 
JMP-E3 GW680908A 1.37 1.33 1.35 0.02 
JMPE4 SKF-62604 -0.11 -0.07 -0.09 0.02 
JMP-E5 GSK1023156A 0.77 0.24 0.505 0.265 
JMP-E6 SB-751399 0.16 0.6 0.38 0.22 
JMP-E7 GW574783B 1.59 2.69 2.14 0.55 
JMP-E8 GW641155B 0.52 0.52 0.52 0 
JMP-E9 GW301789X 0.89 0.95 0.92 0.03 
JMP-E10 GW607049B 3.48 2.93 3.205 0.275 
JMP-F1 GSK620503A 0.1 -0.36 -0.13 0.23 
JMP-F2 GW569530A -2.56 -1.87 -2.215 0.345 
JMP-F3 SB-264865 -2.97 0.2 -1.385 1.585 
JMP-F4 GSK319347A 0.39 0.6 0.495 0.105 
JMP-F5 SB-739452 0.47 0.4 0.435 0.035 
JMP-F6 GSK711701A 0.14 0.65 0.395 0.255 
JMP-F7 GW768505A 1.31 1.14 1.225 0.085 
JMP-F8 SB-814597 0.35 0.46 0.405 0.055 
JMP-F9 GW837331X 3.16 1.88 2.52 0.64 
JMP-F10 SB-678557-A 0.57 0.5 0.535 0.035 
JMP-G1 GW775608X 0.12 0.32 0.22 0.1 
JMP-G2 GI261520A 1.58 0.81 1.195 0.385 
JMP-G3 SB-245392 -0.19 0.09 -0.05 0.14 
JMP-G4 GSK317315A 0.43 0.23 0.33 0.1 
JMP-G5 GW817396X 0.08 0.38 0.23 0.15 
JMP-G6 GW785804X 0.1 0.43 0.265 0.165 
JMP-G7 SB-732881-H 0.03 0.41 0.22 0.19 
JMP-G8 GSK1173862A 1.27 1.6 1.435 0.165 
JMP-G9 GW301888X 0.53 0.64 0.585 0.055 
JMP-G10 GW843682X 0.66 0.42 0.54 0.12 
JMP-H1 GW405841X 1.25 1.24 1.245 0.005 
JMP-H2 SB-409513 0.07 0.19 0.13 0.06 
JMP-H3 GSK619487A 0.03 0.07 0.05 0.02 
JMP-H4 GW410563A 0.07 0.27 0.17 0.1 
JMP-H5 GW784752X 0.27 0.4 0.335 0.065 
JMP-H6 SKF-86002 0.25 0.32 0.285 0.035 
218 
 
JMP-H7 SB-376719 0.34 0.33 0.335 0.005 
JMP-H8 SB-223133 0.24 0.29 0.265 0.025 
JMP-H9 GW708893X 0.54 0.04 0.29 0.25 
JMP-H10 GW759710A 0.79 0.7 0.745 0.045 
JOJ-A1 GW416469X -1.26 -0.97 -1.115 0.145 
JOJ-A2 SKF-86055 -0.71 0.09 -0.31 0.4 
JOJ-A3 SB-682330-A -1.14 -1.04 -1.09 0.05 
JOJ-A4 SB-242719 -0.55 -0.85 -0.7 0.15 
JOJ-A5 SB-333612 0.18 -0.13 0.025 0.155 
JOJ-A6 GSK1030061A -0.41 -0.95 -0.68 0.27 
JOJ-A7 GSK1030059A -0.6 -0.58 -0.59 0.01 
JOJ-A8 GW799251X 1.05 -0.19 0.43 0.62 
JOJ-A9 GW832467X 0.2 0.51 0.355 0.155 
JOJ-A10 GW296115X 2.67 3.85 3.26 0.59 
JOJ-B1 GW830263A -0.27 -0.11 -0.19 0.08 
JOJ-B2 GSK1751853A -0.32 -0.43 -0.375 0.055 
JOJ-B3 GW643971X 0.84 0.3 0.57 0.27 
JOJ-B4 SB-614067-R 0.48 -0.55 -0.035 0.515 
JOJ-B5 GW694590A 3.6 3.3 3.45 0.15 
JOJ-B6 SB-278538 -1.06 -1.31 -1.185 0.125 
JOJ-B7 SB-390523 -0.53 -0.06 -0.295 0.235 
JOJ-B8 GSK200398A -0.55 -0.29 -0.42 0.13 
JOJ-B9 GW829877X -0.19 0.17 -0.01 0.18 
JOJ-B10 GW435821X 0.63 0.58 0.605 0.025 
JOJ-C1 GSK938890A -1.42 -3.46 -2.44 1.02 
JOJ-C2 GW445015X 0.1 -0.52 -0.21 0.31 
JOJ-C3 GW853609X 3.48 2.86 3.17 0.31 
JOJ-C4 SB-400868-A -0.44 -0.56 -0.5 0.06 
JOJ-C5 SB-739245-AC -0.25 -0.88 -0.565 0.315 
JOJ-C6 SB-226879 -0.65 -0.72 -0.685 0.035 
JOJ-C7 GSK1030062A -0.62 -0.7 -0.66 0.04 
JOJ-C8 GW300657X 0.35 -0.26 0.045 0.305 
JOJ-C9 SB-633825 -1.34 -2.17 -1.755 0.415 
JOJ-C10 GSK1030058A 0.38 0.44 0.41 0.03 
JOJ-D1 GW810372X -0.31 0.57 0.13 0.44 
JOJ-D2 GW627512B -0.33 0 -0.165 0.165 
JOJ-D3 SB-360741 -0.12 -0.5 -0.31 0.19 
JOJ-D4 GW580509X -0.16 -0.25 -0.205 0.045 
JOJ-D5 GW631581B 1.1 -0.12 0.49 0.61 
JOJ-D6 GSK1000163A -3.2 0.18 -1.51 1.69 
JOJ-D7 GW703087X 3.01 3.59 3.3 0.29 
JOJ-D8 GW869810X 1.31 1.88 1.595 0.285 
JOJ-D9 GW780159X -0.66 -0.55 -0.605 0.055 
JOJ-D10 SB-239272 0.31 -0.27 0.02 0.29 
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JOJ-E1 GW612286X -2.41 -0.83 -1.62 0.79 
JOJ-E2 GW284408X -1.45 -1.17 -1.31 0.14 
JOJ-E3 GW450241X -1.05 -0.9 -0.975 0.075 
JOJ-E4 GSK300014A 2.08 4.08 3.08 1 
JOJ-E5 GW770220A -0.97 -0.67 -0.82 0.15 
JOJ-E6 GW785974X -0.56 -0.72 -0.64 0.08 
JOJ-E7 GW828525X 1.55 2.82 2.185 0.635 
JOJ-E8 GW406108X -0.66 1.04 0.19 0.85 
JOJ-E9 GW804482X -3.41 -3.63 -3.52 0.395 
JOJ-E10 GSK299115A 0.02 0.93 0.475 0.455 
JOJ-F1 GW290597X -0.76 -0.81 -0.785 0.025 
JOJ-F2 GW644007X -0.84 0.26 -0.29 0.55 
JOJ-F3 GW831090X -0.17 -0.05 -0.11 0.06 
JOJ-F4 SB-409514 -0.72 -0.56 -0.64 0.08 
JOJ-F5 GW794726X -0.13 0.17 0.02 0.15 
JOJ-F6 GW827099X 0.98 1.08 1.03 0.05 
JOJ-F7 GW827106X -0.05 0.11 0.03 0.08 
JOJ-F8 GW846105X 0.7 1.77 1.235 0.535 
JOJ-F9 SB-738482 0.94 1.32 1.13 0.19 
JOJ-F10 GW827396X 2.68 3.19 2.935 0.255 
JOJ-G1 SB-253228 -2.45 -0.28 -1.365 1.085 
JOJ-G2 GW300653X 0.52 0.45 0.485 0.035 
JOJ-G3 GW695874X -1.08 0.01 -0.535 0.545 
JOJ-G4 GW575533A 1.31 -0.2 0.555 0.755 
JOJ-G5 SB-657836-AAA -2.54 -0.61 -1.575 0.965 
JOJ-G6 GW807930X 1.98 1.81 1.895 0.085 
JOJ-G7 GSK943949A -1.1 -1.77 -1.435 0.335 
JOJ-G8 GW659386A 2.33 3.11 2.72 0.39 
JOJ-G9 GSK1511931A -0.17 -0.1 -0.135 0.035 
JOJ-G10 GSK969786A 1.54 1.76 1.65 0.11 
JOJ-H1 GW568326X -2.48 -0.07 -1.275 1.205 
JOJ-H2 GW861893X 1.42 1.89 1.655 0.235 
JOJ-H3 GW275944X 2.5 1.23 1.865 0.635 
JOJ-H4 GW278681X 0.19 -0.58 -0.195 0.385 
JOJ-H5 SB-711237 -0.15 1.12 0.485 0.635 
JOJ-H6 GW305178X 0.1 1.6 0.85 0.75 
JOJ-H7 GW445017X -0.06 -0.61 -0.335 0.275 
JOJ-H8 GW440139B -0.65 -0.52 -0.585 0.065 
JOJ-H9 GW651576X -0.19 -0.55 -0.37 0.18 
JOJ-H10 GW566221B 1.96 1.44 1.7 0.26 
JOK-A1 GSK182497A 1.21 1.4 1.305 0.095 
JOK-A2 GW778894X -0.83 -0.52 -0.675 0.155 
JOK-A3 SB-220455 -1.1 -1.4 -1.25 0.15 
JOK-A4 GW429374A -0.16 0.05 -0.055 0.105 
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JOK-A5 GW784307A -0.54 -0.52 -0.53 0.01 
JOK-B1 GW781673X -1.53 -0.99 -1.26 0.27 
JOK-B2 SB-592602 -1.13 -0.7 -0.915 0.215 
JOK-B3 SB-278539 -1.25 -1.24 -1.245 0.005 
JOK-B4 GSK2213727A -0.73 -0.77 -0.75 0.02 
JOK-B5 GW576484X 1.97 2.06 2.015 0.045 
JOK-C1 GSK238583A -1.63 -1.19 -1.41 0.22 
JOK-C2 GSK1392956A -0.89 -1.23 -1.06 0.17 
JOK-C3 SB-437013 -1.59 -1.55 -1.57 0.02 
JOK-C4 SB-242717 -0.72 -0.91 -0.815 0.095 
JOK-D1 GW827105X 1.94 2.08 2.01 0.07 
JOK-D2 GW830365A -1.76 -0.93 -1.345 0.415 
JOK-D3 GSK317354A -0.48 -0.86 -0.67 0.19 
JOK-D4 SB-742864 -0.93 -0.88 -0.905 0.025 
JOK-E1 GW441756X -1.97 -1.17 -1.57 0.4 
JOK-E2 GR105659X -1.04 -1.13 -1.085 0.045 
JOK-E3 SB-735465 -1.06 -0.99 -1.025 0.035 
JOK-E4 GW806742X 2.59 2.69 2.64 0.05 
JOK-F1 GW589933X -0.75 -1.04 -0.895 0.145 
JOK-F2 SB-750140 -0.8 -0.92 -0.86 0.06 
JOK-F3 GW549390X -0.08 0.29 0.105 0.185 
JOK-F4 GW458344A -1.7 -1.26 -1.48 0.22 
JOK-G1 GW810576X -1.23 -0.69 -0.96 0.27 
JOK-G2 GW772405X -0.13 0.62 0.245 0.375 
JOK-G3 GW282974A -0.64 -0.2 -0.42 0.22 
JOK-G4 SB-431533 -0.37 -0.8 -0.585 0.215 
JOK-H1 GW853606X 0.82 0.72 0.77 0.05 
JOK-H2 SB-732941 -0.67 -0.83 -0.75 0.08 
JOK-H3 GW581744X -1.13 -0.58 -0.855 0.275 
JOK-H4 SB-221466 -0.53 -0.41 -0.47 0.06 
JOI-A1 GW673715X 1.75 2.32 2.035 0.285 
JOI-A2 GW811761X 1.02 -0.2 0.41 0.61 
JOI-A3 GW680975X 0.89 -0.02 0.435 0.455 
JOI-A4 GSK605714A 0.88 0.3 0.59 0.29 
JOI-A5 GW782612X -0.01 0.37 0.18 0.19 
JOI-B1 GSK192082A 2.74 1.72 2.23 0.51 
JOI-B2 SB-707548-A 4.01 3.55 3.78 0.23 
JOI-B3 SB-285234-W 0.81 -0.27 0.27 0.54 
JOI-B4 GR269666A -0.27 0.14 -0.065 0.205 
JOI-B5 GW559768X 0.7 0.38 0.54 0.16 
JOI-C1 SB-675259-M -0.32 -0.21 -0.265 0.055 
JOI-C2 GSK718429A 3.26 2.35 2.805 0.455 
JOI-C3 GW572738X 0.9 -0.11 0.395 0.505 
JOI-C4 GW621431X 0.64 -0.09 0.275 0.365 
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JOI-C5 GW416981X 0.97 0.39 0.68 0.29 
JOI-D1 GSK237701A 0.54 -1.87 -0.665 1.205 
JOI-D2 GW567808A 2.72 2.37 2.545 0.175 
JOI-D3 GSK605714A 0.76 -0.01 0.375 0.385 
JOI-D4 GW561436X 0.78 -0.04 0.37 0.41 
JOI-D5 GW607117X 0.61 0.7 0.655 0.045 
JOI-E1 GSK978744A 0.64 -0.54 0.05 0.59 
JOI-E2 SB-744941 0.65 0.27 0.46 0.19 
JOI-E3 GW574782A 2.94 2.33 2.635 0.305 
JOI-E4 GW575808A 0.72 0.75 0.735 0.015 
JOI-E5 GW654652X 0.57 0.21 0.39 0.18 
JOI-F1 GW513184X 2.98 2.77 2.875 0.105 
JOI-F2 GW622055X 0.96 0.35 0.655 0.305 
JOI-F3 GW589961A 4.23 2.87 3.55 0.68 
JOI-F4 GW569293X 0.64 -0.06 0.29 0.35 
JOI-F5 GSK466317A 0.76 0.67 0.715 0.045 
JOI-G1 GW682841X 0.65 0.22 0.435 0.215 
JOI-G2 GSK1713088A 2.95 2.58 2.765 0.185 
JOI-G3 GW819230X 0.9 0.21 0.555 0.345 
JOI-G4 GW769076X 1.03 0.33 0.68 0.35 
JOI-G5 GW276655X 0.99 0.68 0.835 0.155 
JOI-H1 GW770249A 4.06 3.13 3.595 0.465 
JOI-H2 SB-242721 1.08 -0.14 0.47 0.61 
JOI-H3 GW642138X 3.15 2.45 2.8 0.35 
JOI-H4 GW820759X 0.76 0.5 0.63 0.13 
JOI-H5 GW819077X 1.3 1.52 1.41 0.11 
JOI-A6 GW680191X -0.44 -0.29 -0.365 0.075 
JOI-A7 GW583373A 1.12 1.14 1.13 0.01 
JOI-A8 GW335962X -0.12 -0.73 -0.425 0.305 
JOI-A9 GW301784X -0.7 -0.01 -0.355 0.345 
JOI-A10 GW824645A -0.05 0.41 0.18 0.23 
JOI-B6 GSK554170A -3.58 -0.21 -1.895 1.685 
JOI-B7 GSK1220512A 0.01 0.48 0.245 0.235 
JOI-B8 SB-253226 -0.19 -0.65 -0.42 0.23 
JOI-B9 GW282536X -0.12 -0.09 -0.105 0.015 
JOI-B10 GI98581X -0.07 0.53 0.23 0.3 
JOI-C6 GSK579289A -0.57 -0.5 -0.535 0.035 
JOI-C7 GW779439X 0.79 0.87 0.83 0.04 
JOI-C8 GW734508X 0.37 -0.46 -0.045 0.415 
JOI-C9 GW852849X -0.59 -0.47 -0.53 0.06 
JOI-C10 GW683134A 3.66 3.6 3.63 0.03 
JOI-D6 GW576924A 1.11 1.35 1.23 0.12 
JOI-D7 GW771127A 0.07 -0.15 -0.04 0.11 
JOI-D8 SB-210313 0.51 -0.6 -0.045 0.555 
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JOI-D9 GW580496A 2.21 2.11 2.16 0.05 
JOI-D10 GSK2219385A -1.72 0.37 -0.675 1.045 
JOI-E6 GW633459A 0.75 0.38 0.565 0.185 
JOI-E7 GW795493X 2.14 3.26 2.7 0.56 
JOI-E8 GSK614526A -0.2 -0.5 -0.35 0.15 
JOI-E9 GW568377B -0.34 -0.02 -0.18 0.16 
JOI-E10 GW305074X 2.55 1.29 1.92 0.63 
JOI-F6 GSK466314A -0.16 -0.4 -0.28 0.12 
JOI-F7 SB-250715 -1.93 -0.42 -1.175 0.755 
JOI-F8 GSK1007102B -0.47 -1.07 -0.77 0.3 
JOI-F9 GW693917X 3.12 4.37 3.745 0.625 
JOI-F10 GSK2110236A 0.07 0.78 0.425 0.355 
JOI-G6 GW615311X 0.51 0.64 0.575 0.065 
JOI-G7 SB-284847-BT -0.18 -0.15 -0.165 0.015 
JOI-G8 GSK2220400A 0.26 -0.29 -0.015 0.275 
JOI-G9 GSK635416A -0.22 0.1 -0.06 0.16 
JOI-G10 SB-251527 -0.04 0.47 0.215 0.255 
JOI-H6 GW621823A 0.69 0.67 0.68 0.01 
JOI-H7 SB-254169 -0.05 0.07 0.01 0.06 
JOI-H8 SB-610251-B 0.84 0.8 0.82 0.02 
JOI-H9 SB-693162 -0.26 -0.11 -0.185 0.075 
JOI-H10 GW701427A 0.55 1.14 0.845 0.295 
JOH-A1 GW809885X -0.07 0.72 0.325 0.395 
JOH-A2 GW678313X -0.31 0.32 0.005 0.315 
JOH-A3 GW782912X -0.99 -0.18 -0.585 0.405 
JOH-A4 GW694234A 2.52 3.93 3.225 0.705 
JOH-A5 GW432441X -0.41 -0.35 -0.38 0.03 
JOH-A6 SB-251505 0.06 -0.14 -0.04 0.1 
JOH-A7 GW683109X -0.12 -0.04 -0.08 0.04 
JOH-A8 SB-735467 1.06 -0.36 0.35 0.71 
JOH-A9 GW785404X 0.87 -0.46 0.205 0.665 
JOH-A10 GW743024X 0.61 0.15 0.38 0.23 
JOH-B1 GW572401X -0.88 0.23 -0.325 0.555 
JOH-B2 GW280670X -0.55 0.17 -0.19 0.36 
JOH-B3 GW407323A 1.1 0.26 0.68 0.42 
JOH-B4 GW282449A -0.87 -0.24 -0.555 0.315 
JOH-B5 SB-347804 -0.07 0.75 0.34 0.41 
JOH-B6 SB-242718 0.12 -0.15 -0.015 0.135 
JOH-B7 GW616030X 1.59 -0.44 0.575 1.015 
JOH-B8 SB-358518 -0.26 -0.07 -0.165 0.095 
JOH-B9 SB-737198 -0.37 -0.41 -0.39 0.02 
JOH-B10 GSK994854A 0.81 0.54 0.675 0.135 
JOH-C1 GW406731X -0.95 -0.03 -0.49 0.46 
JOH-C2 GW279320X -1.07 0.22 -0.425 0.645 
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JOH-C3 SB-698596-AC -0.59 0.16 -0.215 0.375 
JOH-C4 GW794607X -0.78 0.42 -0.18 0.6 
JOH-C5 SB-476429-A -1.64 -0.86 -1.25 0.39 
JOH-C6 GW817394X -0.34 0.85 0.255 0.595 
JOH-C7 GW693881A 4.7 4.61 4.655 0.045 
JOH-C8 SB-772077-B -0.58 -0.23 -0.405 0.175 
JOH-C9 SB-431542-A 0.16 0.51 0.335 0.175 
JOH-C10 GSK238063A 1.22 1.63 1.425 0.205 
JOH-D1 GW780056X -0.86 -0.01 -0.435 0.425 
JOH-D2 GW811168X -0.46 1.35 0.445 0.905 
JOH-D3 GW659893X 3.96 3.72 3.84 0.12 
JOH-D4 GW829874X -0.62 0.51 -0.055 0.565 
JOH-D5 GSK270822A -0.77 0.16 -0.305 0.465 
JOH-D6 GW396574X 1.36 1.57 1.465 0.105 
JOH-D7 SB-736302 -0.37 -0.17 -0.27 0.1 
JOH-D8 GSK269962B 0.38 0.87 0.625 0.245 
JOH-D9 GW632580X 0 0.13 0.065 0.065 
JOH-D10 GSK312948A 0.12 -0.11 0.005 0.115 
JOH-E1 GSK248233A -0.09 -0.5 -0.295 0.205 
JOH-E2 GW442130X -0.35 0.48 0.065 0.415 
JOH-E3 GW693481X -1.1 0.25 -0.425 0.675 
JOH-E4 GW679410X -1.21 0.43 -0.39 0.82 
JOH-E5 GW805758X -0.31 0.99 0.34 0.65 
JOH-E6 GW458787A 0.84 0.98 0.91 0.07 
JOH-E7 GW830900A -0.27 0.41 0.07 0.34 
JOH-E8 GW445014X -1.29 -0.41 -0.85 0.44 
JOH-E9 SB-725317 0.05 0.43 0.24 0.19 
JOH-E10 GW459057A 0.4 0.2 0.3 0.1 
JOH-F1 GW683768X -0.43 0.23 -0.1 0.33 
JOH-F2 GW275616X -0.88 0.23 -0.325 0.555 
JOH-F3 GW642125X -0.41 0.57 0.08 0.49 
JOH-F4 GW300660X -0.66 0.67 0.005 0.665 
JOH-F5 GW549034X -1.03 0.09 -0.47 0.56 
JOH-F6 GW708336X -0.66 0.28 -0.19 0.47 
JOH-F7 GW782907X -1.07 0.7 -0.185 0.885 
JOH-F8 SB-743899 -0.69 -0.23 -0.46 0.23 
JOH-F9 GSK980961A -0.74 0.22 -0.26 0.48 
JOH-F10 SB-590885-R 0.15 0.02 0.085 0.065 
JOH-G1 GSK949675A -1.61 -1.11 -1.36 0.25 
JOH-G2 GW786460X -1.42 0.43 -0.495 0.925 
JOH-G3 GW876790X -1.06 0.49 -0.285 0.775 
JOH-G4 GW427984X -0.74 0.3 -0.22 0.52 
JOH-G5 GSK2186269A -1.79 -1.53 -1.66 0.13 
JOH-G6 GW684626B -0.58 0.79 0.105 0.685 
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JOH-G7 GW806290X -0.25 -0.28 -0.265 0.015 
JOH-G8 GW445012X -1.94 -0.02 -0.98 0.96 
JOH-G9 GW711782X -0.32 0.47 0.075 0.395 
JOH-G10 GW576609A 0.92 1.03 0.975 0.055 
JOH-H1 GSK1819799A 0.28 0.78 0.53 0.25 
JOH-H2 GSK625137A -1.09 0.28 -0.405 0.685 
JOH-H3 GW801372X -1.25 0.66 -0.295 0.955 
JOH-H4 GSK317314A -2.1 0.14 -0.98 1.12 
JOH-H5 GW284372X 0.38 0.28 0.33 0.05 
JOH-H6 GW701032X -1.34 0.38 -0.48 0.86 
JOH-H7 SB-216385 -0.55 0.47 -0.04 0.51 
JOH-H8 GW439255X -0.51 0.95 0.22 0.73 
JOH-H9 GW618013X 0.44 0.76 0.6 0.16 
JOH-H10 GSK1326255A 2.16 2.18 2.17 0.01 
TRB2+ATP+EDTA 
 
2.325 2.78 2.5525 0.2275 
      
Appendix Table 1: TRIB2 PKIS1 DSF screen data. 
 
 
Compound ΔTm Standard 
deviation 
Compound information 
GW804482X -3.52 0.395 Discovery of thiophene inhibitors of polo-like kinase.    Bioorganic & 
Medicinal Chemistry Letters  (2009),  19(3),  1018-1021.   
GSK938890A -2.44 1.02 Aminofurazans as potent inhibitors of AKT kinase.    Bioorganic & 
Medicinal Chemistry Letters  (2009),  19(5),  1508-1511. 
GW569530A -
2.215 
0.345 Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR 
Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines.    Bioorganic & 
Medicinal Chemistry Letters  (2003),  13(4),  637-640.   
GSK554170A -
1.895 
1.685 Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-
piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-
ol (GSK690693), a Novel Inhibitor of AKT Kinase.    Journal of Medicinal 
Chemistry  (2008),  51(18),  5663-5679.  
SB-633825 -
1.755 
0.415 Optimization of triarylimidazoles for Tie2: Influence of conformation on 
potency.    Bioorganic & Medicinal Chemistry Letters  (2007),  17(20),  
5514-5517.   
GSK2163632A -1.67 1.29 Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine 
inhibitors of IGF-1R: elimination of an acid-mediated decomposition 
pathway.    Bioorganic & medicinal chemistry letters  (2009),  19(2),  373-
7.  
GSK2186269A -1.66 0.13 Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine 
inhibitors of IGF-1R: elimination of an acid-mediated decomposition 
pathway.    Bioorganic & medicinal chemistry letters  (2009),  19(2),  373 
GW612286X -1.62 0.79 Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-
pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel 
and Potent Vascular Endothelial Growth Factor Receptor Inhibitor.    
Journal of Medicinal Chemistry  (2008),  51(15),  4632-4640 
SB-657836-
AAA 
-
1.575 
0.965 N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, 
selective, inhibitors of JNK2 and JNK3.    Bioorganic & Medicinal 
Chemistry Letters  (2007),  17(5),  1296-1301 
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SB-437013 -1.57 0.02 Optimization of triarylimidazoles for Tie2: Influence of conformation on 
potency.    Bioorganic & Medicinal Chemistry Letters  (2007),  17(20),  
5514-5517. 
GW441756X -1.57 0.4 Discovery and in vitro evaluation of potent TrkA kinase inhibitors: 
oxindole and aza-oxindoles.    Bioorganic & Medicinal Chemistry Letters  
(2004),  14(4),  953-957 
Apendix table 2: PKIS1 ligands with the most destabilising effect on TRIB2. 
 
 
Compound ΔTm Standard 
deviation 
Compound information 
GW837331X 2.52 0.64 Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like 
kinase 1.    Bioorganic & Medicinal Chemistry Letters  (2008),  18(23),  
6214-6217 
GW567808A 2.545 0.175 Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase 
inhibition in the 6-furanylquinazoline series.    Bioorganic & Medicinal 
Chemistry Letters  (2006),  16(17),  4686-4691 
GW574782A 2.635 0.305 Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase 
inhibition in the 6-furanylquinazoline series.    Bioorganic & Medicinal 
Chemistry Letters  (2006),  16(17),  4686-4691 
GW806742X 2.64 0.05 Discovery of a novel and potent series of dianilinopyrimidineurea and 
urea isostere inhibitors of VEGFR2 tyrosine kinase.    Bioorganic & 
Medicinal Chemistry Letters  (2005),  15(15),  3519-352 
GW795493X 2.7 0.56 Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as 
anti-angiogenic agent inhibiting VEGFR2 and Tie-2.    Bioorganic & 
Medicinal Chemistry Letters  (2007),  17(6),  1773-1778 
GW659386A 2.72 0.39 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-4470 
GSK1713088A 2.765 0.185 Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R 
tyrosine kinase inhibitors towards JNK selectivity.    Bioorganic & 
Medicinal Chemistry Letters  (2009),  19(2),  360-364 
GW642138X 2.8 0.35 Novel 4-aminofuro[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual 
inhibitors.    Bioorganic & Medicinal Chemistry Letters  (2005),  15(9),  
2203-2207. 
GSK718429A 2.805 0.455  Knowledge-based design of 7-azaindoles as selective B-Raf 
inhibitors.    Bioorganic & Medicinal Chemistry Letters  (2008),  18(16),  
4610-4614 
GW513184X 2.875 0.105 Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.    Bioorganic 
& Medicinal Chemistry Letters  (2004),  14(9),  2121-2125 
GW827396X 2.935 0.255 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent 
and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good 
Cellular Efficacy.    Journal of Medicinal Chemistry  (2004),  47(19),  
4716-4730 
GSK300014A 3.08 1 Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.    Bioorganic & 
Medicinal Chemistry Letters  (2009),  19(3),  817-820.  CODEN: 
BMCLE8  ISSN:0960-894X.  AN 2009:119140    CAPLUS 
GW853609X 3.17 0.31 Discovery of thiophene inhibitors of polo-like kinase.    Bioorganic & 
Medicinal Chemistry Letters  (2009),  19(3),  1018-1021 
GW607049B 3.205 0.275 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-4470 
GW694234A 3.225 0.705 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-4470 
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GW784684X 3.23 0.35 Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.    Bioorganic & 
Medicinal Chemistry Letters  (2009),  19(3),  817-820.  CODEN: 
BMCLE8  ISSN:0960-894X.   
GW296115X 3.26 0.59 Uings I J; Spacey G D; Bonser R W  Effects of the indolocarbazole 
3744W on the tyrosine kinase activity of the cytoplasmic domain of the 
platelet-derived growth factor beta-receptor.    Cellular signalling   
GW703087X 3.3 0.29 Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.    
Bioorganic & Medicinal Chemistry Letters  
GW694590A 3.45 0.15 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-4470 
GW589961A 3.55 0.68 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-4470 
GW770249A 3.595 0.465 Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as 
anti-angiogenic agent inhibiting VEGFR2 and Tie-2.    Bioorganic & 
Medicinal Chemistry Letters  (2007),   
GW683134A 3.63 0.03 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-4470 
GW693917X 3.745 0.625 Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and 
VEGFR-2 Tyrosine Kinase Receptors.    Journal of Medicinal 
Chemistry  (2007),  50(18),  4453-447 
SB-707548-A 3.78 0.23 Thousands of chemical starting points for antimalarial lead 
identification. Nature. 2010 May 20;465(7296):305-10. doi: 
10.1038/nature09107 
GW659893X 3.84 0.12 Gw52s.    Bioorganic & Medicinal Chemistry Letters  (2006),  16(9),  
2419-2422 
GW693881A 4.655 0.045 Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.    Bioorganic & 
Medicinal Chemistry Letters   
Appendix table 3: PKIS1 ligands with the greatest stabilising effect on TRIB2 
 
UV absorbance to assess the solubility of compounds 
ITC and NMR studies were limited by the poor solubility of the EGFR/HER2 inibitors 
proposed to bind to TRIB2. The compounds afatinib, neratinib, lapatinib, TAK-285 and 
erlotinib were assessed for their solubility in 20 mM Tris-HCl, 100 mM NaCl, 1 mM 
DTT and 2% DMSO (appendix Figure 1). Standard curves were generated by diluting 
known amounts of compound in 100% DMSO and reading UV absorbance at the 
particular compoudns wavelength of maximum absorption (λ max). ATP served as a 
control. The maximum concentration that could be detected by each compound in Tris 
buffer is indicated by a dotted line. The maximum solubilities calculated were as 
follows: afatinib 41.2 μM, neratinib 14.5 μM, lapatinib 17.9 μM, TAK-285 28.3 μM and 
erlotinib 25.9 μM.    
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Appendix Figure 1: Using UV absorbance to detect the maximum solubility of selected small 
molecule inhibitors. Standard curves were generated by diluting the indicated compounds in DMSO 
and reading λ max using a NanoDrop. Compounds (A) ATP, (B) afatinib, (C) neratinib, (D) lapatinib, (E) 
TAK-285 and (F) erlotinib were then diluted in 20 mM Tris-HCl, 100 mM NaCl, 1 mM DTT and 2% 
DMSO to 200 μM. The insoluble compound was pelleted by centrifugation at 16,000 g for 20 minutes 
and the highest UV absorbance reading achieved for the supernatant was used to deduce the maximum 
solubility of each compound in biochemical assay buffer. 
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